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1 SUMMARY 
Deficiency of the mitochondrial enzyme 2-methyl-3-hydroxybutyryl-CoA dehydrogenase 
involved in isoleucine metabolism causes an organic aciduria with an atypical progressive 
neurodegenerative disease course (Zschocke et al, 2000). The symptoms in HSD10 
deficiency patients are not correlated with residual dehydrogenase activity of mutated 
HSD10. LOF and rescue experiments in Xenopus embryos showed that a knock-down of 
HSD10 caused apoptosis. The dehydrogenase activity of HSD10 was not required for cell 
survival suggesting that HSD10 has additional functions. The pathogenetic basis of 
HSD10 deficiency has so far remained elusive but the symptoms observed in patients are 
likely related to defects in general mitochondrial function. Therefore, the effect of HSD10 
LOF on mitochondrial structural and functional integrity was investigated. Embryonic 
Xenopus cells displayed severe disruption of mitochondrial morphology and function 
when translation of HSD10 mRNA was blocked. Similar effects on mitochondria were 
observed in cells derived from conditional HSD10 knock-out mice and in fibroblasts from 
patients with a severe clinical phenotype. In Xenopus overexpression of two HSD10 
mutations, R130C and D86G, associated with severe disease in humans, strongly induced 
apoptosis in a dominant-negative manner which was not due to the unfolded protein 
response that is occasionally triggered by overexpression of (mutated) proteins. In 
contrast, wildtype HSD10 and the Q165H mutation had little effect on apoptosis. 
Expression analysis of apoptosis-associated genes in HSD10 depleted cells or cells 
carrying different HSD10 mutations demonstrated that no specific apoptotic pathway was 
activated. This indicated that intrinsic as well as extrinsic apoptosis signals contribute to 
cell death when HSD10 function is perturbed. 
Symptoms in patients usually develop after metabolic stress situations. Therefore the 
stress response behaviour of fibroblasts carrying HSD10 mutations was studied under 
different stress conditions. In contrast to control cells, fibroblasts from patients were not 
able to stimulate tRNA transcription upon oxidative stress.  Interestingly cells with the 
R130C mutation could cope with stress just like the Q165H mutation. This was 
unexpected, since the R130C mutation causes a severe clinical phenotype whereas the 
Q165H mutation has been found in neurologically normal boys. 
In order to understand the mechanisms behind the physiological function of HSD10 a 
search for its binding partners was performed. In a homology based BLAST in yeast as 
well as in an IMAC approach putative HSD10-interacting proteins were identified. 
Unfortunately none of these candidates were directly connected to mitochondrial function 
or apoptosis.  In a previously performed yeast-2-hybrid screen several HSD10 interaction 
partners had been identified. One of those binding proteins, UXT, was tested for a 
functional interaction with HSD10 in Xenopus embryos. Co-expression of HSD10 and UXT 
enhanced the induction of apoptosis. The mechanism of this functional interaction 
remains to be investigated.  
HSD10 is a component of the RNAseP complex which is essential for the 5’ processing of 
mitochondrial tRNAs. Therefore I tested the function of RNaseP in HSD10 deficiency in 
patient fibroblast and in a rescue experiment in HSD10 depleted cells. The rescue 
experiment, in which wildtype HSD10 function was substituted by the mutations R130C, 
D86G and Q165H indicated that all mutations still have RNaseP activity. This held also 
true for patient fibroblasts where no tRNA precursor accumulation or inhibition of 
mitochondrial translation was detected. Experiments with cells that are depleted of 
mitochondrial DNA and hence do not require mitochondrial transcription or mtRNaseP 
function revealed that these cells still become apoptotic upon HSD10 knock-down. 
Therefore, the apoptosis phenotype upon HSD10 LOF is not dependent on RNaseP 
function. Taken together, these experiments indicate that clinical symptoms in HSD10 
deficiency are not fully explained by an impairment of RNaseP function. 
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2 ZUSAMMENFASSUNG 
Ein Mangel des mitochondrialen Enzyms 2-Methyl-3-Hydroxybutyryl-CoA-Dehydrogenase, 
das eine Rolle im Isoleucin Metabolismus spielt, ist die Ursache einer organischen 
Azidurie mit einem atypischen progressiven neurodegenerativen Verlauf (Zschocke et al, 
2000). Die Symptome des HSD10-Mangels sind nicht mit der Dehydrogenase 
Restaktivität der mutierten HSD10 Proteine korreliert. LOF und Rettungsexperimente in 
Xenopus zeigten, dass ein knock-down von HSD10 Apoptose verursacht. Die 
Dehydrogenase Aktivität von HSD10 ist nicht ausschlaggebend für das Überleben der 
Zelle, was darauf hindeutet, dass HSD10 über zusätzliche Funktionen verfügt. Die 
pathogenetische Grundlage des HSD10-Mangels ist bisher unbekannt, aber den 
Symptomen der Patienten liegt wahrscheinlich eine allgemeine Störung der 
Mitochondrienfunktion zu Grunde. Daher wurde der Effekt eines HSD10 LOF auf die 
mitochondriale Struktur und Funktion untersucht. Xenopus Zellen, in denen die 
Translation von HSD10 mRNA blockiert war, wiesen eine schwere Störung der 
mitochondrialen Morphologie und Funktion auf. Ähnliche Effekte auf die Mitochondrien 
wurden in Zellen von konditionalen HSD10 knock-out Mäusen und in Fibroblasten von 
Patienten mit schwerem klinischen Phänotyp beobachtet.  
In Xenopus hatte die Überexpression der beiden mit einem schweren Krankheitsverlauf 
assoziieren HSD10 Mutationen, R130C und D86G, einen dominant-negativen Effekt auf 
den Anstieg der Apoptose, was nicht mit der „unfolded protein response", die 
gelegentlich durch die Überexpression von (mutierten) Proteinen ausgelöst wird, 
zusammenhing. Im Gegensatz dazu hatten wildtyp HSD10 und die Mutation Q165H 
wenig Einfluss auf die Apoptose. Expressionsanalysen von Apoptose-assoziierten Genen 
in HSD10 depletierten Zellen oder in Zellen mit HSD10 Mutationen zeigten, dass kein 
spezifischer Apoptoseweg aktiviert wurde. Intrinsische wie auch extrinsische Signale 
führen zum Zelltod, wenn die HSD10 Funktion gestört ist. 
In der Regel entwickeln Patienten Symptome nach metabolischen Stresssituationen. 
Deshalb wurde das Verhalten von Fibroblasten mit HSD10 Mutationen unter 
verschiedenen Stressbedingungen untersucht. Im Unterschied zu Kontrollzellen waren 
Fibroblasten von Patienten nicht in der Lage die Transkription von mitochondrialen tRNAs 
zu stimulieren. Interessanterweise konnten Zellen mit der R130C Mutation Stress ebenso 
gut bewältigen wie die Mutation Q165H. Dies war unerwartet, da die R130C Mutation 
einen schweren klinischen Phänotyp verursacht, während die Mutation Q165H in 
neurologisch normalen Jungen gefunden wurde. 
Um die Mechanismen der physiologischen Funktion von HSD10 zu verstehen wurde nach 
Bindungspartnern des Proteins gesucht. In einem BLAST in Hefe sowie in einem IMAC 
Ansatz wurden potentielle Interaktionspartner von HSD10 identifiziert. Leider hatte 
keiner dieser Kandidaten eine direkte Verbindung zu Mitochondrien oder Apoptose. In 
einem yeast-2-hybrid Screen waren einige Interaktionspartner identifiziert worden. Eines 
dieser Proteine, UXT, wurde auf eine funktionelle Interaktion mit HSD10 in Xenopus 
getestet. Co-Expression von HSD10 und UXT verstärkt die Induktion von Apoptose. Der 
Mechanismus dieser funktionellen Interaktion ist bisher nicht bekannt. 
HSD10 ist eine Komponente des RNAseP Komplexes, der die 5’ Prozessierung von 
mitochondrialen tRNAs durchführt. Deshalb wurde die Rolle der RNaseP Funktion im 
HSD10-Mangel an Fibroblasten von Patienten und in einem Rettungsexperiment in 
HSD10 depletierten Zellen getestet. Das Rettungsexperiment, in dem die wildtyp HSD10 
Funktion durch die Mutationen R130C, D86G und Q165H ersetzt wurde, deutete darauf 
hin, dass alle Mutationen RNaseP Aktivität haben. Dies galt ebenfalls für Patienten 
Fibroblasten. Zellen, die keine mitochondriale DNA enthalten und somit die mtRNaseP 
Funktion nicht benötigen, reagieren dennoch mit Apoptose auf einen HSD10 knock-down. 
Der Apoptose-Phänotyp im HSD10 LOF ist demnach nicht abhängig von der RNaseP 
Funktion von HSD10. Diese Experimente zeigen, dass die Symptome des HSD10-Mangels 
nicht vollständig durch eine Beeinträchtigung der RNaseP erklärt werden können. 
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3 INTRODUCTION 
3.1. 17β-hydroxysteroid-dehydrogenase type 10 – an evolutionary conserved 
multifunctional protein 
HSD10 was first identified as an enzyme involved in the oxidation of branched chain fatty 
acids in the rat liver and as such it was named SCHMAD (short chain L-3-hydroxy-2-
methylacyl-CoA dehydrogenase; Luo et al, 1995). Later on it was found in bovine 
mitochondria and it was given an additional name: HADH2 (L-3-hydroxyacyl-CoA 
dehydrogenase type II; Kobayashi et al, 1996). Yan et al. discovered HSD10 in a yeast-
2-hybrid screen for binding partners of the amyloid-β peptide (Yan et al, 1997) and 
named it ERAB (endoplasmic reticulum-associated amyloid β-peptide binding protein), 
since they found it located in the endoplasmic reticulum which later turned out to be an 
artefact. Afterwards HSD10 received several more names like ABAD (amyloid β-binding 
alcohol dehydrogenase; Yan et al, 1999), SCHAD (short chain 3-hydroxyacyl-CoA 
dehydrogenase; He et al, 1999), MHBD (2-methyl-3-hydroxybutyryl-CoA dehydrogenase; 
Zschocke et al, 2000) and 17βHSD10 (17β-hydroxysteroid dehydrogenase type 10; He et 
al, 2001). To sort out all these different names, HSD17B10 and HSD10 were chosen to 
be the official designations for the gene and the gene product, respectively 
(OMIM 300256; Korman & Yang, 2007). 
HSD17B10 is located on the short arm of the X-chromosome (Xp11.2) and is composed 
of six exons stretched over approximately 3 kb (fig. 1; Yang et al, 2005a). Exons 1-3 
form the NAD-binding domain at the amino terminus. The C-terminal domain, which 
binds the substrate and catalyses the enzymatic reaction, consists of exons 4-6 (He et al, 
1998). 
 
The HSD10 protein consists of 261 amino acids and has a molecular mass of about 
27 kD. It forms homotetramers with a molecular mass of 108 kD in vivo. The expression 
of HSD10 occurs ubiquitously in all tissues (He et al, 2000a; He et al, 2001; He et al, 
2003) but predominantly in liver, heart and brain (Yan et al, 1997; He et al, 2003). The 
expression of HSD10 is regulated by C/EBPβ (CCAAT enhancer binding factor β) and 
several isoforms of C/EBPβ (Rotinen et al, 2010). The promoter of HSD17B10 contains a 
CCAAT box at -30/-19 and two binding sites for C/EBPs.  
Due to alternative splicing sites in the mRNA there are several isoforms of HSD10 (Yang 
et al, 2007). The splicing signal at exon 5 is rather weak and can be skipped in favour of 
Figure 1 Localisation of HSD17B10 on the 
X-chromosome (adapted from Yang et al, 
2005a). HSD17B10 is located on Xp11.2 and is 
composed of six exons stretched over 
approximately 3 kb. 
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an alternative splicing site. This results either in the omission of approximately 
55 nucleotides at the end of exon 5 and the beginning of exon 6 processed to form the 
isoform 2 or the choice of an alternative splicing site occasionally results in the exclusion 
of the entire exon 5. Isoform 2 (NM_001037811) is stable and found in normal human 
brain tissue. Exon skipping leads to a frame shift and the formation of a premature stop 
codon. Hence, isoform 3 is unstable since it is probably submitted to nonsense-mediated 
decay. Correct splicing of HSD10 is crucial for maintenance of normal brain function. 
Subcellularly, HSD10 is located in the mitochondrial matrix proven by several different 
methods like confocal and electron microscopy (Yan et al, 1999; He et al, 1999; He et al, 
2002), subcellular fractionation (Luo et al, 1995) and immuno histology (Frackowiak et 
al, 2001). Computational analysis of the amino acid sequence of HSD10 revealed a 
putative mitochondrial localisation signal, ERLVGQ, at the N-terminus of the protein 
(Sambamurti & Lahiri, 1998). Eleven N-terminal amino acids form a positively charged 
amphiphilic α helix that is sufficient but not required for mitochondrial import (He et al, 
2001). HSD10 might have one or more additional mitochondrial localisation signals, 
although an internal or C-terminal targeting signal was not found in the protein 
sequence. 
HSD10 is the only 17β-hydroxysteroid dehydrogenase located in mitochondria. Within the 
17β-HSDs, HSD10 belongs to the family of SDR (short chain dehydrogenases/ 
reductases). It can catalyse NADH-dependent redox reactions of many different 
substrates including branched short chain acyl-CoAs, fatty acids, linear alcohols, amino 
acid catabolites as well as steroids (Kobayashi et al, 1996; Furuta et al, 1997; Yan et al, 
1997; He et al, 1998; He et al, 1999; Yang et al, 2005a). The alcohol dehydrogenase 
activity of HSD10 is marginal (Yan et al, 1999; He et al, 2000b). 
 
3.2. Function of HSD10 in fatty acid metabolism and isoleucine breakdown 
HSD10 oxidises specifically the L-form of L-3-hydroxyacyl-CoAs to 3-ketoacyl-CoAs but 
does not turn over the D-isomere. This reaction is one of the steps in isoleucine 
breakdown before the products acetyl-CoA and propionyl-CoA are generated (fig. 2). In 
its function as MHBD (2-methyl-3-hydroxybutyryl-CoA dehydrogenase), HSD10 catalyses 
the NADH-dependent oxidation of 2-methyl-3-hydroxybutyryl-CoA, an intermediate 
product of the isoleucine metabolism, to 2-methyl-acetoacetyl-CoA (Luo et al, 1995; 
fig. 2). The degradation of branched chain amino acids like isoleucine primarily takes 
place in organs like kidneys, skeletal and heart muscle. β-oxidation is also a source of 
ketone bodies that can provide energy for the brain if glucose levels are low (Eaton et al, 
1996; Rinaldo et al, 2002). Although HSD10 does not play an essential role in ketone 
metabolism under physiological conditions, Yan et al, 2000a and 2005, suggest that it 
can assist the mitochondrial β-hydroxybutyrat-dehydrogenase, which is normally 
responsible for the oxidation of β-hydroxybutyrat, in cellular stress situations. 
HSD10 deficiency clinically manifests in an accumulation of the metabolites 2-methyl-3-
hydroxybutyryl-CoA and tiglylglycin in urinary organic acid assays. So far it is not known 
to what extent the other enzymatic functions of HSD10 play a role in human metabolism. 
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Figure 2 HSD10 in the β-oxidation of short chain methylated acyl-CoAs (adapted from 
Zschocke et al, 2000). The essential amino acid isoleucine becomes metabolised in several steps 
which are catalysed by different enzymes, one of them being HSD10. End products are acetyl-CoA 
and propionyl-CoA which are important initial substances for other metabolic pathways that are 
involved in the generation of cellular energy. 
INTRODUCTION 
 
 
6 
3.3. HSD10 in steroid metabolism  
HSD10 has been suggested to play a role in sex steroid hormone metabolism as well as 
in the metabolism and synthesis of neuroactive steroids.  
In the former function it is relevant for the biosynthesis and inactivation of steroid 
hormones (Yang et al, 2005b) like androgen, estrogen and progesterone. More 
specifically, it oxidises 17β-estradiol to estrone and thereby inactivates it in the placenta 
and ovaries (He et al, 1999; He et al, 2000a) and probably in testis (Ivell et al, 2003). 
HSD10 is abundantly expressed in Leydig cells which might protect these cells from the 
effect of estrogens. Furthermore, it oxidises 3-α-adiol to the physiologically active 
androgen 5α-dihydrotestosteron in vitro (He et al, 2000a; He et al, 2001; He et al, 
2003). 
It has been proposed that HSD10 exerts its role in neuroactive steroid metabolism in the 
brain e.g. by catalysing the oxidation of allopregnanolone to 5α-DHP (5α-
dihydroprogesterone) and of 3α,5α-THDOC (3α,5α- allotetrahydrodeoxycorticosterone) to 
DHDOC (5α-dihydrodeoxycorticosterone; fig. 3). Allopregnanolone and 3α,5α-THDOC 
increase receptor opening frequency and duration and thus are positive modulators of 
GABAA receptors (gamma-aminobutyric acid type A receptors, Lambert & Grover, 1995), 
that become inactivated by HSD10 in vitro. Therefore, the level of these neurosteroids in 
the brain influences neuronal excitability and HSD10 plays a role in the maintenance of 
normal function of GABAergic neurons (He et al, 2005a; He et al, 2005b). In addition, 
5α-DHP can modulate gene expression. 
 
Figure 3 Reactions catalysed by HSD10 in steroid metabolism (modified from Yang et al, 
2007). 17β-estradiol and allopregnanolone are inactivated irreversibly with the concomitant 
reduction of NAD+. 
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3.4. HSD10 deficiency in humans 
Missense mutations in the HSD17B10 gene cause a congenital neurodegenerative disease 
called HSD10 deficiency (Zschocke et al, 2000; Ensenauer et al, 2002; Olpin et al, 2002). 
Biochemically HSD10 deficiency manifests in the accumulation of the metabolites 2-
methyl-3-hydroxybutyryl-CoA and tiglylglycin in urinary organic acid assays.  
HSD17B10 is located on the X-chromosome and although it has been reported to escape 
X-inactivation recent publications indicate that it becomes normally X-inactivated 
(Garcia-Villoria et al, 2010). Boys suffer from a more severe progressive clinical disease 
course than girls (Ofman et al, 2003; Ensenauer et al, 2002). Heterozygous girls show a 
variety of non-progressive symptoms ranging from normal cognitive function to 
psychomotor retardation (Ensenauer et al, 2002; Perez-Cerda et al, 2005; Garcia-Villoria 
et al, 2009). 
HSD10 deficiency has been identified in 15 patients (12 male) from 12 families so far 
(Ensenauer et al, 2002; Olpin et al, 2002; Sutton et al, 2003; Poll-The et al, 2004; Sass 
Sass et al, 2004; Perez-Cerda et al, 2005). The following missense mutations (table 1) 
have been found to be the underlying disease cause: 
 
 
mutation 
 
amino acid exchange 
c.257A>G D86G 
c.364C>G L122V 
c.388C>T R130C 
c.495A>C Q165H 
c.628C>T P210S 
c.740A>G N247S 
c.745G>C E249Q 
Table 1 Mutations causing HSD10 deficiency.  
 
In order to gain insight into the pathogenesis of neurodegeneration in HSD10 deficiency 
and to obtain further information on the biological role of HSD10, three of these 
mutations that cause significantly distinguishable clinical pictures were investigated. The 
R130C mutation causes the classical disease presentation; the D86G mutation is 
associated with a very severe clinical phenotype and patients with the Q165H mutation 
display normal neurological development. Patients usually develop clinical symptoms 
after times of increased metabolic stress like infections or vaccinations. 
Boys with the R130C mutation usually show a progressive neurodegenerative disease 
course starting from year 1 or 2 that can lead to death within few years. Besides the 
progressive loss of motor and mental skills including a progressive loss of sight, the 
patients often develop epilepsy that is difficult to treat (Zschocke et al, 2000; Poll-The et 
al, 2004; Sass et al, 2004; Ensenauer et al, 2002; Olpin et al, 2002; Sutton et al, 2003 
and Ofman et al, 2003). 
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A recently described male patient with the D86G mutation showed severe neurological 
abnormalities and little psychomotor development in the first months of life 
(Rauschenberger et al, 2010). At the age of 6 months the patient showed truncal 
hypotonia with increased muscle tone of arms and legs, gross motor dyskinesia and 
athetosis, smacking of the lips, absent head control and a horizontal nystagmus with 
absence of focusing. Clinical chemical studies revealed intermittently elevated lactate up 
to 5 mM (norm < 2.1) with increased lactate/pyruvate ratios compatible with a 
disturbance in oxidative phosphorylation. HSD10 activity in fibroblasts was only partially 
reduced to 30-70 % of normal (0.72 nmol/min/mg protein, norm 1.04±0.50 and 
2.8 nmol/min/mg protein, norm 7.3±1.2). Repeated electroencephalography was normal 
despite several epileptic seizures in the last month of life. Magnetic resonance 
tomography of the brain yielded no abnormality. Echocardiography revealed a 
progressive hypertrophic cardiomyopathy. Cardiac function and cardiomegaly 
deteriorated rapidly and the boy died at age 7 months of progressive heart failure.  
The Q165H mutation was identified in three boys (brothers and cousin) of one family. 
One child has been entirely normal from birth onwards, whereas in another boy early 
infancy was marked by poor feeding and failure to gain weight necessitating investigation 
aged 8 months. In all three boys a urine organic acid screen revealed metabolites 
ascribed to 2-methyl-3-hydroxy-butyryl-CoA dehydrogenase deficiency. Enzyme studies 
identified a profoundly low HSD10 activity of 0.2 nmol/min/mg (norm 7.3±1.2). 
Cognitive and motor development has been entirely normal up to the present age of 9 
years. Magnetic resonance imaging confirmed normal brain structure and 
echocardiography was unremarkable. 
 
Clinical and enzymatic findings in patients with HSD10 deficiency indicated that 
symptoms are not due to the accumulation of toxic metabolites in the isoleucine 
pathway. A deficiency of the enzyme catalysing the last step in the breakdown of 
isoleucine (3-ketothiolase) causes the same metabolites in urinary organic acid assays 
but a very different clinical picture not including progressive neurodegeneration but 
rather the classical symptoms of an organic aciduria. Also, an isoleucine restrictive diet, 
that avoids the accumulation of potentially toxic metabolites failed to improve the 
condition of patients. 
Observations in these patients indicated that the development and severity of symptoms 
is unusual for an organic aciduria and unrelated to residual enzyme activity but the 
pathogenetic basis of HSD10 deficiency had so far remained elusive. 
In order to characterise the mutations found in patients, they were cloned and expressed 
in bacteria. Recombinant proteins were purified and used to determine the 3D structure 
of HSD10 as well as kinetic constants with different substrates (fig. 4). 
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Residual dehydrogenase activities of 64 % and 28 % were measured for mutations 
R130C and D86G, respectively, which both cause a severe phenotype in patients. 
However, mutation R130C was unstable at room temperature and steadily lost enzymatic 
activity (fig. 4C). This mutation might interfere with the oligomerization of the HSD10 
tetramer (Kissinger et al, 2004) and thus influence its stability. Cofactor binding of NAD+ 
or NADH, as reflected by increased thermal stability (fig. 4D), was observed for both, 
wildtype and D86G. In contrast, mutation Q165H located at the active centre of the 
enzyme showed neither residual activity nor cofactor binding in our experimental 
settings. Inability of the mutation Q165H to bind the cofactor indicates that regardless of 
the substrate, no enzymatic reaction requiring NADH or NAD+ (all known reactions) will 
be sufficiently catalysed by this mutant protein. Surprisingly, this mutation was found in 
patients with normal neurological development. 
Figure 4 Crystal structure, stability and activity of the HSD10 homotetramer from 
HSD10 patients (adapted from Rauschenberger et al, 2010). (A, B) Crystal structure of HSD10. 
(A) Diagram of the homotetramer with bound cofactors to each monomer. (B) Diagram of a 
dimer with the location of the mutations. The location of the active centre is marked by the 
substrate in red. (C) Enzyme activity of HSD10 over time. Kcat/KM of HSD10 wildtype and 
mutations measured in a 30 min interval; substrate 2-methyl-3-hydroxybutyryl-CoA. (D) Stability 
of HSD10 wildtype and mutations. Mean value of Tm determined by DSF (differential scanning 
fluorimetry)-experiments and standard deviation are shown. Black column: no cofactor/substrate, 
gray column: cofactor NAD+, white column: cofactor NADH (* indicates significant cofactor 
binding). (E) Enzyme activity of HSD10 with hydroxybutyryl-CoA as substrate (wildtype enzyme 
is taken as 100 %). (F) Kcat/KM of HSD10 mutations with 2-methyl-3-hydroxybutyryl-CoA as 
substrate in relativity to the wildtype enzyme. KM: Michaelis-Menten-constant, Kcat: turnover 
number.  
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The lack of correlation between residual enzyme activity and disease severity indicates 
that the pathogenesis of HSD10 deficiency is mediated by an as yet unknown non-
dehydrogenase function of HSD10. 
 
3.5. Implication of HSD10 in Parkinson’s, Alzheimer’s and other clinical 
symptoms 
HSD10 has been suggested to be involved in several other clinical conditions apart from 
HSD10 deficiency, like mental retardation, cancer, Parkinson’s and Alzheimer’s. 
An apparently silent mutation in the HSD17B10 gene that affects splicing efficiency has 
been linked to mental retardation, choreoathetosis and abnormal behaviour (Reyniers et 
al, 1999; Lenski et al, 2007). This mutation reduces the amount of HSD10 protein and 
shifts the ratio of alternatively spliced transcripts. Microduplications of HSD17B10 and the 
resulting increase in protein level have also been found to be associated with mental 
retardation (Froyen et al, 2008).  
Moreover, HSD10 seems to play a role in some forms of cancer. It has been suggested 
that a high level of HSD10 might be protective against gynecological cancers (Yang et al, 
2005b) but on the other hand there is also evidence that malignant prostatic epithelial 
cells have elevated HSD10 levels which might promote cancer growth (He et al, 2003). 
Furthermore, Tieu et al, 2004, found a reduced level of HSD10 in dopaminergic neurons 
of Parkinson’s patients. Parkinson’s is a neurodegenerative disease that is accompanied 
by the loss of dopaminergic neurons in the substantia nigra pars compacta. Complex I 
activity of the respiratory chain is impaired in brains of Parkinson’s patients (Dauer & 
Przedborski, 2003). This leads to a disturbance in energy generation and necessitates the 
usage of alternative energy sources like ketone bodies and D-β-hydroxybutyrat 
(Kashiwaya et al, 2000; Tieu et al, 2003). A mouse model of Parkinson’s has been 
established using the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin), 
which blocks complex I (Nicklas et al, 1987) and reproduces typical symptoms of 
Parkinson’s in mice (Langston et al, 1983) including the downregulation of HSD10 (Tieu 
et al, 2004). In this mouse model, Tieu et al. found that a simultaneous overexpression 
of HSD10 has a protective effect on neurons regarding the mitochondrial inhibition 
caused by MPTP. HSD10 improves mitochondrial respiration and ATP production by 
complex I. In addition, they showed by subcellular fractionation that HSD10 is re-
distributed from the mitochondrial matrix to the membrane under oxidative stress caused 
by inhibition of complex I.  
One of the names HSD10 has been given due to its history of identification is ABAD 
(amyloid β-peptide-binding alcohol dehydrogenase). HSD10 was detected in a yeast-2-
hybrid screen as one of the binding partners of amyloid β, a neurotoxic peptide 
implicated in Alzheimer’s (Yan et al, 1997). Alzheimer’s is characterised by dementia due 
to progressive nerve cell death in the brain. Aberrant amyloid β production and its 
deposition in so-called senile plaques plays an important but not yet fully understood role 
in the pathomechanism of Alzheimer’s. 
Binding of amyloid β abolishes the enzyme activity of HSD10 since it blocks its cofactor 
binding site (Yan et al, 1999; Oppermann et al, 1999; Lustbader et al, 2004; Kissinger et 
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al, 2004). It also leads to the production of lipid peroxidating aldehydes like 
hydroxynonenal and malondialdehyd in vivo (Yan et al, 1999). Lipid peroxidation has 
later been shown not to be the reason for amyloid β induced cell death in neurons of 
Alzheimer’s patients (Salim et al, 2000). HSD10 and amyloid β interact directly in 
neuronal mitochondria of Alzheimer’s patients as well as in mice double transgenic for 
HSD10 and a mutant form of human APP (Tg mAPP/ABAD; Lustbader et al, 2004). 
Affected brain regions in Alzheimer’s patients express elevated levels of HSD10 (Yan et 
al, 1997; Yan et al, 2000a; Yang & He, 2001; Lustbader et al, 2004; He et al, 2005b). 
Co-transfection of HSD10 and amyloid β in cultured cells results in an increase in 
cytotoxicity, more specifically in apoptosis, that cannot be seen with HSD10 or amyloid β 
alone (Yan et al, 1999). 
There is evidence that the energy metabolism in the brains of Alzheimer’s patients is 
disturbed. Complex IV activity is diminished in the central and peripheral nervous system 
(Kish et al, 1992; Mutisya et al, 1994; Parker et al, 1994; Maurer et al, 2000; Bosetti et 
al, 2002). In mice transgenic for HSD10 and a mutant form of human APP 
(Tg mAPP/ABAD) it was shown that complex IV activity in neurons and the cerebral 
glucose metabolism are decreased (Yan et al, 1999; Yan & Stern, 2005; Takuma et al, 
2005). In addition, elevated levels of free radicals and hydrogen peroxide were found in 
these neurons. A caspase-3-like activity as well as cytochrome c release and DNA 
fragmentation were strongly increased in neurons from Tg mAPP/ABAD mice leading to a 
significant decrease in cell viability. These double transgenic mice are phenotypically 
unremarkable but they display a reduced learning ability (Lustbader et al, 2004; Takuma 
et al, 2005). 
Amyloid β seems to act on mitochondria since it has been shown to cause increased 
permeability of the outer mitochondrial membrane induced by pro-apoptotic Bax and 
subsequently mitochondrial swelling and caspase activation (Giovanni et al, 2000; Zhang 
et al, 2002). Thus, Alzheimer’s appears to be associated with a mitochondrial dysfunction 
which may be mediated by the interaction of amyloid β and HSD10 leading to oxidative 
stress and apoptotic cell death. 
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3.6. HSD10 – cytoprotective or cytotoxic?  
The expression and localisation of HSD10 is dependent on cellular stress. HSD10 
expression is upregulated in stress situations like hypoxia-ischemia, nutritional stress and 
the presence of amyloid plaques (Yan et al, 2000a; Yan et al, 2000b; Yan & Stern, 
2005). Under normal physiological conditions HSD10 is localised in the mitochondrial 
matrix and is re-distributed to the membrane under stress (Tieu et al, 2004).  
On one hand, a cytotoxic role in Alzheimer’s was implied for HSD10 as it appears to 
mediate the cytotoxic effect of amyloid β (Yan et al, 1997). 
On the other hand, a protective effect of overexpressed HSD10 under conditions of 
oxidative stress was found in the setting of acute brain damage (Yan et al, 2000a) and in 
a mouse model of Parkinson’s (Tieu et al, 2004). In addition, HSD10 can maintain 
cellular energy homeostasis by oxidising ketone bodies to D-3-hydroxybutyrate in 
nutritional stress situations (Yan et al, 2000a; Yan et al, 2000b). Overexpressed HSD10 
also had a protective effect on neurons in mice after strokes induced by transient middle 
cerebral artery occlusion. These publications do not present any functional data that 
would suggest a mechanism for the protective function of HSD10. 
Furthermore, an anti-apoptotic function was suggested for HSD10 in mitochondria. 
HSD10 binds CypD (cyclophilin D; Ren, 2008), a peptidylprolyl isomerase F localised in 
the mitochondrial matrix that is recruited to the inner membrane under oxidative stress 
in order to form the MPTP (mitochondrial permeability transition pore; Connern & 
Halestrap, 1994). Addition of cyclosporin A, an immune suppressor, inhibits the 
formation of the MPTP. It binds to CypD and thereby blocks its participation in pore 
formation. Binding of HSD10 and CypD in the mitochondrial matrix might have the same 
effect as cyclosporin A and inhibit the translocation of CypD and thus the formation of the 
MPTP (fig. 5). Therefore, HSD10 might have a protective, anti-apoptotic function in the 
mitochondrial matrix (Yan & Stern, 2005). 
 
Figure 5 Constitution of the MPTP and its 
inhibition by the interaction between CypD 
and HSD10 (adapted from Szewczyk & Wojtczak, 
2002). CypD is a protein of the mitochondrial 
matrix that can translocate to the membrane 
where it is one of the components of the MPTP 
(mitochondrial permeability transition pore). 
Binding of HSD10 and CypD in the mitochondrial 
matrix might block the function of CypD in the 
initiation of apoptosis. VDAC: voltage dependent 
anion channel, ANT: adenine nucleotide 
transporter. 
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3.7. Intrinsic and extrinsic regulation of apoptosis 
The progressive neurodegeneration observed in HSD10 deficiency seems to be associated 
with apoptotic cell death caused or accompanied by mitochondrial dysfunction. 
Apoptosis is controlled by many different signals. These signals can either originate 
extracellularly as extrinsic inducers like hormones or the lack of growth factors, or they 
can arise intracellularly triggered by intrinsic factors like any disturbance of cellular 
homeostasis e.g. a high concentration of intracellular calcium or anorganic phosphate, 
DNA damage or oxidative stress accompanied by high levels of ROS (reactive oxygen 
species; Strasser et al, 1995). In addition, lack of adenine nucleotides and an alkaline pH 
lead to apoptosis.  
Extrinsic and intrinsic inducers can act pro- or anti-apoptotic. Despite of their diverse 
origin these signals eventually activate a common cell death machinery. Once a certain 
threshold is crossed apoptotic cells develop characteristic features like chromatin 
condensation and margination at the nuclear membrane, cell shrinkage and detachment, 
blebbing of the plasma membrane, cleavage of DNA and finally the fragmentation of the 
cell into so-called apoptotic bodies. 
The extrinsic apoptotic pathway is mediated by death receptors of the TNFR (tumour 
necrosis factor receptor) family (fig. 6). Those receptors consist of an extracellular ligand 
binding domain and an intracellular death domain (Banner et al, 1993; Smith et al, 1994; 
Krammer, 2000). Ligand binding causes trimerization of the TNFR and the binding of 
death proteins to the intracellular death domain. Adaptor molecules like FADD (Fas 
associated death domain protein) link the transmembrane receptor to caspase-8 and 
thereby activate it. This sets the caspase cascade in motion that executes the irreversible 
morphological changes of apoptosis in the cell. Caspases are pro-apoptotic mediators 
that exist in an inactive precursor form and are activated in a caspase cascade by 
proteolytical cleavage. There are initiator caspases including procaspases-2, -8, -9 and   
-10 and executioner caspases including procaspases-3, -6, and -7. The initiator caspase-
8 is specifically activated via the extrinsic pathway and activates the executioner 
procaspase-3 (Peter & Krammer, 2003). 
Mitochondria play an important role in apoptosis (fig. 6) since they can intrinsically 
induce apoptosis (Orrenius, 2004). Mitochondria of an apoptotic cell swell due to MMP 
(mitochondrial membrane permeabilization) including the formation of membrane pores 
like MACs (mitochondrial apoptosis-induced channels) or MPTPs (mitochondrial 
permeability transition pores). This latter pore forms in the inner and outer membrane 
and consists of an ANT (adenine nucleotide transporter) in the inner membrane and a 
VDAC (voltage dependent anion channel) in the outer membrane (fig. 5; Zoratti & Szabo, 
1995; Halestrap & Brenner, 2003). Another component of the MPTP is Bax, a pro-
apoptotic molecule of the Bcl-2 family. It is a cytosolic protein that binds to the VDAC in 
response to apoptotic signals. Binding of CypD (cyclophilin D) to ANT facilitates a calcium 
induced conformational change in the specific adenine nucleotide transporter to an 
unspecific pore. Formation of the MPTP makes the membrane permeable and causes 
mitochondrial swelling supported either by additional channels in the outer membrane 
formed by members of the Bcl family (Bax, Bad, Bak, Bid) or by disintegration of the 
outer membrane (Gross et al, 1999). Additionally, the mitochondrial membrane potential 
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is disturbed and thus ATP production is impossible. Proteins of the intermembrane space 
like cytochrome c, AIF (apoptosis inducing factor) and Smac (second mitochondria-
derived activator of caspase) leak from mitochondria into the cytosol. Released 
cytochrome c binds Apaf-1 (apoptotic-protease-activating factor 1) which in turn 
proteolytically activates caspase-9 and thus initiates the caspase cascade. SMACs bind 
and thereby deactivate IAPs (inhibitors of apoptosis proteins) which normally suppress 
the activity of caspases. Procaspase-9 is specific for the intrinsic induction of apoptosis 
and both, procaspase-8 and -9, activate the executioner procaspase-3 (Green & 
Kroemer, 1998; Green, 1998; Green & Reed, 1998; Susin et al, 1999; Kroemer & Reed, 
2000; Green & Kroemer, 2004). AIF released from mitochondria enters the nucleus and 
mediates the condensation and fragmentation of DNA.  
 
 
Apoptosis is a strictly regulated process with several different mechanisms of regulation 
at the protein level. As described above, proteolytic cleavage activates caspases but also 
posttranslational modifications such as phosphorylation and the subcellular re-distribution 
of proteins like BAX and cytochrome c contribute to the regulation of apoptosis. On the 
other hand, apoptosis is also regulated transcriptionally through a number of 
transcription factors including p53, myc, NF-κB, FOXO, HOX and Snail (Bates & Vousden, 
1999; Gilley et al, 2003; Dudgeon, 2009). For example, apoptosis caused by cellular 
stress upon DNA damage is regulated by transcription factors of the p53 and AP-1 family. 
HOX and Snail proteins modulate developmental apoptosis and NF-κB and FOXO family 
members are regulators of apoptosis mediated by proinflammatory cytokines or growth 
factors. Additionally, members of the Bcl-2 family have been shown to be 
Figure 6 Overview of intrinsic and extrinsic induction of apoptosis (from Green, 1998). 
Both pathways converge on the activation of effector caspases (like caspase-3, -6 and -7) and the 
cleavage of key substrates like lamin and DNA.  
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transcriptionally regulated by the zinc finger protein WT1 (Loeb, 2006) and by p53 (Bates 
& Vousden, 1999). 
These transcription factors activate the expression of pro-apoptotic Bcl-2 family 
members, caspases, death receptors and their ligands and downregulate the 
transcription of the anti-apoptotic Bcl-2 family and IAPs (inhibitors of apoptosis proteins). 
Hence, the intrinsic apoptotic pathway is transcriptionally regulated via the pro- and anti-
apoptotic Bcl-2 family members and the extrinsic pathway by the means of death 
receptors and IAPs, respectively. 
 
3.8. HSD10 function in the model organisms Drosophila and mouse 
A complete knock-out of HSD10 is embryonic lethal in Drosophila as well as in mice 
(Rumig, 2006; Torroja et al, 1998).  
The homolog of HSD10 in Drosophila, Scully, exerts the same enzymatic functions as 
human HSD10 (Shafqat et al, 2003) but it is a cytosolic enzyme rather than 
mitochondrially localised. The N-terminal sequence of human HSD10 forms a positively 
charged amphiphilic α helix that can act as a mitochondrial localisation signal, but there 
might be at least one additional mitochondrial importing signal (He et al, 2001). 
Drosophila HSD10 is missing six of these amino acids at the N-terminus compared to 
human or Xenopus HSD10 which possibly causes the cytosolic distribution. The remaining 
protein sequence exhibits 69 % identity with the human sequence. A knock-down of 
HSD10 in Drosophila results in early embryonic lethality. Thus, four different mutations 
have been introduced by EMS (ethyl methanesulphonate) and x ray in Drosophila larvae 
(Torroja et al, 1998). Two of these (scu174 and scuS152) are point mutations that cause 
the amino acid exchanges L33Q and F120I in two well-conserved residues. One mutation 
(scu3127) is a 254 base pair deletion that introduces a frame shift after 86 amino acids 
and removes the catalytic centre. The fourth mutation (scu4058) is a deletion of two base 
pairs that results in a frame shift after 205 amino acids. The catalytic centre in this 
mutation is intact. All of these mutations are early embryonic lethal. Mutants with the 
scu3127 mutation are viable during embryonic development but die as third instar larvae. 
Scully is expressed at a very low level in unfertilized eggs and increases during 
embryonic development. Mature gonads show a particularly high expression of Scully. 
Mutant pupal testes are reduced in size whereat the degree of reduction is: scu174 > 
scu4058 > scuS152 > scu3127. In mosaic analysis, scu3127 again showed the mildest 
phenotype although this mutation introduces a large deletion with a frame shift after only 
86 amino acids and abolishes the catalytic centre. 
Cells in mutant flies exhibit large multilayered accumulations of membraneous material 
and a high amount of clear cytoplasmic vesicles of lipid nature. Nucleoli are not as 
compact as in control flies and contain many cavities. Mitochondria are fewer and smaller 
and comprise fewer and swollen cristae. Torroja et al. argued that these cellular changes 
are due to a defect in the β-oxidation of fatty acids like those observed in human 
pathologies (Torroja et al, 1998; Eaton et al, 1996; Torroja et al, 1998 Wanders et al, 
1999; Rinaldo et al, 2002). 
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Homozygous knock-out mice are not viable and die at a very early developmental stage 
(Rumig, 2006). To study the function of HSD10 in vivo several conditional knock-out 
lines have been established. 
The so-called ERAB/neo line is generated by crossing animals that still contain the 
neomycin resistance gene in the 5’ UTR together with exon 1 of HSD10 within the loxP 
sites with Cre deleter mice. It has been shown before that the insertion of a neomycin 
resistance gene in introns may cause the disruption of normal gene expression. This 
crossing yields males with a decreased HSD10 expression in all organs except the spleen. 
These animals are phenotypically unremarkable until the age of 11-14 weeks when they 
start to develop physical changes like a scrubby fur and a progressive movement 
disorder that results in complete immobilisation and breathing difficulties. They die or are 
dispatched between week 15-24. Internally those animals display a highly enlarged 
bladder and abnormal bleeding in the gut. Bloodflow is decreased and bleeding through 
the tail vein is not possible. The lymph nodes, thymus and most of all the spleen are 
reduced in size but not altered in their structure. Only the testes are remarkably changed 
and have a highly decreased number of mature spermatids that probably causes the 
observed subfertility of these male mice. Spleen, kidneys, bowel, testes, liver, thymus 
and the cerebrum show highly increased levels of apoptosis. Symptoms in these 
ERAB/neo mice are distantly comparable to the clinical phenotype observed in HSD10 
deficiency patients. Therefore, the urinary organic acids were tested for metabolites 
indicative of a disturbed isoleucine metabolism but no elevated organic acids were 
detected. 
A conditional knock-out in endothelial cells and hematopoetic stem cells was generated 
by the Cre recombinase under the control of the Tie2 promoter. Tie2 is a receptor 
tyrosine kinase expressed predominantly in vascular endothelium. Those ERAB/Tie2 
animals exhibit almost the same phenotype as the ERAB/neo line but the onset of 
symptoms does not take place until week 20-22 and those animals deteriorate faster. In 
addition, they suffer from convulsions and die or are put to death around week 26. 
Heterozygous as well as homozygous females are unremarkable. 
An additional conditional knock-out was established in T-cells by a Cre recombinase 
under the control of the Ick promoter. The resulting homozygous ERAB/Ick males and 
females are phenotypically unremarkable and fertile but show an increased thymus cell 
number. Thymus cells were used to investigate apoptosis in vivo in a HSD10 knock-out 
situation. Either the intrinsic or the extrinsic apoptotic pathway was induced chemically in 
these cells and HSD10 knock-out thymus cells were much more sensitive to the intrinsic 
induction of apoptosis than control cells. Thus, HSD10 had a protective effect on 
mitochondrially mediated apoptosis in thymus cells. 
Another conditional knock-out in noradrenergic neurons was generated with a Cre 
recombinase under the control of the DBH promoter (dopamine β-hydroxylase). These 
mice are viable and fertile but die around week 26. 
 
INTRODUCTION 
 
 
17 
3.9. HSD10 in the development of Xenopus laevis 
The clinical phenotype observed in patients and the respective residual enzyme activity of 
mutant HSD10 suggests a dehydrogenase-independent function in embryonic 
development for HSD10 corroborated by the early embryonic lethality in the knock-out 
mouse (Rumig, 2006) and Drosophila (Torroja et al, 1998). 
One of the best model organisms for developmental studies is Xenopus laevis. Eggs can 
be easily manipulated and selective targeting of manipulation is possible in Xenopus 
embryos because the dorsal/ventral and the left/right axes can be determined already at 
the 4-cell stage due to pigmentation differences of the animal blastomeres in so-called 
“Kleins”. Fate maps are available (Bauer et al, 1994) that enable the tracing of each 
blastomere in the early embryo to the adult frog. Thus, a very localised and exclusive 
manipulation of distinct body regions is possible.  
In Xenopus a complete knock-out of HSD10 is not embryonic lethal in contrast to mice 
and Drosophila since HSD10 is also provided maternally and the Morpholino 
oligonucleotide-mediated knock-down is only carried out in specific regions of the body. 
Zygotic transcription of Xenopus HSD10 (NCBI Locus BC077977) starts at neurula stages 
and takes place in ventral parts of the somites, the neural tube, the pronephros and the 
eyes (Rauschenberger et al, 2010). 
Knock-down of HSD10 leads to a reduction of brain tissue and eyes that does not affect 
the a/p (anterior/posterior) patterning of the brain shown by the spatial expression 
patterns of the forebrain marker BF1 and the fore-/midbrain marker otx2 
(Rauschenberger, 2007). Apoptosis was enhanced in injected tissue. The phenotype 
caused by HSD10 knock-down as well as the elevated level of apoptosis can be rescued 
by human HSD10 wildtype protein. The mutated HSD10 proteins found in human 
patients, however, showed remarkable differences in their ability to rescue the apoptotic 
phenotype. The Q165H mutation, which has less than 3 % residual enzymatic activity but 
was identified in three neurologically normal boys, partially rescued HSD10 MoATG-
induced apoptosis. In contrast, injection of the mutations R130C and in particular D86G 
failed to rescue, and instead further enhanced apoptosis. D86G has considerable residual 
enzyme activity despite being associated with a very severe clinical phenotype. The 
inability of the R130C and D86G mutants to rescue apoptosis was not due to protein mis-
localisation. In Xenopus A6 cells wildtype and all mutated proteins co-localised with 
mitochondria. Thus, apoptosis after HSD10 loss-of-function is not dependent on the 
dehydrogenase activity of HSD10, arguing for a non-enzymatic function of this protein 
which is required in mitochondria. 
Furthermore, a knock-down of HSD10 in Xenopus leads to a severe reduction in blood 
vessel formation (Rauschenberger, 2007; Guerra, 2010). 
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3.10. Interaction partners of HSD10 
As described above HSD10 can bind to amyloid β in vitro and in vivo in brains of 
Alzheimer’s patients.  
Also mentioned above, is the physical interaction between HSD10 and CypD 
(cyclophilin D) in the mitochondrial matrix (Ren, 2008) that might prevent CypD from 
translocation to the membrane and formation of the MPTP. 
In addition, HSD10 binds to the estrogen receptor α which is not only present in the 
nucleus and cytosol but also in mitochondria (Jazbutyte et al, 2009). The mitochondrial 
genome contains ERE (estrogen response elements) that are regulated by the ligand-
receptor-complex and they postulate that the estrogen receptor α plays a role in the 
regulation of estrogen levels by modulating HSD10 activity. Estrogen is essential for 
cellular integrity since it reduces oxidative stress and this maintains mitochondrial 
structure and function and inhibits apoptosis. 
In a yeast-2-hybrid screen, where HSD10 was used as bait and a HeLa cDNA library as 
prey, two potential interaction partners were identified: PCBP1 and UXT (unpublished 
data). PCBP1 (PolyC binding protein 1) binds to mRNAs that contain a DICE 
(differentiation control element) in the cytoplasm and thereby represses their translation, 
e.g. the endogenous L1 cell adhesion molecule mRNA, which contains two DICE motifs in 
the 3′ untranslated region. Upon phosphorylation it releases the mRNAs for translation 
and migrates to the nucleus where it is a transcription factor for target genes like eIF4E 
(eukaryotic translation initiation factor 4E; Lynch et al, 2005) and GDF15 (growth 
differentiation factor 15; Huo et al, 2009). It also binds caper-α and plays a role in 
splicing. UXT (ubiquitously expressed transcript) is implicated in several cellular 
functions. One of them is the promotion of the NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells) enhanceosome in the nucleus and as such it plays a role in 
mitochondrial aggregation and apoptosis. 
Moreover, HSD10 functions in a complex called RNaseP which is involved in the 
processing of human mitochondrial tRNAs (Holzmann et al, 2008). 
 
3.11. HSD10 as a component of human mitochondrial RNaseP 
Mitochondria contain their own circular genome (Nass & Nass, 1963a; Nass & Nass, 
1963b) in 2-10 copies per mitochondrion (Wiesner et al, 1992) and consequently in 100-
10000 copies per cell depending on the cell type. mtDNA is inherited uniparentally from 
the mother in most organisms. It is particularly vulnerable to oxidative damage due to its 
vicinity to the respiratory chain that generates ROS and this leads to a rapid mutation 
rate of mtDNA (Brown et al, 1979). In humans the double stranded mtDNA consists of 
around 16.6 kb. The so-called heavy strand (H-strand) contains more guanine than the 
cytosine rich strand called light strand (L-strand). In total, 13 proteins of the respiratory 
chain are encoded in mitochondria but the majority of mitochondrial proteins is coded for 
by nuclear DNA and imported (Shoffner, 1995; Neupert, 1997). In addition, 22 tRNAs 
(transfer RNAs) and two rRNAs (ribosomal RNAs) are mitochondrially encoded. mtDNA 
has no introns and no non-coding sequences between the genes (Anderson et al, 1981; 
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Wallace et al, 1992; Zeviani et al, 1998). The displacement loop (D-loop) is the only non-
coding section of the mitochondrial genome and encloses the origin of replication of the 
H-strand (OH) and the promoters for L- and H-strand transcription (PL and PH ; fig. 7). 
Replication starts at the OH and continues until it reaches the OL that folds a stem-loop 
structure and initiates replication of the L-strand that proceeds back using the H-strand 
as a template. This makes mtDNA replication a bi-directional and asynchronous process 
(Clayton, 1982). Transcription of mtDNA starts from both promoters, proceeds along the 
mtDNA circle and creates a long polycistronic RNA. By cutting out interjacent tRNAs from 
the polycistronic transcript according to the “tRNA punctuation model of RNA processing 
in human mitochondria” rRNAs and mRNAs are liberated, polyadenylated and 
subsequently translated (Ojala et al, 1980; Ojala et al, 1981). The genetic code in human 
mitochondria is different from the one in the nucleus (Wallace, 1982), e.g. AUA codes for 
methionine and not isoleucine (Anderson et al, 1981; Montoya et al, 1981). 
 
Mitochondrial tRNAs are transcribed as immature precursors in long polycistronic 
transcripts, in which they fold into their secondary structure (fig. 8). They are excised at 
the 3’ end by tRNaseZ and the 5’ end by an enzyme complex called RNaseP (ribonuclease 
P; Robertson et al, 1972). Cleavage by RNaseP precedes 3’ end maturation by RNaseZ in 
many systems including human mitochondria (Levinger et al, 2001; Levinger et al, 
2004). Once the tRNAs are cut from the polycistronic transcript they are post-
transcriptionally modified e.g. by methylation and the addition of CAA at the 3’ terminus. 
Figure 7 Circular and double stranded human 
mitochondrial DNA (modified from Holland & 
Huffine, 2001). It encodes 13 proteins of the 
respiratory chain, 2 rRNAs and 22 tRNAs. The 
abbreviated amino acid names show the position of 
the respective tRNA genes. The replication origins 
of the outer heavy and inner light strand are 
indicated with OH and OL, respectively. PH and PL 
are the transcription initiation sites. ND: NADH 
dehydrogenase, CO: cytochrome c oxidase. 
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Recently, HSD10 has been shown to be a component of the human mitochondrial RNaseP 
complex (Holzmann et al, 2008). Until the components of this complex were identified, 
all RNaseP enzymes that have been characterised so far in various species consisted of a 
RNA moiety plus one or more proteins (reviewed in Hartmann & Hartmann, 2003; 
Willkomm & Hartmann, 2007). The RNAs have a similar core structure and seem to be 
capable of mediating cleavage of the 5’ leader sequence of tRNAs even in the absence of 
protein (Guerrier-Takada et al, 1983). Thus, tRNA 5’ maturation in addition to ribosomal 
protein synthesis was considered to be the only cellular process catalysed by a ribozyme 
universally persistent since the hypothetical prebiotic RNA world. In contrast, RNaseP 
from human mitochondria (mtRNaseP) has been shown to be a RNA free, protein-only 
enzyme (Holzmann et al, 2008). Its components were identified from mitochondrial 
extract in five different two-step purification procedures. RNaseP was partially purified in 
these preparations and the protein composition of the different purifications was 
compared for proteins they have in common and yielded the “partial purification overlap 
proteome”. These analyses rendered three proteins that functionally reconstituted 
mtRNaseP in vitro without any RNA contribution: MRPP1, MRPP2 (HSD10) and MRPP3 
(mitochondrial Ribonuclease P proteins 1-3). 
Excision of mitochondrial tRNAs at the 3’ and 5’ end from the long polycistronic transcript 
and subsequent modification, the addition of CAA at the 3’ terminus and 
aminoacetylation yields mature tRNAs. Classical tRNAs fold into a cloverleaf secondary 
structure and a L-shaped tertiary structure whereas human mitochondrial tRNAs can 
deviate structurally from this cloverleaf (Helm et al, 2000; fig. 9). The classical cloverleaf 
tRNAs like human mitochondrial tRNAV, tRNAI and tRNAM consist of a very conserved 
number of nucleotides in their respective domains (Sprinzl et al, 1998). 
Figure 8 Schematic presentation of mitochondrial tRNA processing (modified from Hurto, 
2011). Mitochondrial tRNAs are cleaved from the long polycistronic transcript first at the 3’ end by 
RNaseZ followed by an incision at the 5’ end by RNaseP. Arrows mark the cleavage position. 
According to the “tRNA punctuation model of RNA processing in human mitochondria” the excision 
of interjacent tRNAs (e.g. tRNAM and tRNAA) yields mature rRNAs and mRNAs (e.g. ND1, ND2 and 
COX1). ND1 and ND2: NADH dehydrogenase subunit 1 and 2, COX1: cytochrome c oxidase 
subunit 1.  
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Possible variations include the absence of the entire D-loop and an extended anticodon 
stem in tRNAS or absent nucleotides that are highly conserved in classical tRNAs 
suggesting that the formation of the tertiary L-shape does not occur (fig. 9).  
 
Mutations in mitochondrial tRNAs cause a disturbance of mitochondrial translation that 
elicits many different clinical syndromes including MERRF (myoclonic epilepsy and ragged 
red muscle fibers; Finnila et al, 2001), mitochondrial myopathy (Swalwell et al, 2006), 
CPEO (chronic progressive external ophtalmoplegia; Spagnolo et al, 2001), progressive 
respiratory failure (Bruno et al, 2003), MELAS (mitochondrial encephalomyopathy, lactis 
acidose, stroke-like episodes; Tzen et al, 2003) and ADPD (Alzheimer's disease and 
Parkinson's disease; Wallace et al, 1992). 
Mutation of one of the components of RNaseP inhibits the correct processing of 
polycistronic mitochondrial transcripts and thereby also disrupts mitochondrial 
translation. Therefore, the function of HSD10 in mitochondrial tRNA processing might be 
the underlying reason for the clinical phenotype in HSD10 deficiency patients. 
Figure 9 Structure of human mitochondrial tRNAs (from http://mamit-trna.u-strasbg.fr/ 
mutations.asp?idAA=22). (A) Classical cloverleaf tRNAV. Classical tRNAs consist of an acceptor 
stem (7 bp), connector (2 nt), D-stem and -loop (variable, 3-4 bp and 8-10 nt), second connector 
(1 nt), anticodon stem (5 bp), anticodon loop (7 nt), variable region, T-stem and -loop (variable, 
typically 5 bp and 7 nt). (B) Structurally different tRNAS. This tRNA with an absent D-loop is the 
most extreme example of deviate tRNA structures in human mitochondria. bp: base pairs, nt: 
nucleotides.  
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3.12. Purpose of this study 
HSD10 is implicated in two neurodegenerative disorders, Alzheimer’s and HSD10 
deficiency, but the pathogenetic basis has so far remained elusive. This study should 
contribute to understand the role of HSD10 for cellular integrity and also help to find the 
underlying cause for the clinical picture observed in HSD10 deficiency patients by 
characterising the different mutations. 
Several lines of evidence suggest that HSD10 has other functions in addition to the 
known enzymatic dehydrogenase activity. 
1. The clinical symptoms in HSD10 deficiency patients are not correlated with 
residual enzymatic dehydrogenase activity of mutated HSD10 and experiments in 
Xenopus embryos revealed that dehydrogenase activity of HSD10 was not 
required for cell survival (Rauschenberger et al, 2010).  
2. The symptoms observed in HSD10 deficiency patients rather resemble a 
mitochondriopathy (Finsterer, 2004) than an organic aciduria and are likely 
related to defects in general mitochondrial function.  
3. Recently it was demonstrated that HSD10 is a component of the human 
mitochondrial RNaseP which is essential for the processing of mitochondrial 
tRNAs. 
The aim of this work is to investigate the role of wildtype and mutated HSD10 in 
mitochondria under physiological and stress conditions. In order to elucidate the 
components and mechanisms that link HSD10 to mitochondrial function proteins which 
interact physically and functionally with HSD10 will be identified. 
Furthermore it will be tested whether impaired RNAseP function can be detected in 
patients carrying mutations in the HSD17B10 gene.  
Taken together, these experiments are designed to help to characterise the so far 
unknown non-dehydrogenase function that HSD10 obviously has in the maintenance of 
cellular integrity and that is impaired in HSD10 deficiency and maybe in other 
neurodegenerative diseases. 
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4 RESULTS 
4.1. Localisation and amount of HSD10 in human cells under various 
conditions 
To ensure that the phenotype observed in HSD10 deficiency patients is not simply due to 
mis-direction of intracellular protein transport or impaired mitochondrial localisation of 
mutated HSD10, patient fibroblasts and HEK293 cells were used to show the intracellular 
localisation under physiological and cellular stress conditions. Furthermore, the amount 
of mitochondria and HSD10 protein and mRNA in patient fibroblasts was determined to 
exclude differences in protein level or mitochondrial content as a cause for the observed 
disease phenotype. 
4.1.1. Mitochondrial localisation of HSD10 in HSD10 deficiency patient 
fibroblasts 
HSD10 contains a mitochondrial targeting signal at its N-terminus (He et al, 2001) and 
was shown to be localised in mitochondria in human cells (Yan et al, 1999) and Xenopus. 
Drosophila HSD10 has some differences in the N-terminal sequence and possibly 
therefore shows a cytosolic localisation pattern (Torroja et al, 1998). To investigate if the 
mutations interfere with the normal localisation pattern, HSD10 of patient fibroblasts was 
co-stained together with the mitochondrial marker porin (fig. 10). 
Figure 10 Localisation of HSD10 in HSD10 deficiency patient fibroblasts. Fibroblasts were 
cultivated on chamber slides and proteins were detected using mouse monoclonal anti-HSD10 
antibody (1:100) and rabbit polyclonal anti-porin (1:500). After incubation with secondary 
antibodies (anti-mouse Alexa 488, 1:500, and anti-rabbit Alexa 594, 1:1000) the cells were 
counterstained with DAPI nuclear stain and mounted in Fluorescence Mounting Media. Scale bars: 
10 µm. (A-C) Mitochondrial porin staining in control cells, R130C and Q165H. (A’-C’) HSD10 
staining in control cells, R130C and Q165H and merged images of both stainings (A’’-C’’). 
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Mitochondria form a dynamic reticular network throughout the cell which is regulated by 
frequent fission and fusion events (Okamoto & Shaw, 2005). The fluorescent signal of 
HSD10 and porin appears as a fibrous network within the cytosol (fig. 10; A-C and A’-C’). 
Merged images show clear co-localisation of the mitochondrial marker porin and HSD10 
in wildtype and mutant fibroblasts (fig. 10; A’’-C’’). A small fraction of HSD10 might not 
be mitochondrially localised but distributed in the cytosol. All proteins show a similar 
cellular distribution pattern. Since the fluorescent signal is captured under comparable 
conditions for each sample a semi-quantitative conclusion can be drawn about the 
abundance of mitochondria and HSD10 in patient fibroblasts. The amount and structure 
of the mitochondrial network does not seem to be altered in mutant fibroblasts in 
comparison to wildtype. In contrast, the level of HSD10 is reduced in fibroblasts carrying 
the Q165H mutation and significantly reduced in R130C fibroblasts, respectively. This 
finding is in agreement with the aforementioned instability of the R130C mutation, but 
the Q165H mutation has been shown to be stable (fig. 4). 
Wildtype and mutant HSD10 is localised mitochondrially with the possibility of a small 
cytosolic contingent. This semi-quantitative approach suggests, that the mitochondrial 
content and its structure are unchanged in patient fibroblasts and that the protein level in 
R130C fibroblasts is reduced. 
 
Unfortunately, fibroblasts carrying the D86G mutation are not available for cell culture 
based studies since they are viable but grew very slowly. Due to this slow growth rate 
they were only used for a few experiments like immune fluorescence staining and 
electron microscopy. While investigating the cellular morphology of patient fibroblasts, 
some differences in nuclear morphology of fibroblasts carrying the D86G mutation 
became apparent compared to control cells.  
Figure 11 Cell morphology of patient fibroblasts. (A) Fluorescent nuclear staining of patient 
fibroblasts using 0.8 µg Hoechst nuclear stain per ml medium. Scale bars: 20 µm. (B) Fibroblasts 
were sectioned for electron microscopy. Scale bars: 1 µm. 
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A nuclear staining with Hoechst revealed regular and round nuclei in control cells and in 
fibroblasts with the R130C and Q165H mutation (fig. 11A). In contrast, fibroblasts 
carrying the D86G mutation display multiple nuclei per cell or strongly fragmented nuclei. 
Electron microscopic pictures affirmed this observation by showing fragmented and 
constricted nuclei with the D86G mutation and a regular elongated nuclear shape in 
control cells and the R130C and Q165H mutation (fig. 11B). The slow growth rate and 
multiple nuclei per cell suggest that the D86G mutation causes defects in cell division. 
Additionally, the observed fragmentation of nuclei could be a sign for nuclear 
fragmentation during apoptosis. 
 
4.1.2. Mitochondrial and HSD10 content in HSD10 deficiency patient fibroblasts 
To further investigate the semi-quantitative conclusions from the co-immunostainings 
using antibodies against HSD10 and porin (fig. 10) and to quantitatively exclude 
differences in protein amount or a reduction of mitochondrial content as a cause for the 
observed disease phenotype, the relative amount of two mitochondrial markers and of 
HSD10 was measured in patient fibroblasts. mRNA and protein levels of TOMM20 
(translocase of outer mitochondrial membrane 20) and Grp75 (75 kD glucose regulated 
protein also known as mortalin) were determined. Those two proteins served as 
mitochondrial marker at which the former is a transporter protein of the outer 
mitochondrial membrane and the latter is a heat shock protein located in the 
mitochondrial matrix. Together they were used to determine the amount of mitochondria 
on the basis of TOMM20 mRNA (fig. 12A) and Grp75 protein levels (fig. 12B) in mutant 
fibroblasts relative to control cells. Additionally, HSD10 mRNA and protein levels were 
measured in comparison to control fibroblasts. 
 
Figure 12 Content of mitochondrial material and HSD10 in fibroblasts from HSD10 
deficiency patients. (A) Total RNA isolated from fibroblasts was transcribed into cDNA and 
subjected to qRT-PCR with primers for HSD10 and TOMM20. qRT-PCR was normalised against 
GAPDH and relative expression levels were calculated using a standard curve. (B) For detection of 
HSD10 and Grp75 protein levels cells were lysed and analysed by SDS-PAGE and Western Blot 
using anti-Grp75 (1:5000), anti-HSD10 (1:500) and anti-β actin (1:5000) antibodies. 
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Comparison of the relative expression levels of HSD10 mRNA in patient fibroblasts shows 
that the amount of HSD10 transcripts is almost equal in the cells analysed (fig. 12A). In 
agreement with the finding that the R130C mutation is unstable, and in line with the 
immunostaining of R130C fibroblasts (fig. 10), less HSD10 protein can be detected in 
fibroblasts carrying this mutation (fig. 12B). The amount of HSD10 in fibroblasts carrying 
the Q165H mutation also seems to be slightly reduced compared to control cells although 
this mutation does not alter the stability of the protein (fig. 4). Again this is consistent 
with the semi-quantitative finding of the immunostaining of Q165H fibroblasts. The 
content of mitochondrial material is not significantly reduced in patient fibroblasts judged 
by the amount of mitochondrial marker Grp75 protein (fig. 12B) and TOMM20 mRNA (fig. 
12A). 
Wildtype and mutant HSD10 mRNA is almost equal in patient and control fibroblasts but 
HSD10 protein is significantly decreased in R130C and slightly decreased in Q165H cells. 
Mitochondrial material is not reduced in patients. 
 
4.1.3. HSD10 translocates from the mitochondrial matrix to the membrane 
under oxidative stress 
The localisation of HSD10 is dependent on cellular stress and a protective function for 
HSD10 in cells under oxidative stress has been postulated (Tieu et al, 2004). To 
investigate the exact intracellular localisation of HSD10 under physiological or stress 
conditions cells were treated with rotenone or left untreated. Rotenone is a chemical that 
induces oxidative stress by interfering with the electron transport chain in mitochondria. 
Specifically, it inhibits the transfer of electrons from iron-sulfur centres in complex I to 
ubiquinone and thereby prevents the formation of ATP. 
Mitochondria were isolated from untreated cells or cells stressed with rotenone and the 
membrane fraction was analysed separated from the matrix as to their content of HSD10 
protein in comparison to a reference protein (Grp75) that is localised in the mitochondrial 
matrix and does not change its distribution upon stress (fig. 13). The analysis of the 
behaviour of HSD10 under stress was thought to help and characterise or even reveal 
differences between mutant proteins.  
Figure 13 Translocation of HSD10 from the mitochondrial matrix to the membrane under 
oxidative stress. HEK293 cells were treated with 50 µM rotenone overnight or were left 
untreated. Mitochondria were isolated and separated into membrane and matrix fractions which 
were subsequently analysed by SDS-PAGE and Western Blot using anti-Grp75 (1:1000) and anti-
HSD10 (1:500) antibodies. 
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A small amount of Grp75 can be found in the isolated membrane fraction although Grp75 
is localised in the mitochondrial matrix and does not change its position under stress. 
This is probably due to incomplete separation of the two compartments by this kind of 
differential centrifugation. However, in unstressed cells HSD10 can only be detected in 
the mitochondrial matrix fraction (fig. 13). In contrast to the localisation in the 
mitochondrial matrix under these physiological conditions, HSD10 shifts to the membrane 
under oxidative stress induced by rotenone treatment. 
It had been planned to use this experimental procedure for the identification of 
differences between wildtype and mutant HSD10 when applied to patient fibroblasts. 
Although mutant proteins are imported into mitochondria they could have reduced ability 
to translocate to the membrane under stress. Unfortunately, it was not possible to carry 
out this kind of subcellular fractionation using mutant fibroblasts due to technical 
problems. 
To analyse this in greater detail including the localisation of mutant proteins an 
immunogold staining of electron microscopy sections would be useful but unfortunately 
the commercially available antibody against HSD10 did not detect its antigen on these 
sections. 
Hence, this experiment merely confirmed the previously published result that under 
physiological conditions wildtype HSD10 is localised in the matrix and translocates to the 
mitochondrial membrane under oxidative stress (Tieu et al, 2004). 
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4.2. Mitochondrial morphology and function after HSD10 loss-of-function 
Since HSD10 is located in the mitochondrial matrix and patients with HSD10 deficiency 
show signs of mitochondrial dysfunction such as elevated lactate concentrations, the 
mitochondrial morphology was analysed by Mitotracker staining and electron microscopy 
in fibroblasts derived from patients. Furthermore, mitochondria in a knock-down and 
knock-out situation were investigated in the Xenopus and mouse animal model, 
respectively.  
4.2.1. Mutations D86G and R130C cause severe disruption of mitochondrial 
morphology 
In order to investigate the impact of mutant HSD10 on mitochondria, mitochondria of 
fibroblasts derived from HSD10 deficiency patients were visualised by Mitotracker 
staining (fig. 14A) and subsequently analysed by electron microscopy (fig. 14B). 
Figure 14 Mitochondrial morphology in patient fibroblasts. (A) 300 nM Mitotracker Green FM 
were used on cells fixed with 3.7 % formaldehyde on coverslips and mitochondria were visualised 
by fluorescent microscopy. Scale bars: 10 µm. (B) Fibroblasts were sectioned for electron 
microscopy. Pictures of 10-43 random systematically chosen visual fields were taken in a 
magnification of 11.5×103, scale bars: 100 nm. Mitochondria were classified into 3 groups (1 – 
dense, dark; 2 – loosely packed; 3 – depleted cristae). Counted visual fields were 22 (control), 11 
(R130C), 43 (D86G) and 10 (Q165H) and total numbers of evaluated mitochondria were 281 
(control), 203 (R130C), 1,017 (D86G) and 86 (Q165H). ** indicates significance at p < 0.0001, 
* gives significance at p = 0.0366 - 0.0857 adjusted for multiple comparisons within the 
experiment compared to control fibroblasts. 
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Although the mitochondrial network stained with porin antibody was not altered in 
fibroblasts with mutated HSD10 compared to control cells (fig. 10) the Mitotracker 
staining revealed differences in the mitochondrial organisation of mutant fibroblasts 
(fig. 14). Wildtype cells and fibroblasts carrying the Q165H mutation comprise a 
filamentous network-like structure of mitochondria. Cells with the R130C and D86G 
mutations show punctate and fragmented mitochondrial organisation (fig. 14A). 
Mitochondria consist of an outer membrane and an inner membrane which folds into 
membrane staples, so-called cristae. Electron microscopy showed that the majority of 
mitochondria in control cells have wildtype morphology with dark mitochondria densely 
packed with cristae (fig. 14B). Fibroblasts carrying the Q165H mutation maintain 
wildtype morphology of almost half of the mitochondria, 30 % display an intermediate 
phenotype with loosely packed and/or swollen cristae and 27 % show depletion of cristae 
and appear “empty”. In contrast, in cells carrying the D86G and R130C mutation 65-
85 % of the mitochondria display an aberrant phenotype (group 2 and 3). Mitochondria 
classified as group 3 are not only morphologically distinct but on average also smaller 
than wildtype mitochondria. 
These findings show that mutations D86G and R130C cause severe disruption of 
mitochondrial morphology. 
 
4.2.2. Mitochondrial disintegration after conditional HSD17B10 knock-out in 
mice 
Since a knock-out of HSD17B10 in mice results in early embryonic lethality at gastrula 
stages (B. Arnold, unpublished data), a conditional HSD17B10 knock-out mouse line was 
established. HSD17B10 was eliminated in noradrenergic neurons by mating mice carrying 
a floxed allele of HSD17B10 with a DBH-Cre line. This conditional knock-out eliminates 
HSD10 in noradrenergic neurons of the CNS (central nervous system) as well as the PNS 
(peripheral nervous system). Noradrenergic neurons in the CNS are for example located 
in the LC (locus coeruleus) and in the PNS in the SCG (superior cervical ganglia) and the 
inferior cervical ganglia (stellate ganglia). 
The LC is part of the reticular formation in the hindbrain which is probably responsible for 
the control of orientation and attention. It is also involved in mediation of many of the 
sympathetic effects during stress responses by increasing noradrenaline secretion which 
in turn alters cognitive function, increases motivation and inhibits the parasympathetic 
tone. 
The SCG (superior cervical ganglia) lie posterior to the internal carotid artery, opposite of 
the second and third cervical vertebrae. They contain neurons that play a role in the 
sympathetic innervation to the face. Stellate ganglia are found at the level of the seventh 
cervical vertebrae, anterior to the neck of the first rib. They arise from a fusion of the 
inferior cervical and the first thoracic ganglia. Stellate ganglia are sympathetic ganglia 
that render the inferior cardiac nerve, and offsets to blood vessels. 
RESULTS 
 
 
30 
To analyse the morphology of mitochondria in a HSD10 knock-out situation brains from 
DBH-Cre conditional knock-out mice were cut in Vibratome sections to pinpoint the small 
region of the LC which is more pigmented than the surrounding tissue (fig. 15A). Its light 
blue colour is due to melanin enclosed in the noradrenergic nerve cell bodies. The LC is 
located in the brain stem in the lateral floor of the fourth ventricle in the dorsal wall of 
the rostral pons. This region was then sectioned for electron microscopy and evaluated 
by means of mitochondrial morphology (fig. 15B and C).  
 
In the loci coerulei of DBH-Cre HSD10 deficient mice, almost 30 % of the mitochondria 
show depletion of cristae and appear “empty”, more than 50 % of the mitochondria are 
loosely packed and have swollen cristae, while normal morphology (dense, dark) is only 
found in 20 % (fig. 15C). In the cerebellum of the same mice, which lack noradrenergic 
Figure 15 Mitochondrial morphology in brains of mice with a conditional knock-out in 
noradrenergic neurons (DBH-Cre). (A) Brains from knock-out mice were Vibratome sectioned 
(50 µm) and the loci coerulei were dissected and prepared for electron microscopy. Scale bar: 
100 µm. (B) Pictures of 33 random systematically chosen visual fields were taken in a 
magnification of 11.5×103, scale bars: 100 nm. Mitochondria were classified into 3 groups (1 – 
dense, dark; 2 – loosely packed/swollen cristae; 3 – depleted cristae). The total number of 
evaluated mitochondria was 10,167 (cerebellum) and 2,446 (locus coeruleus). (C) Classified 
mitochondria in percent. Sections of the cerebellum, which lacks noradrenergic neurons, served as 
a control. * indicates significance (p < 0.0001) of differences to the cerebellum. 
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neurons, 50 % of the mitochondria have wildtype morphology, 40 % display the 
intermediate phenotype and only 10 % appear “empty” and without cristae.  
 
To analyse the morphology of the mitochondria in a HSD10 knock-out situation in the 
PNS, ganglia from these HSD17B10 DBH-Cre conditional knock-out mice were isolated.  
SCG and stellate ganglia were isolated, cryosectioned and sectioned for electron 
microscopy to analyse the ganglia tissue as well as the mitochondria morphologically 
after HSD10 knock-out (fig. 16). 
 
Ganglia from knock-out mice are already distinguishable by eye right after isolation 
because they are smaller and look porose compared to control ganglia (fig. 16A). Also 
Figure 16 Morphology of ganglia derived from mice with a conditional knock-out in 
noradrenergic neurons (DBH-Cre). (A) Isolated ganglia, scale bars: 500 µm. (B) 
Cryosectioned ganglia. Sections are 15 µm, scale bars: 150 µm. (C) Pictures of 4 to 13 random 
systematically chosen visual fields were taken in a magnification of 11.5×103, scale bars: 100 nm. 
Mitochondria were classified into 3 groups (1 – dense, dark; 2 – loosely packed/swollen cristae; 3 – 
depleted cristae). The total number of evaluated mitochondria was 840 (SCG control), 335 (SCG 
HSD10-/-) and 196 (stellate ganglia control) and 666 (stellate ganglia HSD10-/-), respectively. 
* indicates significance (p < 0.0001) of differences to control ganglia. 
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when cryosectioned the morphological differences are obvious at least in the SCG of 
HSD17B10-/- mice. Those ganglia exhibit large fissures within the tissue (fig. 16B). 
A similar picture of mitochondrial morphology as in the CNS (fig. 15) is observed in the 
PNS (peripheral nervous system) in SCG but not in stellate ganglia. Mitochondria are 
morphologically severely altered in superior cervical ganglia isolated from DBH-Cre 
conditional knock-out mice (fig. 16C). More than 85 % of mitochondria show an aberrant 
phenotype (group 2 and 3), while normal morphology (dense, dark) is only found in 
15 %. In addition, mitochondria of the groups 2 and 3 are significantly larger than 
wildtype mitochondria, whereas the aberrant phenotype in patient fibroblasts is 
accompanied by a smaller size of these mitochondria. This effect of a HSD10 knock-out 
on mitochondrial morphology cannot be observed in stellate ganglia. In these ganglia 
almost 50 % of the mitochondria have wildtype morphology, around 30 % display the 
intermediate phenotype and only 15-20 % appear “empty” and without cristae in both 
the control animals and mice with the DBH-Cre conditional knock-out.  
In general, cells that show this altered mitochondrial morphology also exhibit nuclei and 
nuclear budding containing large amounts of condensed chromatin which suggests that 
these cells are apoptotic. 
The EM analysis of two independent primary cell types (neurons of the CNS and PNS) 
from HSD17B10 DBH-Cre conditional knock-out mice thus confirmed in a genetic system 
that HSD10 is required for mitochondrial structural integrity in the CNS and the PNS. The 
same morphological changes in mitochondria are observed in fibroblasts from patients 
and in neurons from conditional knock-out mice indicating that they are cell type 
independent. 
 
4.2.3. HSD10 knock-down in Xenopus impairs mitochondrial integrity 
In order to study the effect of HSD10 loss-of-function on mitochondrial morphology in 
early vertebrate embryos Xenopus was used as an experimental model. In Xenopus 
embryos, translation of mRNAs can be specifically blocked by Mo (Morpholino) antisense 
oligonucleotides. MoHSD10ATG targets the coding region of HSD10 and specifically 
suppresses HSD10 translation in Xenopus embryos (Rauschenberger et al, 2010). 
Antisense MoHSD10ATG was microinjected into the prospective ectoderm and the injected 
region (animal cap) was explanted and cultured. Explanted animal caps differentiate into 
a homogeneous tissue, the so-called atypical epidermis. After 2 days in culture, when 
control embryos had reached tailbud stage, the animal caps were sectioned for electron 
microscopy. 
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Electron microscopic analysis revealed that the morphology of mitochondria in animal cap 
explants is changed after HSD10 knock-down (fig. 17). 80 % of mitochondria show a 
severe reduction of cristae and a generally irregular shape (group 2 and 3). This 
phenotype is rarely observed in uninjected samples (25 %) or in tissue in which the 
MoHSD10ATG is injected together with a human HSD10 expression construct (30 %).  
This experiment demonstrates by loss-of-function analysis that HSD10 is required for 
structural integrity of mitochondria in early vertebrate embryos. 
 
Having shown by loss-of-function analysis that HSD10 is required for structural integrity 
of mitochondria in various systems, the next question was whether HSD10 knock-down 
also impaired mitochondrial function. Antisense MoHSD10ATG was microinjected into the 
prospective ectoderm and the injected region (animal cap) was explanted and cultured. 
After 2 days in culture, when control embryos had reached tailbud stage, pyruvate 
turnover was measured as a parameter of mitochondrial function.  
Figure 17 Mitochondrial morphology in Xenopus animal caps after knock-down of HSD10. 
Animal caps were dissected from Xenopus embryos injected with 20 ng MoHSD10ATG alone or 20 ng 
MoHSD10ATG together with 150 pg hHSD10 (pT-Rex-DEST30) and sectioned for electron 
microscopy. Pictures of 24 random systematically chosen visual fields were taken in a magnification 
of 6.6×103, scale bars: 100 nm. Mitochondria were classified into 3 groups (1 – dense, dark; 2 – 
loosely packed; 3 – depleted cristae). * indicates significance at p < 0.0001 compared to 
uninjected control animal caps. Total numbers of evaluated mitochondria per sample were 1,193 
(control), 653 (MoHSD10ATG) and 945 (MoHSD10ATG+hHSD10). 
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MoHSD10ATG-injected samples display a 40 % reduction in pyruvate turnover compared 
to the uninjected or MoCo injected tissue (fig. 18). Impaired mitochondrial function is 
specific because co-injection of a human HSD10 expression construct which is not 
targeted by the MoHSD10ATG rescues pyruvate turnover almost to the level of uninjected 
controls. 
This loss-of-function analysis shows that HSD10 is required for functional integrity of 
mitochondria. 
 
Figure 18 Mitochondrial function in Xenopus animal caps after knock-down of HSD10. 
Animal caps were dissected from Xenopus embryos injected with 20 ng control MoCo or 
MoHSD10ATG alone or 20 ng MoHSD10ATG together with 150 pg hHSD10 (pT-Rex-DEST30) and the 
turnover of 1-C14 pyruvate was measured. CPM (Counts per minute) are shown in relation to 
uninjected control (100 %) and the standard error for two independent experiments is given. 
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4.3. Induction of apoptosis after HSD10 gain- and loss-of-function 
It has been shown previously that HSD10 loss-of-function elicits an increase in apoptosis 
(Rauschenberger et al, 2010). TUNEL staining of Xenopus embryos which received the 
MoHSD10ATG only into the right side of the body showed enhanced apoptosis on the 
injected side. Induction of apoptosis after siRNA-mediated knock-down of HSD10 was 
confirmed in human SHSY5Y cells and also in dendritic cells from mice with a conditional 
knock-out in endothelial cells and haematopoietic stem cells (Tie2-Cre).  
The increase in apoptosis rate in Xenopus embryos caused by HSD10 knock-down can be 
rescued by human HSD10 wildtype. The mutated HSD10 proteins found in human 
patients, however, show remarkable differences in their ability to rescue the apoptotic 
phenotype. The Q165H mutation, which has less than 3 % residual enzymatic activity but 
was identified in three neurologically normal boys, partially rescued MoHSD10ATG-induced 
apoptosis. In contrast, the mutations R130C and in particular D86G failed to rescue, and 
instead further enhanced apoptosis. Both mutations have considerable residual enzyme 
activity despite being associated with a very severe clinical phenotype.  
These experiments demonstrated that loss of HSD10 results in induction of apoptosis 
independent of the cell type and organism. The rescue experiments furthermore showed 
that apoptosis after HSD10 loss-of-function is not dependent on the enzymatic 
dehydrogenase activity of HSD10, arguing for a non-enzymatic function of this protein 
which is required in mitochondria. 
 
4.3.1. HSD10 gain-of-function in Xenopus induces apoptosis 
Since co-injection of the R130C and D86G mutation together with MoHSD10ATG into 
Xenopus embryos enhanced the induction of apoptosis even further than the knock-down 
of HSD10 alone, the effect of these mutations on the apoptosis rate was investigated 
(fig. 19). Expression plasmids carrying the three different mutations were microinjected 
into the right body half of Xenopus embryos. After two days (stage NF 33/34) these 
embryos were TUNEL stained and scored for apoptosis on each body half (fig. 19A). The 
left side was used as an internal control and the amount of apoptotic spots on the right 
(injected) side was normalised against the left (uninjected) control side (fig. 19B).  
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Embryos injected with human wildtype HSD10 show a mild increase in apoptosis on the 
injected side (fig. 19B). In contrast, when injected with the mutations R130C and D86G, 
induction of apoptosis is very much enhanced compared to the uninjected internal control 
side. Overexpression of the Q165H mutation does not result in such a severe increase 
but only in a mild induction of apoptosis comparable to the effect of human wildtype 
HSD10. 
This gain-of-function experiment shows that not only the loss-of-function of HSD10 but 
also the overexpression leads to a mild induction of apoptosis. The two severe mutations 
R130C and D86G strongly induce apoptosis and seem to have a dominant-negative effect 
on the initiation of apoptosis.  
 
4.3.2. Apoptosis induced by HSD10 gain-of-function is not due to the unfolded 
protein response 
The ER (endoplasmic reticulum) orchestrates the synthesis and processing of nearly all 
proteins in eukaryotic cells. Soluble and membrane proteins are delivered to the ER as 
linear polypeptides that acquire their secondary structure and posttranslational 
modifications in the ER lumen. Overexpression or mutation of proteins can induce 
accumulation of unfolded or misfolded proteins which causes ER stress and initiates the 
UPR (unfolded protein response). Mitochondria can also activate a UPR. UPR coordinates 
the interplay of processing and degrading unfolded proteins and activates both adaptive 
and apoptotic pathways. 
To check if the apparent dominant-negative effect of the R130C and D86G mutations on 
induction of apoptosis is due to their overexpression and accumulation in the ER and a 
subsequent activation of the UPR eventually leading to apoptosis, the upregulation of one 
mediator of the UPR, CHOP, was determined (fig. 20). CHOP (C/EBP homologous protein, 
Figure 19 Quantitative analysis of the effect of wildtype and mutant HSD10 on the 
apoptosis rate. (A) Experimental scheme. Embryos were injected with 150 pg DNA in 5 nl (pT-
Rex-DEST30 containing cDNA coding for HSD10 WT or the mutations R130C, D86G, Q165H). (B) 
Quantification of TUNEL staining on the right (injected) side of tailbud stage embryos (stage 
NF 33/34) normalised against the left (control) side. The standard error for 3 individual 
experiments (n = 42–51 embryos) is shown. Significant differences between control and injected 
embryos were calculated using the student t-test. * indicates significance at p ≤ 0.0001. 
RESULTS 
 
 
37 
also known as growth arrest- and DNA damage-inducible gene 153, GADD153) is a 
transcription factor that is upregulated in the UPR of ER and mitochondria.  
Expression constructs coding for HSD10 wildtype or the three different mutations were 
microinjected into the prospective ectoderm and the injected region (animal cap) was 
explanted and cultured. When control embryos had reached stage NF 31 positive control 
animal caps were treated with TM (tunicamycin). TM is a mixture of homologous 
nucleoside antibiotics that inhibits the enzyme GPT (GlcNAc phosphotransferase), which 
catalyses the first step of glycoprotein synthesis. By blocking the synthesis of all N-linked 
glycoproteins tunicamycin induces the UPR in the ER and is used as a positive control for 
CHOP upregulation. After two days in culture (stage NF 33/34) animal caps were used to 
measure CHOP levels as an indicator for UPR after overexpression of mutant and wildtype 
HSD10. 
 
Neither the overexpression of HSD10 wildtype nor the three mutations cause an 
upregulation of CHOP (fig. 20). Only tunicamycin treated Xenopus embryos show an 
upregulation of CHOP mRNA.  
Therefore, the UPR of the ER or mitochondria is not induced by overexpression of HSD10 
wildtype or mutations in Xenopus embryos and thus is not the elicitor of apoptosis after 
HSD10 injection. 
 
Figure 20 Upregulation of CHOP after overexpression of HSD10 wildtype and mutations. 
Xenopus embryos were injected with 5 nl in each blastomere at the 4-cell-stage containing 150 pg 
DNA (pT-Rex-DEST30 HSD10 WT or the mutations R130C, D86G, Q165H) and animal caps were 
dissected. Animal caps treated with 2.5 µg/ml TM (tunicamycin) from stage NF 31 were used as a 
positive control. Total RNA was isolated at stage NF 33/34 and transcribed into cDNA which was 
then subjected to qRT-PCR with primers for CHOP and ODC (Ornithine decarboxylase). qRT-PCR 
was normalised against ODC and relative expression levels compared to uninjected and untreated 
animal caps were calculated using a standard curve. The standard error for two independent 
experiments is given. 
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4.3.3. Analysis of the apoptotic pathway induced by HSD10 loss-of-function 
Apoptosis is controlled by many different signals. These signals can either originate 
extracellularly as extrinsic inducers like hormones or the lack of growth factors or they 
can arise intracellularly triggered by intrinsic factors like stress, increased calcium levels 
or DNA damage. Extrinsic and intrinsic inducers can act pro- or anti-apoptotic. Despite of 
their diverse origin these signals eventually activate a common cell death machinery. For 
example, both, extrinsically activated procaspase-8 and intrinsically activated 
procaspase-9 proteolytically cleave and thereby set off the executioner procaspase-3. 
The Human Apoptosis PCR Array by RealTimePrimers.com is a primer library that 
contains 88 primer sets directed against apoptosis genes. This array was used as a 
means to help to determine whether the mitochondrial phenotype observed upon HSD10 
loss-of-function is the source or a consequence of the induction of apoptosis by profiling 
the changes that occur in human cells upon HSD10 knock-down (fig. 21) or mutation 
(fig. 22). Since both pathways include mediators that are specifically activated in the 
intrinsic or the extrinsic induction of apoptosis, the pattern of genes that are upregulated 
upon HSD10 knock-down should reveal which apoptotic pathway is initiated by HSD10 
loss-of-function. 
Figure 21 Apoptotic gene regulation in response to siRNA mediated HSD10 knock-down 
in HeLa cells. HeLa cells were treated with 20 pmol of two different siRNAs targeting HSD10, a 
negative control siRNA (40 pmol) and a vehicle control, respectively. Total RNA was isolated 48 h 
post transfection and transcribed into cDNA by M-MuLV-RT. This cDNA served as a template for the 
human apoptosis array primer library. Relative gene expression was determined by the ddCT 
method. Measured CT values were normalised against the mean of four different housekeeping 
genes (β-actin, β-2-microglobulin, glyceraldehyde-3-phosphate dehydrogenase and β-glucuroni-
dase) in a first step. Since transfection reagents generally have a toxic effect on cells, the second 
normalisation was carried out against the vehicle control (0.5 µl Lipofectamine for each well in a 
24-well-plate). Likewise, short dsRNA has been shown to influence gene expression, so the last 
normalisation was done against the CT values for the inert negative control siRNA. Shown in this 
graph are genes that are up- or downregulated more than 2-fold with both siRNAs targeting HSD10 
in two independent experiments and their mean fold regulation. 
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Both specific siRNAs caused an efficient knock-down of HSD10 down to 22 and 31 % for 
siRNA3 and siRNA5, respectively, compared to control siRNA treated cells.  
The CT values obtained with primers of the Human Apoptosis PCR Array for samples 
treated with siRNA specific for HSD10 were normalised against the mean of four different 
housekeeping genes, the vehicle and the negative siRNA control. Therefore, all changes 
that are unspecific and simply due to differences in total RNA concentration or to the 
transfection process should be eliminated. Also, only changes of more than 2-fold which 
were found in two independent experiments were taken into account. 
Among the upregulated genes are two that are pro-apoptotic (TNFRSF9 and TNFSF15) 
and one (CD40) that is pro-apoptotic but can also be anti-apoptotic depending on the 
context (fig. 21). The downregulated genes comprise a mixture of pro- and anti-apoptotic 
genes. It has been shown that the knock-down of HSD10 causes an increase in apoptosis 
(Rauschenberger et al, 2010), thus the upregulation of pro-apoptotic and the 
downregulation of anti-apoptotic genes was expected. The opposite, the upregulation of 
anti- and the downregulation of pro-apoptotic genes might be a compensatory 
mechanism of the cells at the beginning of apoptosis. 
In order to distinguish between the extrinsic and intrinsic pathway, the pattern of 
regulated genes upon transfection with FADD (Fas-Associated protein with Death 
Domain) or upon treatment with rotenone and sodium azide (NaN3) was determined. 
FADD was used as a positive control because it bridges death receptors at the cell 
surface to caspase-8 through its death domain to form the DISC (death-inducing 
signalling complex) and thus extrinsically induces apoptosis.  
Rotenone and NaN3 both affect the mitochondrial respiratory chain. Rotenone induces 
oxidative stress by inhibiting complex I and NaN3 inhibits complex IV by blocking the 
oxygen binding site in the active centre of cytochrome-c-oxidase irreversibly. Both 
inhibitors induce the intrinsic pathway of apoptosis and were found to cause a strong 
increase in BIRC3, CASP5 and TNFSF15 expression. 
The pattern of genes that are regulated upon HSD10 knock-down (fig. 21) does not point 
to one well-defined apoptotic pathway. The upregulation of TNFSF15 might be specific for 
mitochondrial involvement in apoptosis, since a control treated with rotenone and NaN3 
as well as a knock-down of HSD10 strongly increased TNFSF15 expression. The 
transfection with FADD which triggers the extrinsic apoptosis pathway showed no 
upregulation of TNFSF15. However, usually the TNF superfamily is associated with the 
extrinsic apoptosis pathway. 
 
Overexpression of HSD10 and especially the D86G and R130C mutation have been shown 
to induce apoptosis in Xenopus embryos (fig. 19). In order to analyse whether patient 
fibroblasts show a pattern of up- or downregulated genes that is characteristic for an 
increase in (intrinsic or extrinsic) apoptosis, the apoptosis PCR array was also used to 
determine up- or downregulated genes on a background where HSD10 is mutated 
(fig. 22). 
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The genes, which are up- or downregulated in patient fibroblasts in comparison to control 
cells, are a mixture of pro- and anti-apoptotic genes (fig. 22). Notably, half of the 
regulated genes and the ones that are highly changed in their expression in mutant 
fibroblasts are members of the TNF family. The pattern of regulated genes is not 
characteristic for the intrinsic or extrinsic apoptotic pathway but death receptors of the 
TNFR family mediate the extrinsic apoptotic pathway.  
The following table (table 2) summarises the regulation of the expression of 88 apoptotic 
genes in response to HSD10 loss-of-function mediated by siRNA knock-down or 
mutation, tested with the human apoptosis PCR array. 
 
Figure 22 Apoptotic gene regulation in HSD10 deficiency patient fibroblasts. Total RNA 
was isolated from control fibroblasts or cells carrying the R130C or Q165H mutation, respectively. 
RNA was transcribed into cDNA by M-MuLV-RT and subsequently served as a template for the 
human apoptosis array primer library. Relative gene expression was determined by the ddCT 
method. Mean CT values of two experiments were normalised against the mean of four different 
housekeeping genes (β-actin, β-2-microglobulin, glyceraldehyde-3-phosphate dehydrogenase and 
β-glucuronidase) and afterwards to control fibroblasts. In this graph, genes that are up- or 
downregulated more than 2-fold for at least one of the tested mutations and their fold regulation in 
a logarithmic scale are shown. 
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APAF1 x  --- --- --- --- MCL1  x --- --- --- --- 
ATM x  --- ↑ --- --- MYD88 x  ↓ --- ↑↑↑ ↑↑↑ 
BAG1  x --- --- --- --- CARD4 x  --- --- --- --- 
BAG3  x --- --- --- --- RIPK1 x  ↓↓↓ ↓↓ --- --- 
BAG4  x --- ↑ --- --- RIPK2 x  --- --- --- --- 
BAK1 x  --- --- --- --- RPA3 x x --- --- --- --- 
BAX x  ↓ --- --- --- TANK x  --- --- --- --- 
BCL10 x  --- --- --- --- TNF x x ↓ ↓ --- --- 
BCL2  x --- --- --- --- TNFRSF10A x  --- --- --- --- 
BCL2A1  x ↓ ↓ --- --- TNFRSF10B x  --- --- --- --- 
BCL2L1  x --- --- --- --- TNFRSF10C  x --- --- ↑ --- 
BCL2L11 x  --- --- --- --- TNFRSF10D  x --- --- --- --- 
BCL2L2  x --- --- --- --- CASP8 x  --- --- --- --- 
BFAR  x --- --- ↑↑ ↑↑ CASP8AP2 x  --- --- --- --- 
BIK x  ↓ ↑ --- --- CFLAR x x --- --- --- --- 
BIRC1  x --- --- --- --- CHEK1  x --- --- --- --- 
BIRC2  x --- --- --- --- TNFRSF11B x x ↓ --- ↑↑ ↑↑ 
BIRC3  x --- --- --- ↑ TNFRSF17  x ↓ --- --- --- 
BIRC4  x --- --- ↑ ↑ TNFRSF1A x  --- --- --- --- 
BIRC5  x --- --- --- --- TNFRSF21 x  --- --- --- ↓ 
BIRC6  x --- ↑ --- --- CD40 x  ↑ ↑ ↑ ↑↑ 
BNIP3  x --- --- --- --- TNFRSF8 x  ↓ ↓ --- --- 
BRE  x --- --- --- ↑ TNFRSF9 x  ↑ ↑ ↑ --- 
BOK x  --- --- --- --- TNFSF10 x  ↓ ↓ --- --- 
CASP1 x  ↓ ↓ --- --- TNFSF11  x ↓ ↓ --- --- 
CASP10 x  --- ↓ --- --- TNFSF13 x  --- --- --- --- 
CASP4 x  ↓ ↓ --- --- TNFSF13B  x --- --- --- --- 
CASP2  x --- --- --- --- TNFSF15 x  ↑ ↑ ↑↑ --- 
CASP3 x  --- --- --- ↑ TNFSF18  x --- ↓ ↑ ↑ 
CASP5 x  --- --- --- --- TNFSF4  x --- --- ↑ --- 
CASP6 x  --- --- --- --- CD40LG  x ↓ ↓ --- --- 
CASP7 x  --- --- --- --- FASLG x  --- --- --- --- 
CHEK2 x  --- --- --- --- TNFSF7  x --- --- --- --- 
CIDEA x  --- --- --- --- TNFSF8 x  ↓ --- --- --- 
CIDEB x  --- --- --- --- TNFSF9 x x --- --- ↑ ↑ 
CRADD x  --- --- --- --- TP53 x  --- --- ↑ ↑ 
DAPK1 x  --- --- --- --- TP73L x  --- --- --- --- 
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DAPK2 x  ↓ ↓ --- ↑ TRAF1  x ↓ ↓ --- --- 
DFFA  x --- --- --- --- TRAF3 x  ↓ --- --- --- 
DFFB x  --- --- --- --- TRAF4  x ↓ --- --- --- 
FADD x  --- --- --- --- TRAF5 x  ↓ --- --- --- 
GADD45A x  ↑ --- --- --- TRAF6 x x --- --- --- --- 
HRK x  --- --- --- --- TRIP x  --- --- --- --- 
LTBR x  ↓ ↓ --- --- DIABLO x  --- --- --- --- 
Table 2 Regulation of the expression of 88 apoptotic genes in response to HSD10 loss-
of-function. This table lists apoptotic genes that are up- or downregulated (↑ or ↓) or highly up- or 
downregulated (↑↑ or ↓↓) upon siRNA mediated knock-down of HSD10 or in fibroblasts carrying 
mutation R130C and Q165H, respectively. 
 
There are several genes that are regulated upon treatment with one or both siRNAs or in 
response to the mutations in HSD10, but there are only three genes that are upregulated 
with both siRNAs and at least one mutation (highlighted in table 2). Those three genes, 
CD40, TNFRSF9 and TNFSF15, are regulated in both loss-of-function situations and all 
three have a pro-apoptotic function. Also, all three genes are members of the TNF 
(tumour necrosis factor) superfamily and this protein family is associated with the 
extrinsic pathway of apoptosis induction. 
Therefore, they might be responsible for the increase in extrinsically activated apoptosis 
upon HSD10 knock-down or knock-out and upon overexpression of mutant HSD10. 
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4.4. HSD10 function and characterisation of mutations under cellular stress 
conditions 
A protective effect of overexpressed HSD10 under conditions of oxidative stress was 
found in the setting of acute brain damage (Yan et al, 2000a) and in a mouse model of 
Parkinson disease (Tieu et al, 2004). Reduction or loss of HSD10 in Xenopus, mouse and 
humans has adverse effects on mitochondrial integrity and leads to enhanced apoptotic 
cell death and reduced viability (fig. 14-17; Rauschenberger et al, 2010).  
Furthermore, clinical deterioration in HSD10 deficiency patients is triggered by infections 
or other stress situations. In response to metabolic stress, HSD10 protein translocates 
from the mitochondrial matrix to the inner mitochondrial membrane and this might be 
important for maintaining mitochondrial integrity as this is an essential site e.g. for 
assembly of the mitochondrial membrane permeability transition pore (Tieu et al, 2004, 
and fig. 13).  
Thus, HSD10 may be a component serving to protect mitochondria at times of increased 
metabolic stress. It appears plausible that its protective effect might be disturbed by 
altered HSD10 protein structure due to specific mutations. 
To determine whether mutated and control cells behave differently under various stress 
conditions and if mutated fibroblasts can still cope with stress like control cells can, 
cultured cells were put under various metabolic stress conditions. Metabolic stress was 
induced by sodium azid (NaN3), hydrogen peroxide (H2O2) and heat (43°C). NaN3 inhibits 
complex IV of the respiratory chain and the cells die due to an arrest of ATP production. 
H2O2 causes oxidative stress by accumulation of ROS (reactive oxygen species). Severe 
oxidative stress can cause cell death, since ROS alter fundamental structures of the cell 
like DNA, proteins and lipids. Elevated temperature turns on a more general stress 
response including the upregulation of heat shock proteins caused by an accumulation of 
denatured proteins. Heat shock proteins function as intra-cellular chaperones that e.g. 
assist proper protein folding and conformation.  
Patient fibroblasts were exposed to these various stressors or left untreated and were 
subsequently scored for viability after one hour or after incubation overnight (fig. 23). 
RESULTS 
 
 
44 
 
The applied concentration of chemicals and the appropriate temperature were titrated to 
a level where control cells show a small effect in cell viability. Mutated fibroblasts have a 
higher level of dying cells than control cells to begin with, but here the increase in non-
viable cells elicited by the various stressors was monitored. Fibroblasts carrying the 
R130C mutation seem to be more sensitive to NaN3 induced stress (fig. 23 left) whereas 
Q165H fibroblasts display an even lower reaction to this kind of stress than control cells. 
Likewise, Q165H fibroblasts might be less sensitive to H2O2 induced oxidative stress than 
R130C or control cells (fig. 23 middle). In contrast, fibroblasts with the Q165H mutation 
are more sensitive to heat induced cellular stress, whereas R130C fibroblasts display only 
a slight elevation comparable to control cells (fig. 23 right). 
Although the alterations in mutated fibroblasts are not striking, one can conclude from 
this set of experiments that these cells behave differently from control cells under stress.  
 
To investigate the effect of various stressors acting on mitochondrial components on 
patient fibroblasts in further detail and in a more quantifiable manner, the CellTiter-Glo® 
Luminescent Cell Viability Assay was used. A thermostable luciferase generates a stable 
“glow-type” luminescent signal proportional to the amount of ATP present, which signals 
the presence of metabolically active cells and thus this assay determines the number of 
viable cells in culture. 
Cultured fibroblasts were put under various stress conditions and scored for viability with 
the CellTiter-Glo assay after six hours (fig. 24). A variety of inhibitors of the respiratory 
chain was applied to induce cellular stress (table 3). The four enzyme complexes that 
form the respiratory chain are partly encoded in the nucleus or in the mitochondrial 
genome. They are located at the inner mitochondrial membrane and transfer electrons 
from metabolites to oxygen through a sequence of redox reactions. This releases free 
energy which is used for the formation of ATP. Inhibition of each step of the respiratory 
chain can cause cellular stress or even cell death (Nelson & Cox, 2005).  
Figure 23 Sensitivity of HSD10 deficiency patient fibroblasts to different stress factors. 
Cultured fibroblasts were treated with 50 mM NaN3 for 1 hour or 200 µM H2O2 for 1 hour or 43 °C 
overnight. Cell viability was then determined with trypan blue absorption and microscopic 
evaluation of the percentage of dead blue cells. Values represent the mean and standard error of 2, 
4 or 5 biological replicates for H2O2, NaN3 and heat, respectively. Significant differences between 
untreated cells and cells under stress were calculated using the student t-test. ** indicates 
significance at p ≤ 0.01 and * denotes significance at p = 0.0456–0.0691 compared to the 
untreated control. 
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A list of inhibitors used for this experiment together with their effect, the used 
concentration and the vehicle they are solved in is given below (table 3). 
 
inhibitor vehicle concentration 
 
effect 
 
 
antimycin 
ethanol 50 – 200 µM 
binds to complex III (cytochrome c 
oxidoreductase) which results in the 
formation of large quantities of 
superoxide and inhibits the oxidation of 
ubiquinol and ultimately preventing the 
formation of ATP 
2-decyl-4- 
quinazolinyl amine 
(DQA) 
ethanol 500 nM – 2 µM inhibits complex I 
 
carbonylcyanide-3-
chlorophenylhydrazone 
(CCCP) 
ethanol 4 – 16 µM 
uncoupler of the mitochondrial 
respiratory chain, that inhibits ATP 
production by the uncoupling of 
oxidative phosphorylation  
(Volkov et al, 2001) 
malonic acid water 4 – 16 mM 
blocks complex II as a competitive 
inhibitor 
 
sodium azide 
water 25 – 100 mM 
binds irreversibly to the oxygen binding 
site in the active centre of complex IV 
(cytochrome-c-oxidase) 
oligomycin ethanol 50 – 200 µM 
inhibits complex V (ATP synthase) by 
blocking its proton channel 
β-fluoropyruvic  
acid 
water 250 µM – 1 mM 
inactivates pyruvate dehydrogenase 
by acetylation of the active centre 
(Flournoy & Frey, 1989) 
 
amyloid-β 
water 500 nM – 2 µM 
fragment 25-35 decreases the 
membrane potential in mitochondria as 
well as the activity of complex I, 
II/III and IV (Cardoso et al, 2001) 
 
rotenone 
ethanol 50 – 200 nM 
inhibits the transfer of electrons from 
iron-sulfur centres in complex I to 
ubiquinone and thereby prevents the 
formation of ATP 
hydrogen peroxide water 50 – 200 µM 
causes oxidative stress by accumulation 
of reactive oxygen species 
Table 3 Various inhibitors used to induce cellular stress in HSD10 deficiency patient 
fibroblasts. Cultured fibroblasts were treated with a variety of inhibitors, which are listed here 
together with the used concentration and their effect in the cell.  
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This experiment was designed to determine whether mutated and control cells behave 
differently under various stress conditions. The analysis of cellular viability in response to 
a variety of inhibitors shows that under these experimental settings the mutated 
fibroblasts show only very little significant differences in their behaviour under stress (fig. 
24). Fibroblasts with the Q165H mutation display significant changes in cellular viability 
in comparison with control cells upon treatment with the chemicals CCCP, NaN3 and 
oligomycin. With the R130C mutation only oligomycin has a significant effect on cellular 
viability.   
Since patients with the R130C mutation show a severe clinical phenotype which develops 
after times of increased metabolic stress, it was expected that this mutation is more 
sensitive to stress than control cells or cells with the Q165H mutation. However, in no 
case investigated here does the R130C mutation show higher sensitivity to stress than 
the Q165H mutation. 
 
Figure 24 Viability of mutated fibroblasts under various stress conditions. Cultured 
fibroblasts were treated with a variety of inhibitors (see table 3). After six hours the CellTiter-Glo® 
Luminescent Cell Viability Assay was performed and relative fluorescence units were measured on 
a luminescence microplate reader according to the manufacturer’s instructions. Shown in the 
diagram is the viability of fibroblasts relative to untreated cells. Values represent the mean of 
relative fluorescence units and standard error of 5 biological replicates. Significant differences 
between mutated and control cells were calculated using the student t-test. * indicates significance 
at p ≤ 0.01. 
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4.5. Identification of interaction partners of HSD10 
In response to metabolic stress, HSD10 protein translocates from the mitochondrial 
matrix to the inner mitochondrial membrane and this might be important for maintaining 
mitochondrial integrity (Tieu et al, 2004; fig. 13). It appears plausible that interaction of 
HSD10 with an integral protein of the mitochondrial membrane or with a soluble protein 
in the mitochondrial matrix could mediate its protective effect and that this interaction is 
disturbed by altered HSD10 protein structure due to specific mutations. To better 
understand the implication of HSD10 in the maintenance of cellular integrity it would be 
of great interest to know which proteins it binds to under physiological or stress 
conditions and whether the mutated proteins show any differences in their ability to bind 
these potential interaction partners. 
 
4.5.1. Homology based BLAST in yeast 
The budding yeast (Saccharomyces cerevisiae) is a very well established model organism 
and a lot is known about its pathways and protein functions and interactions. Therefore, 
to gain a notion on potential binding partners of HSD10 a BLAST in yeast was performed. 
First, the yeast homolog of HSD10 was identified in a so-called WU-BLAST2, which stands 
for Washington University Basic Local Alignment Search Tool Version 2.0 (table 4). The 
emphasis of this tool is to find regions of sequence similarity quickly, with minimum loss 
of sensitivity. The query was carried out in the Saccharomyces Genome Database (more 
precisely, yeastORF.pep) with the human DNA (NM_004493 and NM_001037811) and 
protein sequence of HSD10 (NP_004484.1). The results of this BLAST are summarised in 
the table below (table 4).  
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Sequences producing significant alignments 
Score 
(bits) 
 
E-value 
 
Identities 
YKR009C FOX2 SGDID:S000001717, Chr XI from 456697-
453995, reverse complement, Verified ORF, "Multifunctional 
enzyme of the peroxisomal fatty acid β-oxidation pathway; has 
3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase 
activities" Length = 901 
266 2.5e-21 28 % 
YDL114W YDL114W SGDID:S000002272, Chr IV from 255604-
256530, Uncharacterised ORF, "Putative protein of unknown 
function with similarity to acyl-carrier-protein reductases; is not 
an essential gene" Length = 309 
153 8.2e-10 25 % 
YNL202W SPS19 SGDID:S000005146, Chr XIV from 259579-
260457, Verified ORF, "Peroxisomal 2,4-dienoyl-CoA reductase, 
auxiliary enzyme of fatty acid β-oxidation; homodimeric enzyme 
required for growth and sporulation on petroselineate medium; 
expression induced during late sporulation and in the presence 
of oleate" Length = 293 
151 1.2e-09 26 % 
YKL055C OAR1 SGDID:S000001538, Chr XI from 335801-
334965, reverse complement, Verified ORF, "Mitochondrial 3-
oxoacyl-[acyl-carrier-protein] reductase, may comprise a type II 
mitochondrial fatty acid synthase along with Mct1p" Length = 
279 
141 1.4e-08 28 % 
YMR226C YMR226C SGDID:S000004839, Chr XIII from 
722395-721592, , reverse complement, Verified ORF, 
"NADP(+)-dependent dehydrogenase; acts on serine, L-allo-
threonine, and other 3-hydroxy acids; green fluorescent protein 
fusion protein localises to the cytoplasm and nucleus; may 
interact with ribosomes, based on co-purification experiments" 
Length = 268 
130 2.2e-07 30 % 
YIR036C IRC24 SGDID:S000001475, Chr IX from 422862-
422071, reverse complement, Uncharacterised ORF, "Putative 
benzil reductase; (GFP)-fusion protein localises to the cytoplasm 
and is induced by the DNA-damaging agent MMS; sequence 
similarity with short-chain dehydrogenase/reductases; null 
mutant has increased spontaneous Rad52p foci" Length = 264 
116 8.3e-06 23 % 
YLR426W YLR426W SGDID:S000004418, Chr XII from 
987059-987138, 987210-988110, Uncharacterised ORF, 
"Putative protein of unknown function; the authentic, non-
tagged protein is detected in highly purified mitochondria in 
high-throughput studies; proposed to be involved in resistance 
to mechlorethamine and streptozotocin" Length = 327 
90 0.0099 21 % 
Table 4 Yeast proteins homologous to human HSD10. This table shows the results of a 
WU-BLAST2 of human HSD10 protein (NP_004484.1) on the yeastORF.pep database at the 
Saccharomyces Genome Database. Seven yeast proteins display similarity to human HSD10 with 
an E-value < 0.01. 
 
On nucleic acid level, the HSD10 gene has no similarity with the yeast genome. Based on 
protein sequence, some yeast genes have a low level of similarity (up to 35 %) with the 
HSD10 protein (table 4). On this low level of conservation, it is difficult to judge if there 
is also a functional conservation or not. The protein with the highest rank in similarities in 
yeast is FOX2. FOX2 (Multifunctional enzyme of the peroxisomal fatty acid β-oxidation 
pathway) has 3-hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities. 
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Although it only has low similarity with human HSD10 (28 % identities), another 
interesting hit is OAR1, since it is the only protein that is localised in the same cellular 
compartment as HSD10 apart from one putative protein. OAR1 (Mitochondrial 3-oxoacyl-
[acyl-carrier-protein] reductase) may comprise a type II mitochondrial fatty acid 
synthase along with Mct1p, a malonyl-CoA transferase. 
 
Physical interaction between homologous proteins in yeast could point towards binding 
partners in humans or model organisms like Xenopus or mice, which could then be tested 
for actual binding to HSD10, e.g. in immunoprecipitation experiments. Therefore, a 
search for interaction partners of the protein with the highest level of similarities to 
human HSD10, FOX2, was performed on the Saccharomyces Genome Database, more 
precisely BioGRID (Biological General Repository for Interaction Datasets). The following 
table lists interaction partners of FOX2 (table 5). For the mitochondrial OAR1 no 
interaction partners were found. 
 
 
Physical interaction 
 
reference 
bait/query 
 
interaction type 
 
hit  
Cdc34p Affinity Capture-MS Fox2p Krogan et al, 2006 
Fox2p Affinity Capture-MS 
Pby1p 
Cyk3p 
Rga2p 
Krogan et al, 2006 
Pex11p Affinity Capture-Western Fox2p Marelli et al, 2004 
Akl1p 
Cmk1p 
Ipl1p 
Pcl1p 
Pcl9p 
Pho80p 
Sky1p 
Snf1p 
Tos3p 
Tpk1p 
Biochemical Activity Fox2p Ptacek et al, 2005 
Smc3p Co-fractionation Fox2p White et al, 2004 
Rsp5p Reconstituted Complex Fox2p Gupta et al, 2007 
Table 5 Interaction partners of the yeast protein FOX2, a homolog to human HSD10. A 
search for physical interaction partners of the protein found to be most homologous to human 
HSD10 (table 4) was performed on the BioGRID database at the Saccharomyces Genome 
Database. This table lists published interactions between FOX2 and other proteins, their type of 
interaction and the according reference. 
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The interaction partners of FOX2 listed in table 5 are also putative interaction partners of 
HSD10 since FOX2 possibly is the yeast homolog to human HSD10. Among these 
interaction partners of FOX2 are many different protein classes. 
The two most interesting interaction partners are Cmk1p and Rsp5p considering their 
cellular function. Cmk1p (Calmodulin-dependent protein kinase 1p) is involved in stress 
tolerance (Sakaguchi et al, 2010) and Rsp5p, an E3 ubiquitin ligase, plays important 
roles in stress resistance, heat shock and transcription initiation (Cardona et al, 2009). 
Apart from that, FOX2 interacts with several kinases (Akl1p, Ipl1p, Sky1p, Snf1p, Tos3p, 
Tpk1p) that are involved in cellular processes like endocytosis (Henry et al, 2003), 
kinetochore-microtubule attachment (King et al, 2007), ion homeostasis (Porat et al, 
2006) and glucose repression/derepression (Ye et al, 2008). It also plays a role in cell 
cycle regulation and cell division since it interacts with proteins like Cdc34p, Cyk3p, 
Rga2p, Pcl1p, Pcl9p and Pho80p which are a cell division cycle 34 homolog, a protein 
involved in cytokinesis (Korinek et al, 2000), a Cdc42p GTPase-activating protein (Zheng 
et al, 1993), G1-cyclin homologs and a cyclin-dependent kinase. 
Pex11p regulates peroxisome biogenesis und morphogenesis (Kobayashi et al, 2007; 
Rottensteiner et al, 2003) and functions in medium-chain fatty acid oxidation (van 
Roermund et al, 2000) and Pby1p is a P-body associated protein. Smc3p is a member of 
the structural maintenance of chromosomes (SMC) family (Heidinger-Pauli et al, 2010) 
and a subunit of cohesion. 
Taken together, all these interaction partners of FOX2 in yeast are also potential binding 
partners of HSD10 in humans. Considering the role of HSD10 for mitochondrial integrity 
and cell viability under normal or stress conditions, Cmk1p and Rsp5p are especially 
interesting candidates for a functional interaction with HSD10.  
 
4.5.2. Functional interaction of human HSD10 and UXT in vivo 
In a yeast-2-hybrid system, where HSD10 was used as bait and a HeLa cDNA library as 
prey, two potential interaction partners were identified: PCBP1 and UXT. PCBP1 (PolyC 
binding protein 1) binds to mRNAs that contain a DICE (differentiation control element) 
in the cytoplasm and thereby represses their translation. Upon phosphorylation it 
releases the mRNAs for translation and migrates to the nucleus where it functions as a 
transcription factor and plays a role in splicing. UXT (ubiquitously expressed transcript) is 
a small prefoldin-like protein implicated in several cellular functions. One of them is the 
promotion of the NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
enhanceosome in the nucleus and as such it plays a role in mitochondrial aggregation 
and apoptosis. 
Since UXT is involved in regulation of apoptosis it was tested for functional interaction 
with HSD10. UXT is predominantly localised in the nucleus (Markus et al, 2002) but also 
present in the cytoplasm, e.g. as a component of centrosomes (Zhao et al, 2005). 
Although the greater part of HSD10 is detectable in mitochondria in immunofluorescence 
stainings (fig. 10) a small part might be distributed in the cytosol. Also, a Western Blot 
showing HSD10 overexpression in HEK cells pointed towards an additional cytosolic 
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fraction of HSD10 (data not shown). Based on this, it was assumed that UXT and HSD10 
bind to each other in the cytosol. This might inhibit the transport of UXT to the nucleus, 
its binding to NFκB, and subsequently the induction of apoptosis. According to this 
hypothesis, an overexpression of UXT in Xenopus embryos should induce an increase in 
apoptosis which should be opposed by a simultaneous co-injection of HSD10. In this 
situation HSD10 could have a protective function in the cell. 
The human constructs for UXT and HSD10 were used for the expression on the right 
body half of Xenopus embryos and after 2 days in culture (stage NF 33/34) the embryos 
were subjected to TUNEL staining ancelld scored for apoptosis on each side (fig. 25). The 
left side was used as an internal control and the amount of apoptotic spots on the right 
(injected) side was normalised against the left (uninjected) side. 
 
 
Human wildtype HSD10 has been shown before to induce a small increase in apoptosis 
rate (fig. 19). In line with previous publications on UXT function in humans, 
overexpression of UXT in Xenopus embryos leads to an increase in apoptosis (fig. 25). 
Co-injection of HSD10 together with UXT do not result in a rescue of the apoptotic 
phenotype elicited by UXT. In contrast, an additive effect of the apoptosis inducing 
functions of UXT and HSD10 can be observed. Thus, human UXT and HSD10 do not 
appear to interact functionally in Xenopus embryos.  
 
Figure 25 Induction of apoptosis by UXT in the presence of HSD10. (A) Experimental 
scheme. Embryos were injected into one blastomere of the 4-cell-stage with 150 pg of DNA (pT-
Rex-DEST30_hHSD10 and pcDNA4/HisMaxB_hUXT). (B) Quantification of TUNEL staining on the 
right (injected) side of tailbud stage embryos (stage NF 33/34) normalised against the left (control) 
side. The standard error for 4 individual experiments (n = 36–62 embryos) is shown.  
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4.5.3. Pull-down/IMAC approach to identify binding partners of HSD10 
Pull-down experiments and IMAC (immobilised metal ion affinity chromatography) are 
tools to verify potential binding partners identified e.g. in yeast-2-hybrid systems or 
based on computational predictions. Here they were used to find proteins that bind to 
HSD10 in vivo. 
The pull-down of potential binding partners of HSD10 was performed by overexpressing 
xHSD10_myc in Xenopus embryos and using an anti-myc antibody coupled to magnetic 
AG-beads. Overexpressed xHSD10_myc can bind to its interaction partners in vivo and 
after 1 day in culture (stage NF 19) the protein was extracted and an anti-myc antibody 
coupled to magnetic AG-beads was added. The beads are used to pull-down tagged 
HSD10 together with potential interaction partners which should still be bound under the 
experimental conditions. Only when the complexes are purified from the cell extract is 
the binding between HSD10 and potential binding partners released. In comparison with 
an unspecific pull-down where an IgG-antibody was used, the protein bands specific for 
HSD10 should be visible on a SDS-gel (fig. 26). Likewise, endogenous HSD10 was pulled-
down from mitochondrial extract prepared from untreated HEK cells by an anti-HSD10 
antibody (fig. 26). Isolating mitochondria before the pull-down enriches HSD10 in the 
input and should be more capable to find interaction partners in mitochondria. 
Figure 26 Pull-down of xHSD10_myc and endogenous HSD10 together with potential 
binding partners. 150 pg xHSD10_myc were injected into Xenopus embryos at the 4-cell-stage. 
Embryos were cultivated until stage NF 19 and their protein extract was used to pull-down 
overexpressed xHSD10_myc together with bound proteins with 1 µg anti-myc antibody coupled to 
magnetic AG beads. Mitochondrial extract from confluent HEK cells grown on three 10 cm plates 
was subjected to a pull-down with 2 µg anti-HSD10 antibody to isolate endogenous HSD10 
together with its binding partners. All pulled-down proteins were run on a SDS-PAGE and detected 
by silver staining. Squares indicate bands which are specific for HSD10 pull-down opposed to a 
pull-down with IgG. 
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The comparison of the actual pull-down with the IgG control shows that there are several 
bands that are specifically pulled-down with anti-myc and anti-HSD10, respectively. With 
this method it was not possible to yield single neat bands on the SDS-gel.  
In order to obtain more specific and identifiable bands on the silver stained gel, HSD10 
protein was purified via IMAC prior to interaction partner binding. For this purpose E.coli 
BL21(DE3) were transformed with prokaryotic expression plasmids (pET15b_His/hHSD10 
and p11/His for the mutations) for human wildtype and mutated HSD10. The proteins 
were isolated from bacteria and purified via IMAC. Prior to elution an extract of 
mitochondrial proteins prepared from HEK cells was added to the column (fig. 27). In this 
situation potential interaction partners in the mitochondrial extract can bind while they 
flow by the His-tagged HSD10 bound to the Ni2+ agarose in the column. Together they 
are eluted from the column and separated on a denaturing SDS-gel. Silver staining and 
the subsequent comparison of the proteins eluted with HSD10 or an unrelated His-tagged 
control protein yields bands that are specific for HSD10 and are not due to binding of 
proteins to the Ni2+ agarose or incomplete purification. A successive comparison between 
bands that eluted with HSD10 wildtype or one of the three mutations might reveal 
binding partners that show differences in their ability to bind to wildtype or mutated 
HSD10.  
 
Figure 27 IMAC of wildtype and mutated HSD10 proteins together with potential binding 
partners. His-tagged HSD10 and a His-tagged control protein were expressed in E.coli BL21(DE3). 
Purification of these proteins was carried out on an IMAC column. Prior to elution an extract of 
mitochondrial proteins prepared from confluent HEK cells grown on three 10 cm plates was added. 
Elution of His-tagged proteins from the Ni2+ agarose was achieved by addition of 250 mM 
imidazole. 80 µl of the eluate were subjected to SDS-PAGE on a large size gel and proteins were 
detected by a silver staining kit according to the manufacturer’s instructions. Squares and numbers 
indicate bands which are specific for HSD10 wildtype protein (square 1 and 2) or the three 
mutations (square 3 and 4). 
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Comparison of the bands that come up with HSD10 or an unrelated control protein and 
comparison between wildtype and mutated HSD10 shows that indeed, there are two 
bands (band 1 and 2) visible with wildtype HSD10 that are not present with the 
mutations (fig. 27). The other way around, there are also two bands (band 3 and 4) that 
are found with all three mutations but not with wildtype HSD10. 
To identify these proteins the four bands were analysed by MS (mass spectrometry). For 
this purpose they were cut out of the silver stained gel and enzymatically digested by 
trypsin into smaller peptides. Subsequently these peptides were introduced into the mass 
spectrometer and identified by tandem mass spectrometry, which involves multiple steps 
of mass spectrometry selection, with some form of fragmentation occurring in between 
the stages. 
 
This analysis yields the amino acid sequence of several different peptides per band 
(table 6). Proteins that are bound to His-tagged HSD10 in the IMAC column can either be 
of bacterial origin and stem from the expression of HSD10 in E.coli or they can be human 
and originate from the mitochondrial extract applied to the columns. Therefore, these 
peptides were subjected to a BLAST search in a human or bacterial database at the NCBI 
(National Center for Biotechnology Information) and the results are listed in the table 
below (table 6).  
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peptides in band 1 
 
peptides in band 2 peptides in band 3 peptides in band 4 
K.DVQTALALAK.G K.DVQTALALAKGK.F R.VLDVNLMGTFNVIR.L R.VVEPLITLAK.T 
K.GGIVGMTLPIAR.D K.IFVDEGPSMK.R K.LFNELGPR.F R.RVVEPLITLAK.T 
K.GQTHTLEDFQR.V R.TSHITVVVSDR.- R.TRDNEIVAK.L R.AGDNAPMAYIELVDR.S 
R.VDVAVNCAGIAVASK.T K.IFVDEGPSMKR.I K.INALETVTIASK.A R.TYLYQGIAER.N 
K.VCNFLASQVPFPSR.L K.VSQALDILTYTNKK.A  R.GANLVNGLLYIDLER.V 
K.LGNNCVFAPADVTSEK.D R.ALNAAGFR.I  R.NFDLSPLMR.Q 
R.LVAGEMGQNEPDQGGQR.G K.STPFAAQVAAER.A  R.IAISERPALNS.- 
K.GLVAVITGGASGLGLATAER.L K.AILAAAGIAEDVK.I  K.FNDAVLR.H 
K.FGRVDVAVNCAGIAVASK.T K.AILAAAGIAENVK.I  R.FNDAVIR.N 
K.KLGNNCVFAPADVTSEK.D R.FGGESVLAGSIIVR.Q  R.FNNAVIR.N 
K.SQAHTLEDFQR.V R.LQAFEGVVIAIR.N  R.AGLQFPVGR.I 
K.LGEYGFQNALIVR.Y   R.AGIQFPVGR.I 
K.DAFLGSFLYEYSR.R   R.FNNLGLR.G 
R.KVPQVSTPTLVEVSR.S   K.FGGNLGLR.F 
R.VATVSLPR.S   R.FGGDGLLR.E 
K.LSSPATLNSR.V   K.AQLQEIAQTK.M 
R.LGEHNIDVLEGNEQFINAAK.I   R.AQLQQIAQTK.A 
R.VGYLVVSTDR.G     
K.VMLQAYDEGR.L     
R.VGYIVVSTDR.G     
K.LGEYGFQNALLVR.Y     
K.KVPQVSTPTLVEVSR.S     
R.VGYIVVTSDR.G     
R.VGYIVISSDR.G     
R.LVGQGASAVLLDLPNSGGEAQAK.K       
Table 6 MS results of proteins found in IMAC of wildtype and mutated HSD10 proteins 
together with potential binding partners. Bands distinguishable in the IMAC approach to find 
binding partners (fig. 27) that were detectable with wildtype HSD10 but not with the mutations or 
the other way around were analysed in MS. This table lists the peptides identified in MS that 
compose the indicated bands. 
 
MS of four bands detected in the IMAC to be specific for wildtype or the three mutations 
(fig. 27 and table 6), respectively, and a successive BLAST search in a human or 
bacterial database at the NCBI revealed several potential binding partners for HSD10 
(table 7). BLAST results that are only found with one peptide are assumed to be 
unspecific since the peptides that are used for the BLAST search are very short, and also 
unnamed protein products are not considered specific. Thus, the remaining specific 
results are listed in table 7. 
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BLAST results only found with  
wildtype HSD10 (bands 1 and 2) 
BLAST results only found with  
mutated HSD10 (bands 3 and 4) 
 
human database 
 
bacterial database human database bacterial database 
3-
ketodihydrosphingosine 
reductase 
membrane-bound ATP 
synthase α-subunit 
AtpA 
H2A histone family, 
member V 
heat shock protein 
IbpA 
α-fetoprotein ATP synthase gamma 
subunit 
 
50S ribosomal protein 
L11 and L17 
albumin 
Chain K and M, 
Ternary Complex 70s 
Ribosome (= 30S 
ribosomal protein S10 
and S12) 
 
Chain N, Ternary 
Complex 70s Ribosome 
(= 30S ribosomal 
protein S13) 
 
50S ribosomal protein 
L22 
  
 
30S ribosomal protein 
S11 and S13 
  
Table 7 Potential binding partners of wildtype HSD10 and mutations R130C, D86G and 
Q165H. BLAST search results of peptides identified in MS of proteins that were co-purified with 
HSD10 wildtype or mutations (table 6) obtained from a human or bacterial database are listed in 
this table. BLAST search results that were only found with one short peptide or that belonged to 
unnamed protein products or were part of HSD10 itself were rendered unspecific. The remaining 
potentially specific interaction partners are listed here. 
 
Proteins that are specific for wildtype HSD10 and came up in a BLAST search in a human 
database are 3-ketodihydrosphingosine reductase, α-fetoprotein and albumin. KDHSR  
(3-ketodihydrosphingosine reductase) plays a role in the biosynthesis of sphingolipids at 
the cytosolic side of the ER by reducing 3-keto-sphinganine to dihydrosphingosine 
(Takabe et al, 2008). Sphingolipids are essential membrane components of eukaryotic 
cells. Like HSD10, KDHSR belongs to the SDR (short-chain dehydrogenase/reductase) 
family. It shows the typical SDR active-site motif YXXXK, which is preceded by a 
conserved Ser 13 residues upstream as well as a Rossman fold in the nucleotide binding 
domain and the nucleotide binding motif GXXXGXG.  
AFP (α-fetoprotein) is a mammalian glycoprotein and a member of the albuminoid gene 
superfamily. During normal development, AFP is synthesised in the fetal yolk sac 
endoderm and liver, and diffuses rapidly into the maternal circulation. After birth, the 
AFP level drops rapidly in the maternal serum, but remains high in the newborn for about 
four weeks associated with continued proliferation of hepatocytes in the liver until liver-
cell proliferation ceases. Then the AFP level declines rapidly and only small quantities 
remain present in adults. AFP functions as a transporter protein carrying e.g. copper, 
nickel and fatty acids in fetal serum (Sell, 2008). 
Albumin is a globular protein produced in liver cells. It is present in and outside of blood 
vessels and is responsible for the maintenance of osmotic pressure by retaining water 
molecules in the vessels. Hydrophobic compounds like fatty acids, some vitamins or 
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hormones need to be bound to albumins to be transported in the blood flow. Since 
albumins are H+ acceptors and donors they also play a role in stabilising the pH of the 
blood (Chuang & Otagiri, 2007; Hankins, 2006; van der Vusse, 2009). 
 
Proteins that are specific for wildtype HSD10 and came up in a BLAST search in a 
bacterial database are membrane-bound ATP synthase (α-subunit AtpA and gamma 
subunit) and several ribosomal proteins. 
Membrane-bound ATP synthase is composed of the F1 complex which is the catalytic core 
and comprises 5 subunits (alpha, beta, gamma, delta, epsilon) linked to the F0 
membrane-embedded proton channel that consists of at least three subunits (A-C), nine 
in mitochondria (A-G, F6, F8). Both the F1 and F0 complexes are rotary motors that 
rotate in opposite directions in order to drive ATP synthesis. The α-subunit AtpA can bind 
nucleotides in the F1 catalytic cylinder formed by three alpha and three beta subunits 
whereas the gamma subunit forms the central shaft that connects the F0 rotary motor to 
the F1 catalytic core (Abrahams et al, 1994; Stock et al, 1999).  
Ribosomal proteins that belong to the 30S subunit (S10, S11, S12 and S13) or the 50S 
subunit (L22), respectively, are found to be potential bacterial interaction partners of 
wildtype HSD10. 
 
One protein that is only found with mutated HSD10 and came up in a BLAST search in a 
human database is H2A histone family, member V. 
Histones are basic proteins that are responsible for the nucleosomal structure in 
eukaryotes. Nucleosomes consist of DNA wrapped around a histone octamer composed of 
two of each core histones (H2A, H2B, H3 and H4). The H2A family performs essential 
roles in maintaining structural integrity of the nucleosome, chromatin condensation, and 
binding of specific chromatin-associated proteins (Farris et al, 2005; Li et al, 2005; 
Raisner et al, 2005). 
 
Proteins that are specific for mutated HSD10 and came up in a BLAST search in a 
bacterial database are heat shock protein IbpA and several ribosomal proteins. 
Heat shock protein IbpA is a molecular chaperone that binds denatured proteins and 
facilitates their subsequent refolding by the ATP-dependent chaperones DnaK, DnaJ, 
GrpE and ClpB. It has been shown that IbpA can protect E.coli cells from oxidative 
damage caused by copper and from thermal stress (Matuszewska et al, 2008; Thomas & 
Baneyx, 1998) 
Ribosomal protein S13 that belongs to the 30S subunit is found to be a potential bacterial 
interaction partner of mutated HSD10. 
 
Among these possible binding partners (table 7) are three potentially specific results. 
Due to their localisation in mitochondria and their role in energy metabolism and stress 
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response, the ATP synthase subunits, ribosomal proteins and IbpA, might be specific 
binding partners of HSD10 in mitochondria.  
In summary, there are several findings among these potential binding partners that are 
most likely unspecific. Proteins that are separated from HSD10 by their subcellular 
localisation, like AFP, albumin or H2A, are probably unspecific. Likewise, KDHSR might 
turn up in this BLAST search because it comprises the same motifs as HSD10 and the 
peptides that are used as a query are very short. 
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4.6. Function of HSD10 as a component of human mitochondrial RNaseP 
Recently, HSD10 has been shown to be a component of the human mitochondrial RNaseP 
complex. This enzyme endonucleolytically cuts the 5’ end of tRNAs. In contrast to other 
RNaseP complexes, human mtRNaseP (mitochondrial RNaseP) has been shown to be a 
RNA free, protein-only enzyme that consists of three proteins: MRPP1, MRPP2 (HSD10) 
and MRPP3.  
Furthermore, it has been shown that knock-down of one of these proteins and a 
consequential loss of mtRNaseP activity in HeLa cells causes the accumulation of two 
mitochondrial tRNA precursors (Holzmann et al, 2008).  
 
4.6.1. Accumulation of tRNA precursors after HSD10 loss-of-function 
In order to establish a system to test the mutated HSD10 proteins for their mtRNaseP 
activity, the accumulation of several precursor (mt)tRNAs was determined in HeLa cells 
over a nine day time course after knock-down of HSD10 by two different siRNAs (fig. 28). 
The previously published accumulation (Holzmann et al, 2008) did only occur for one of 
two tested siRNAs for HSD10 and was only shown for two tRNA precursors, which were 
very different in their level of accumulation. Therefore, two previously used siRNAs 
targeting HSD10 (siRNA3 and siRNA5) were tested for their effect on accumulation of 
several tRNA precursors. 
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Figure 28 Accumulation of tRNA precursors after HSD10 knock-down. Transient 
transfection of HeLa cells was achieved using Lipofectamine and 60 pmol of two different siRNAs 
targeting HSD10 (siRNA3 and siRNA5). Total RNA was isolated from these cells after two to nine 
days post transfection and the RNA was transcribed into cDNA using Maxima Reverse Transcriptase 
and random primers or primers specific for (mt)tRNA sequences (orange arrow in A). This cDNA 
was subjected to qRT-PCR with internal tRNA primers for detection of the whole amount of 
mitochondrial tRNA transcript (precursor and mature, orange and pink arrows in A) and primers 
that cover the 5’ leader sequence as well as part of the tRNA to quantify the amount of 
mitochondrial precursor tRNAs (orange and green arrows in A). (A) Displays the binding sites of 
tRNA specific primers and (B) shows the proof of knock-down efficiency by two different siRNAs 
against HSD10 over several days relative to cells treated with 60 pmol inert negative control siRNA. 
Random primed cDNA was subjected to qRT-PCR and CT values were normalised against GAPDH 
and control siRNA treated cells. Relative expression levels of HSD10 were calculated using a stan-  
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Treatment of HeLa cells with 60 pmol of two different siRNAs results in an efficient 
knock-down of HSD10 over more than nine days (fig. 28B). Three days after knock-down 
of HSD10 with siRNA3 mitochondrial tRNA precursor levels increase to a temporary peak 
at 7- to 47-fold above those of control siRNA treated cells (fig. 28C, left). With siRNA5 
the temporary maximum of mitochondrial tRNA precursor accumulation is found after 
four to five days post transfection and ranges from an 11- to 91-fold increase compared 
to cells treated with control siRNA (fig. 28C, right). In line with siRNA transfections being 
transient, HSD10 mRNA knock-down and concurrent precursor (mt)tRNA accumulation 
return to normal levels within the nine days examined (fig. 28B and C). The two different 
siRNAs used to knock-down HSD10 give rise to slightly different kinetics of precursor 
(mt)tRNA accumulation. In both cases precursors of tRNAM, tRNAI, tRNAF and tRNAV are 
among the tRNAs with the highest accumulation but the time point at which the highest 
accumulation can be detected varies. 
The total amount of tRNAs also shows alterations upon treatment with siRNA targeting 
HSD10. It rises up to almost 20-fold above or 0,01-fold below the level of cells treated 
with control siRNA. In order to take into account the deviation of total tRNA amount and 
still be able to compare the accumulation of tRNA precursors, the ratio of total tRNA to 
tRNA precursor was calculated. In cases where the precursor increases more than the 
total amount of a certain tRNA the ratio falls below 1. Fig. 28E clearly shows that for 
almost all tRNAs and timepoints investigated here, this ratio is < 1. 
In conclusion, a transient knock-down of HSD10 leads to the inhibition of RNaseP activity 
judged by the consequential accumulation of mitochondrial tRNA precursors.  
 
4.6.2. Reconstitution of RNaseP activity using mutated HSD10 after HSD10 loss-
of-function 
The function of HSD10 in mitochondrial tRNA processing might be the underlying reason 
for the clinical phenotype in HSD10 deficiency patients. Mutations in mitochondrial tRNAs 
cause a disturbance of mitochondrial translation possibly resembling the mutation of one 
of the components of RNaseP. Mitochondrial tRNA mutations are known to elicit many 
different clinical syndromes including mitochondrial myopathy (Swalwell et al, 2006), 
CPEO (chronic progressive external ophtalmoplegia; Spagnolo et al, 2001), MELAS 
(mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes; Tzen et al, 
2003) and ADPD (Alzheimer's disease and Parkinsons's disease; Wallace et al, 1992). 
dard curve. (C) and (D) denote the accumulation of nine different mitochondrial tRNA precursors 
(C) and changes of the total amount of nine different mitochondrial tRNAs (D) in relativity to cells 
treated with an inert negative control siRNA (control siRNA = 1) over a time course of nine days. 
Specifically primed cDNA was subjected to qRT-PCR with tRNA specific primers and CT values were 
normalised against GAPDH. Relative expression levels of immature (mt)tRNA precursor and the 
total tRNA amount were calculated using the ddCT method. (E) Shows the ratio of total (mt)tRNA 
amount to immature precursor for nine different (mt)tRNAs over a time course of nine days after 
knock-down of HSD10. pt: post transfection, TF-TC: T stands for tRNA and the second letter 
denotes the specific amino acid according to the one letter code for amino acids. 
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To test the mutations found in HSD10 deficiency patients for their residual activity in 
tRNA processing, a rescue experiment was performed (fig. 29). After siRNA mediated 
knock-down of endogenous HSD10 and co-transfection with constructs coding for HSD10 
wildtype or mutations, the accumulation of several precursor (mt)tRNAs was determined 
in HeLa cells after three days. 
 
Co-transfection of siRNA targeting HSD10 and a concomitant overexpression of HSD10 
wildtype and mutations resulted in very different expression levels of HSD10 (data not 
shown). The higher the expression level was compared to endogenous HSD10, the higher 
was the ability of wildtype or mutated HSD10 to re-establish the function of mtRNaseP 
and thus, to rescue the accumulation of mitochondrial tRNA precursors. Samples with 
equivalent HSD10 expression at the physiological level of HSD10 expression in cells 
treated with a negative control siRNA were chosen for analysis of tRNA levels to be able 
to draw a conclusion about the ability of mutated HSD10 to function in the (mt)RNaseP 
complex at physiological quantities (fig. 29A).  
Three days after knock-down of HSD10 with siRNA3 mitochondrial tRNA precursors 
accumulate indicated by a decrease of the total amount/precursor ratio below the level of 
cells treated with control siRNA (control siRNA = 1). Co-transfection of HSD10 DNA does 
Figure 29 Accumulation of tRNA precursors after HSD10 knock-down and rescue. 
Transient co-transfection of HeLa cells was achieved using Lipofectamine and 60 pmol of siRNA3 as 
well as 1 µg of DNA (pT-Rex_DEST30 containing cDNA for HSD10 wildtype and mutations). Total 
RNA was isolated from these cells after three days post transfection and the RNA was transcribed 
into cDNA using Maxima Reverse Transcriptase and random primers or primers specific for 
(mt)tRNA sequences. This cDNA was subjected to qRT-PCR with internal tRNA primers for detection 
of the whole amount of mitochondrial tRNA transcript (precursor and mature) and primers that 
cover the 5’ leader sequence as well as part of the tRNA to quantify the amount of mitochondrial 
precursor tRNAs. (A) Displays the relative expression levels of HSD10 in HeLa cells co-transfected 
with siRNA against HSD10 and cDNA coding for HSD10 wildtype or the mutations. Random primed 
cDNA was subjected to qRT-PCR and CT values were normalised against GAPDH. Relative 
expression levels of HSD10 were calculated using a standard curve. (B) Shows the ratio of total 
(mt)tRNA amount to immature precursor for five different (mt)tRNAs three days after knock-down 
of HSD10 with siRNA3 and rescue with HSD10 wildtype and mutations. 
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rescue this accumulation in part depending on the tRNA in question and the respective 
DNA being wildtype or bearing a mutation (fig. 29B). HSD10 wildtype rescues the 
accumulation of tRNA precursors for all tested tRNAs. The R130C mutation rescues three 
out of five tested tRNAs (TF, TL and TI), the D86G mutation rescues all except for TV, 
and Q165H is able to bring tRNA precursor levels back to normal for three tRNAs (TF, TI, 
TM). Taken together to a mean of the five tested tRNAs despite the great variability 
between the different tRNAs, all mutations alike are able to rescue the accumulation of 
immature precursors from 200 % in the knock-down situation back to 143 % of the 
normal level (level of tRNA precursors in control siRNA treated cells = 100 %; 
ctr siRNA = 1, siRNA3 = 0.5, HSD10 wildtype = 1.7, all mutations = 0.7). The mutations 
are not as active in their RNaseP activity as the wildtype protein, which even over-
compensates and reduces tRNA precursor levels to 59 % of the normal level. 
This experiment does not show a clear pattern of rescue with HSD10 wildtype or the mild 
Q165H mutation but not with the two severe mutations as it was the case for the rescue 
of the apoptosis phenotype (Rauschenberger et al, 2010). Nevertheless, it gives clear 
evidence that the expression of the two severe mutations R130C and D86G does not 
have a dominant-negative effect on (mt)RNaseP activity in contrast to the apoptotic 
phenotype shown before (fig. 19). 
 
4.6.3. RNaseP activity in patient fibroblasts under physiological and oxidative 
stress conditions 
To investigate if the disturbed function of (mt)RNaseP is the cause for the observed 
disease phenotype in HSD10 deficiency patients, mitochondrial tRNA levels were 
determined in patient fibroblasts. The severe R130C but not the mild Q165H mutation 
should display a considerable accumulation of (mt)tRNA precursors comparable to a 
HSD10 knock-down. 
Transfection of cells is only a transient effect which does not necessarily reflect the 
condition of patient cells that carry a mutation right from the start. Furthermore, co-
transfection of siRNA and DNA that can be targeted by the siRNA does probably result in 
the expression of a mixture of endogenous wildtype HSD10 and transfected wildtype or 
mutated HSD10. To eliminate these factors mitochondrial tRNA levels were determined in 
HSD10 deficiency patient fibroblasts directly (fig. 30).  
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In patient fibroblasts mitochondrial tRNA precursors are not accumulated as expected. 
The total amount of mitochondrial tRNA (fig. 30B) as well as the level of precursors 
(fig. 30A) is strongly decreased compared to control cells. In both cases the reduction is 
higher for cells with the R130C mutation than in fibroblasts with the Q165H mutation. 
The ratio of total amount of tRNA to precursors is only slightly altered for some tRNAs 
compared to control cells which points to a concurrent reduction of both tRNA forms 
(fig. 30C). For other tRNAs the ratio is > 1, indicating the stronger decrease of immature 
precursor relative to the total amount of tRNAs. The reduction of all tRNA forms might be 
the long-term response of the cells to the mutations and the permanently impaired 
(mt)RNaseP activity in patients in contrast to the transient effects upon siRNA mediated 
knock-down of HSD10 shown before (fig. 28).  
As described above, HSD10 seems to play a role in the protection of cells against 
metabolic stress and this protective effect might be disturbed by altered HSD10 protein 
structure due to specific mutations. Under physiological conditions, the amount of total 
Figure 30 tRNA levels in HSD10 deficiency patient fibroblasts. Total RNA was isolated from 
control cells or cells carrying the R130C or Q165H mutation and the RNA was transcribed into cDNA 
using Maxima Reverse Transcriptase and random primers or primers specific for (mt)tRNA 
sequences. This specifically primed cDNA was subjected to qRT-PCR with internal tRNA primers for 
detection of the whole amount of mitochondrial tRNA transcript (precursor and mature) and 
primers that cover the 5’ leader sequence as well as part of the tRNA to quantify the amount of 
mitochondrial precursor tRNAs. CT values were normalised against GAPDH. Relative expression 
levels were calculated using the ddCT method whereat levels in control cells were set to 1. (A) 
Denotes the amount of nine different (mt)tRNA precursors in relativity to control cells 
(control = 1). (B) Displays changes of the total amount of (mt)tRNAs in relativity to control cells. 
(C) Shows the ratio of total (mt)tRNA amount to immature precursor. 
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(mt)tRNA as well as (mt)tRNA precursors is reduced in fibroblasts with the R130C and 
the Q165H mutation (fig. 30). In order to investigate whether mutated and control 
fibroblasts respond differently to cellular stress conditions, their ability to process 
(mt)tRNAs was examined (fig. 31). Oxidative stress was induced by two different 
concentrations of rotenone and the cells were scored for their level of total and precursor 
(mt)tRNA after one or two days.  
 
Interestingly, the amount of mitochondrial tRNA precursors increases in control 
fibroblasts under all oxidative stress conditions tested, as indicated by the ratio of total 
tRNA to precursor < 1 (fig. 31A). In contrast, cells carrying the R130C mutation display a 
decrease of mitochondrial tRNA precursors upon oxidative stress induced by rotenone 
Figure 31 Amount of tRNA precursors in HSD10 deficiency patient fibroblasts under 
oxidative stress. Fibroblasts were treated with 150 nM or 500 nM rotenone for one or two days. 
Total RNA was isolated from control cells or cells carrying the R130C or Q165H mutation and the 
RNA was transcribed into cDNA using Maxima Reverse Transcriptase and random primers or 
primers specific for (mt)tRNA sequences. This specifically primed cDNA was subjected to qRT-PCR 
with internal tRNA primers for detection of the whole amount of mitochondrial tRNA transcript 
(precursor and mature) and primers that cover the 5’ leader sequence as well as part of the tRNA 
to quantify the amount of mitochondrial precursor tRNAs. CT values were normalised against 
GAPDH. Relative expression levels were calculated using the ddCT method whereat levels in 
untreated cells were set to 1. (A) Shows the ratio of total (mt)tRNA amount to immature precursor 
for five different tRNAs in control fibroblasts. Changes in control cells under various oxidative stress 
conditions are shown in comparison to untreated control cells (control = 1). (B) Displays the ratio 
of total (mt)tRNA amount to immature precursor in R130C fibroblasts. Alterations in cells with the 
R130C mutation under various oxidative stress conditions are shown in comparison to untreated 
R130C cells (control = 1). (C) Shows the ratio of total (mt)tRNA amount to immature precursor for 
five different tRNAs in Q165H fibroblasts. Changes under various oxidative stress conditions are 
shown in comparison to untreated Q165H cells (control = 1). 
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treatment indicated by the ratio of total tRNA to immature precursors > 1 (fig. 31B). 
Cells carrying the benign Q165H mutation exhibit a mixture of slightly increased and 
decreased (mt)tRNA precursors (fig. 31C). In these cells, there is an obvious trend of 
precursor accumulation upon oxidative stress like in control fibroblasts. But also a slight 
decrease of mitochondrial tRNA precursors that is found in fibroblasts with the R130C 
mutation can be observed with the Q165H mutation. The overall amount of total tRNA 
varies slightly but does not change significantly in all cases.  
Thus, mutated fibroblasts behave differently under oxidative stress. Control fibroblasts 
react to oxidative stress by an accumulation of unprocessed mitochondrial tRNA 
precursors. Mutated fibroblasts are not able to respond in the same way but rather 
display a decrease depending on the mutation. 
 
4.6.4. Effect of impaired RNaseP activity on mitochondrial translation 
HSD10 plays a role in the correct post transcriptional processing of mitochondrial tRNAs 
and concurrently functions in the maturation of mitochondrial mRNAs and rRNAs 
according to the “tRNA punctuation model of RNA processing in human mitochondria” 
(Ojala et al, 1981). Therefore, in a HSD10 loss-of-function scenario polycistronic 
mitochondrial transcripts are not processed correctly and consequentially not only the 
immature precursors of (mt)tRNAs but also the level of unprocessed mitochondrially 
encoded mRNAs accumulate. The concurrent lack of mature (mt)tRNAs and mature 
mRNAs caused by impaired (mt)RNaseP function due to HSD10 knock-down or mutation 
should lead to a reduction or stop of protein translation for all proteins that are encoded 
mitochondrially. Proteins that are transcribed from nuclear DNA and that are imported 
into mitochondria after they have been translated in the cytosol should not be affected.  
To analyse on a translational level, whether a decrease in mitochondrial protein 
translation occurs after HSD10 loss-of-function and whether mutated and control 
fibroblasts respond differently to oxidative stress conditions, protein amounts of two 
different subunits of complex IV were determined. Complex IV (cytochrome c oxidase, 
COX) is a large integral membrane protein complex of the respiratory electron transport 
chain in mitochondria. It transfers electrons from cytochrome c to oxygen, converting 
them to water. In addition, it transports protons across the membrane, helping to 
establish the membrane potential that drives the motor force of ATP synthase. The 
complex consists of 13 subunits in mammals, ten of which originate in the nucleus (e.g. 
subunit COXIV) and three in mitochondria (e.g. subunit COXI). The amount of the 
nuclear encoded subunit IV of complex IV (COXIV) should not be affected by HSD10 loss-
of-function by knock-down or mutation. In contrast, the amount of the mitochondrially 
encoded subunit I of complex IV (COXI) should display a decrease upon HSD10 knock-
down. In this situation the correct processing of mitochondrial transcripts and 
consequentially the translation of proteins encoded in mitochondria is abolished. Existing 
endogenous protein is not concerned but every protein becomes degraded after a certain 
time and is newly synthesised. A disturbance in the synthesis should cause a decrease in 
mitochondrially encoded proteins (in this case subunit COXI) which would probably arise 
with a delay to the accumulation of tRNAs after 3-4 days. Thus, the impact of impaired 
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mitochondrial translation will be detectable at least 4 days after HSD10 knock-down 
depending on the stability of the tested protein subunits.  
HSD10 was knocked-down in HeLa cells and the amount of COXIV and COXI was 
determined on a Western Blot (fig. 32A). This system also provides the possibility to test 
the mutations found in HSD10 deficiency patients for differences in their behaviour under 
physiological and oxidative stress conditions (fig. 32B). Therefore, untreated fibroblasts 
or fibroblasts treated with rotenone were analysed for their amount of nuclear and 
mitochondrially encoded protein subunits, respectively. 
 
The comparison of COXI and COXIV protein levels in cells where HSD10 is efficiently 
knocked-down indicates that the amount of mitochondrially encoded subunit COXI is 
slightly reduced upon HSD10 knock-down (fig. 32A top). However, the nuclear encoded 
subunit COXIV is significantly stronger reduced. In patient fibroblasts the mitochondrially 
encoded subunit COXI is not reduced but rather increased (fig. 32B left, top) under 
physiological conditions (- rotenone), whereas the nuclear encoded subunit COXIV is 
again strongly reduced compared to control cells (fig. 32B left, middle). There are no 
significant changes in protein amounts (COXI, COXIV or tubulin) upon rotenone 
treatment. 
This suggests that mitochondrial translation is slightly impaired upon HSD10 knock-down 
but not affected in patient fibroblasts under physiological or oxidative stress conditions. 
 
Figure 32 Comparison of nuclear and mitochondrial translation after HSD10 loss-of-
function. (A) Transient transfection of HeLa cells was achieved using Lipofectamine and 60 pmol 
of an inert negative control siRNA or siRNA3 and 5 targeting the ORF of HSD10. Protein extract was 
prepared four days post transfection and analysed by SDS-PAGE and Western Blot using anti-COXI 
and anti-COXIV antibodies. HSD10 and actin levels were analysed as knock-down and loading 
controls. (B) Fibroblasts from HSD10 deficiency patients were left untreated or were treated with 
500 nM rotenone for three days before protein extract was prepared and analysed by SDS-PAGE 
and Western Blot using anti-COXI and anti-COXIV antibodies. Tubulin levels were detected as a 
loading control. ctr: control. 
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4.6.5. RNaseP dependency of apoptosis induced by HSD10 loss-of-function 
It has been shown previously in Xenopus embryos, in human cells and in cells from 
conditional knock-out mice that HSD10 loss-of-function elicits an increase in apoptosis 
(Rauschenberger et al, 2010). This phenotype has been attested to be specific for HSD10 
knock-down since it can be rescued by the addition of human HSD10 wildtype and 
partially by the mild Q165H mutation. 
Unfortunately, the deployed apoptotic pathway is still unknown but next it was analysed 
if the induction of apoptosis is dependent on the function of HSD10 as a component of 
the (mt)RNaseP complex. To address this question, a siRNA mediated knock-down of 
nuclear encoded HSD10 was performed in cells that have been depleted of mitochondrial 
DNA (fig. 33). Low doses of ethidium bromide inhibit replication of mitochondrial DNA 
and thus generate so-called rho zero (rho0, ρ0) cells which lack mitochondrial DNA and 
as a consequence critical subunits of the respiratory chain. Those cells still have small 
mitochondria but they cannot support normal oxidative phosphorylation and depend on 
supplementation of pyruvate (2.5 mM) and uridine (100 µg/ml) in the culture medium. 
Rho0 cells are generally used to examine the role that mitochondria play in distinct 
physiological pathways e.g. apoptosis (Chandel & Schumacker, 1999; Lee et al, 2004).  
If the induction of apoptosis upon knock-down of HSD10 is due to impaired (mt)RNaseP 
activity and thus dependent on mitochondrial translation, rho0 cells that do not comprise 
mitochondrial DNA and consequentially mitochondrial translation should not be affected 
by the apoptotic phenotype caused by HSD10 knock-down. 
BTK-143 osteogenic sarcoma cells were used for HSD10 knock-down either as untreated 
wildtype cells or as rho0 cells depleted of their mitochondrial DNA (fig. 33). As a control 
BTK-143 rho0 cells were re-substituted with mitochondrial DNA (haplotype H or T). 
Transient knock-down of HSD10 in these cells was performed and the ratio of apoptotic 
cells was determined by DAPI staining and microscopic evaluation of the morphological 
structure of nuclei. DAPI (4’, 6-diamidino-2-phenylindole) preferentially binds to AT rich 
parts of DNA and fluoresces in bright blue when excited with ultraviolet light. It is used 
as a specific marker for nuclei and enables the analysis of nuclear morphology. Apoptotic 
nuclei are discernible by an irregular nuclear membrane and beginning chromatin 
condensation early in apoptosis. At later stages nuclear fragmentation and the formation 
of nuclear apoptotic bodies takes place. Nuclear apoptotic bodies are irregular blebbings 
of the nuclear membrane containing membrane-bound chromatin. 
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The normal ratio of apoptotic BTK-143 cells in culture lies between 2.6 and 3.6 % judged 
by the percentage of apoptotic nuclei in the untreated control and in cells treated with an 
inert negative control siRNA (fig 32D). This applies to all BTK-143 cells: wildtype, rho0 or 
haplotype T and H, respectively. DNaseI incubation and transfection with apoptosis 
inducing FADD (Fas-Associated protein with Death Domain) were used as a positive 
control. These treatments increase the ratio of apoptotic cells to 4.8-8.8 %. Likewise, 
transfection with HSD10 targeting siRNA3 and siRNA5 raises the ratio of apoptotic cells to 
4.8-6.6 % for siRNA3 and 6.8-8.6 % for siRNA5 in control as well as in rho0 BTK-143 
cells.  
Interestingly, HSD10 knock-down in rho0 BTK-143 cells causes an increase in apoptosis 
although these cells do not comprise mitochondrial translation and thus, (mt)RNaseP 
function. Therefore, the induction of apoptosis upon HSD10 loss-of-function is not 
dependent on RNaseP function in mitochondria. 
Figure 33 Apoptosis induced by HSD10 knock-down in BTK-143 cells. BTK-143 osteogenic 
sarcoma cells were used as wildtype cells (WT), rho0 cells (depleted of mitochondrial DNA) or as 
two control cell lines haplotype H and haplotype T (depleted of mitochondrial DNA and re-
substituted with mitochondrial DNA). BTK-143 cells were transfected with 1 µg of FADD plasmid or 
60 pmol of inert negative control siRNA, siRNA3 or siRNA5, using Lipofectamine. 48 hours post 
transfection cells were fixed and samples used as a positive control were treated with DNaseI for 
10 min prior to the labelling procedure. Chamber slides were then transferred to DAPI for 10 min, 
mounted in Mowiol and observed by fluorescent microscopy. Exemplary pictures of normal nuclei 
(A) and apoptotic nuclei (B) in contrast to mitotic nuclei (C) stained with DAPI are shown. (D) 
Indicates the percentage of apoptotic nuclei for each sample scored by their morphological 
appearance in DAPI staining. Significant differences compared to cells treated with negative control 
siRNA were calculated by the student t-test. * indicates significance at p ≤ 0.01. ctr: control, WT: 
wildtype, haplo H and T: haplotypes H and T. 
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To verify these results obtained with DAPI staining, the activity of a key mediator in 
apoptosis, caspase-3, was determined (fig. 34). Caspase-3 is activated in apoptotic cells 
both by extrinsic and intrinsic signals. It is an executioner caspase that is responsible for 
chromatin condensation and DNA fragmentation. 
Again, BTK-143 osteogenic sarcoma cells were used for HSD10 knock-down with siRNA3 
either as untreated wildtype cells or as rho0 cells depleted of their mitochondrial DNA. As 
a control BTK-143 osteogenic sarcoma rho0 cells were re-substituted with mitochondrial 
DNA (haplotype H or T). The ratio of apoptotic cells was determined by microscopic 
evaluation of active caspase-3 positive cells in immunofluorescent stainings (fig. 34). 
 
The knock-down efficiency of the transient transfection of BTK-143 cells with siRNA3 was 
confirmed by a simultaneous immunostaining for HSD10 protein (data not shown). Since 
the fluorescent signal for active caspase-3 and HSD10 was captured under comparable 
conditions for each sample a semi-quantitative conclusion can be drawn about the 
abundance of HSD10 in the knock-down samples compared to controls. The fluorescent 
signal was categorised as “normal” or “weaker than normal”. On average, 7.6 % of 
control siRNA treated cells have a weaker signal for HSD10 than normal (2.7 % in 
haplotype H cells to 13.9 % in haplotype T cells, data not shown). In contrast, 34.4 % of 
Figure 34 Caspase-3 activity induced by HSD10 knock-down in BTK-143 cells. 
BTK-143 osteogenic sarcoma cells were used as wildtype cells (WT), rho0 cells (depleted 
of mitochondrial DNA) or as two control cell lines haplotype H and haplotype T (depleted 
of mitochondrial DNA and re-substituted with mitochondrial DNA). BTK-143 cells were 
transfected with 60 pmol of inert negative control siRNA or siRNA3, using Lipofectamine. 
48 hours post transfection cells were fixed and active caspase-3 was detected using 
polyclonal rabbit anti-cleaved caspase-3 antibody (1:100). After incubation with the 
secondary antibody (anti-rabbit Alexa 594, 1:1000) cells were washed, counterstained 
with DAPI nuclear stain and mounted in Fluorescence Mounting Media. Cells were 
counted in five randomly chosen visual fields and the percentage of caspase-3 positive 
cells is indicated here for each sample. Significant differences compared to cells treated 
with negative control siRNA were calculated by the student t-test. * indicates significance 
at p ≤ 0.01. ctr: control, WT: wildtype, haplo H and T: haplotypes H and T. 
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siRNA3 treated cells display a lower signal for HSD10 than normal (27.3 % in haplotype 
H cells to 39.3 % in wildtype cells).  
The ratio of BTK-143 cells, that are positive for active caspase-3 after transfection with 
an inert negative control siRNA, lies between 1.4 and 16.7 % judged by the percentage 
of fluorescent cells in all BTK-143 cells (wildtype, rho0, haplotype H and T). Transfection 
with siRNA3 targeting HSD10 raises the ratio of apoptotic cells to 21-62.5 % judged by 
the percentage of cells that are positive for active caspase-3 (fig. 34). This verifies the 
result shown before, that HSD10 knock-down in rho0 BTK-143 cells causes an increase in 
apoptosis (fig. 34) although these cells do not comprise mitochondrial translation and 
thus, (mt)RNaseP function. 
In conclusion, these experiments show that the induction of apoptosis after HSD10 loss-
of-function is not dependent on the mitochondrial transcription and translation machinery 
including RNaseP. An as yet unknown function of HSD10 that is independent of its 
dehydrogenase and tRNA 5’ processing function is required for cellular integrity and 
viability.  
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5 DISCUSSION 
5.1. A dehydrogenase-independent function of HSD10 is essential for 
mitochondrial integrity 
Several lines of evidence support the suggestion that HSD10 has an additional function 
apart from its important dehydrogenase role in mitochondrial metabolism. HSD10 loss-
of-function led to enhanced apoptotic cell death (Rauschenberger et al, 2010) and had 
adverse effects on mitochondrial structural integrity (fig. 14-17). 
First, complete loss of the HSD10 protein in Drosophila is embryonic lethal (Torroja et al, 
1998). Also in mouse causes the complete HSD10 knock-out lethality at very early stages 
of embryogenesis (day 5 p.f.; Rumig, 2006). It is unlikely that the embryonic lethality is 
due to the lack of enzyme activity, because it was shown for defects in comparable 
metabolic enzymes that toxic metabolites are efficiently eliminated by the placenta. A 
conditional knock-out in mice led to severely disrupted mitochondrial morphology in 
neurons of the CNS in the locus coeruleus and in some neurons of the PNS in the 
superior cervical ganglia (fig. 15 and 16), indicating that HSD10 is essential for 
mitochondrial integrity. 
Knock-down of HSD10 in Xenopus was not embryonic lethal since HSD10 is also provided 
maternally and the knock-down was only carried out in specific regions of the body by 
targeted microinjection. Knock-down of HSD10 in Xenopus animal caps resulted in a 
severe disruption of mitochondrial structure, and also mitochondrial function was 
impaired (fig. 17 and 18). Both effects could be rescued by co-injection of a human 
wildtype HSD10 construct. Additionally, the knock-down of HSD10 in Xenopus led to 
enhanced apoptosis in injected tissue and this effect could also be rescued by human 
HSD10 wildtype protein (Rauschenberger et al, 2010). The mutated HSD10 proteins 
found in human patients, however, showed remarkable differences in their ability to 
rescue the apoptotic phenotype. The Q165H mutation, which has less than 3 % residual 
enzymatic activity but was identified in three neurologically normal boys, partially 
rescued HSD10 MoATG-induced apoptosis. In contrast, injection of the mutations R130C 
and in particular D86G failed to rescue, and instead further enhanced apoptosis 
(Rauschenberger et al, 2010). D86G has considerable residual enzyme activity (28 %) 
despite being associated with a very severe clinical phenotype.  
Thus, HSD10 is required for mitochondrial integrity in Xenopus and mice. Apoptosis after 
HSD10 loss-of-function is not dependent on the dehydrogenase activity of HSD10, 
arguing for a non-dehydrogenase function of this protein. 
 
Secondly, HSD10 deficiency in humans causes an atypical organic aciduria (Zschocke et 
al, 2000; Ensenauer et al, 2002; Olpin et al, 2002). Neurological abnormalities in organic 
acidurias are usually attributed to accumulation of toxic substrates proximal to a specific 
enzymatic block, causing secondary interference with energy metabolism (Deodato et al, 
2006). Primary apoptotic nerve cell death as it was observed in HSD10 deficiency is not 
usually a feature of organic acidurias. Measurements of enzymatic activity in patient 
fibroblasts revealed that the R130C and D86G mutations associated with classical and 
neonatal neurodegenerative forms of HSD10 deficiency had up to 64 % residual activity 
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compared to the wildtype protein. In contrast, the Q165H mutation that was identified in 
three children with normal neurological development was associated with less than 3 % 
residual enzymatic activity (Rauschenberger et al, 2010). Thus, the severity of the 
clinical phenotype is not at all correlated with the enzymatic activity of the mutated 
HSD10 proteins. Also, symptoms observed in patients are not due to the accumulation of 
toxic metabolites in the isoleucine pathway. 3-ketothiolase deficiency, the enzyme 
catalysing the last step in the breakdown of isoleucine, causes the same metabolites in 
urinary organic acid assays but a completely different clinical picture not including 
progressive neurodegeneration but rather the classical symptoms of an organic aciduria 
(Ozand et al, 1994). Also, an isoleucine restrictive diet that avoids the accumulation of 
potentially toxic metabolites failed to improve the condition of patients (unpublished 
data). 
In contrast to most other metabolic disorders, no null mutations that completely 
eliminate the protein have been identified in HSD10 deficiency patients. One particular 
mutation, R130C, is found in more than half of the cases and has usually occurred de 
novo in the respective patients (Ofman et al, 2003; Perez-Cerda et al, 2005). There is no 
evidence that the corresponding nucleotide change c.388C>T represents a hypermutable 
position, raising the possibility that most other mutations in the HSD17B10 gene are not 
observed because they are incompatible with life. This again is highly unusual for organic 
acidurias that usually manifest after birth only, since prenatally toxic metabolites are 
removed via the placenta.  
Protein localisation of mutated HSD10 was not altered in patient fibroblasts (fig. 10) 
indicating that simple mis-localisation of the mutations cannot be causative for the 
clinical phenotype. 
Therefore, the loss of enzyme activity, the accumulation of toxic metabolites, and the 
protein localisation, are not the reason for the clinical phenotype of HSD10 deficiency 
patients. 
In contrast to an immuno fluorescent staining of the mitochondrial protein porin which 
did not show any differences in the mitochondrial network between control and mutated 
fibroblasts (fig. 10), the staining with a Mitotracker and the electron microscopic analysis 
(fig. 14) revealed alterations of the reticular network as well as the subcellular structure 
of mitochondria. Fibroblasts from HSD10 deficiency patients carrying the two severe 
mutations displayed aberrant mitochondria in contrast to control cells and cells with the 
Q165H mutation. The observed fragmentation of the mitochondrial network is known to 
be a feature of apoptotic cell death (Karbowski & Youle, 2003). This indicates that a non-
dehydrogenase effect of HSD10 is required for mitochondrial integrity and a loss-of 
HSD10 function triggers mitochondrial disintegration and apoptosis (Rauschenberger et 
al, 2010 and fig. 14). 
Cellular energy failure caused by mitochondrial dysfunction is thought to play an 
important role in the development of AD (Alzheimer’s disease), and several studies 
indicated that this effect is caused by a direct interaction of amyloid β with HSD10 (Yan 
et al, 1997; Lustbader et al, 2004). HSD10 protein or transcript was found to be 
increased in affected neurons in human AD as well as in AD mouse models and it has 
been suggested that overexpression of HSD10 amplifies amyloid β -mediated 
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mitochondrial toxicity (Chen & Yan, 2007). However, a recent study showed that a 
mitochondrial bioenergetic deficit precedes HSD10 overexpression and Alzheimer’s 
pathology in an AD mouse model (Yao et al, 2009). The results of our study, the first to 
examine the effect of HSD10 loss-of-function, indicate that adverse effects observed as a 
consequence of the binding of amyloid β to HSD10 are more likely due to the loss of a 
non-enzymatic HSD10 function, and that increased amounts of (non-functional) HSD10 
protein may be produced as a secondary or compensatory mechanism. It thus remains 
possible that the mitochondrial interaction of amyloid β with HSD10, triggering early 
dysfunction of energy homeostasis, is one of the first steps in the pathogenesis of AD. 
 
5.2. HSD10 function in apoptosis, RNaseP activity and cellular stress 
5.2.1.  HSD10 function in apoptosis 
Not only the loss-of-function of HSD10 but also its overexpression led to a mild induction 
of apoptosis (fig. 19). The two mutations R130C and D86G strongly induced apoptosis 
and may have a dominant-negative effect on the initiation of apoptosis which is not due 
to the UPR of the ER or mitochondria that is often triggered by overexpression of 
(mutated) proteins (fig. 20). Interestingly, the R130C mutation induced apoptosis in a 
dominant-negative manner (fig. 19) although it has been shown that the mutated protein 
is less stable (Rauschenberger et al, 2010).  
The characterisation of the apoptotic pathway that is initiated by HSD10 loss-of-function 
revealed three genes, CD40, TNFRSF9 and TNFSF15, that were upregulated with both 
siRNAs targeting HSD10 (table 2). Interestingly, two of these genes, TNFRSF9 and 
TNFSF15 were also upregulated in fibroblasts with the R130C mutation, which is 
associated with a severe clinical disease course, but not with the benign Q165H 
mutation. All three genes are members of the TNF (tumour necrosis factor) superfamily 
and have a pro-apoptotic function (Georgopoulos et al, 2006; Schwarz et al, 1996; 
Simon et al, 2001; Yu et al, 2001). Proteins of this family are associated with the 
extrinsic pathway of apoptosis induction, although ligand binding to CD40 has been 
reported to also trigger the intrinsic pathway and upregulation of Bax expression 
(Georgopoulos et al, 2006). TNFSF15 is a cytokine that can activate NFκB signalling (Wen 
et al, 2003) and was found to inhibit angiogenesis by blocking endothelial cell 
proliferation (Yu et al, 2001). Both functions are very interesting since UXT, a potential 
binding partner of HSD10, is also involved in NFκB signalling (see 5.3.) and angiogenesis 
was found to be impaired in Xenopus embryos upon HSD10 knock-down (Guerra, 2010; 
Rauschenberger, 2007). In addition mice with a conditional knock-out of HSD10 in 
vascular endothelium (Tie2-cre mice) indicated that these animals have an aberrant 
blood system (Rumig, 2006). Organisation and structure of endothelial tissue appears 
normal but blood flow and the ability of blood vessels to dilate after a contraction are 
seriously inhibited (unpublished data). In contrast, Xenopus embryos depleted of HSD10 
exhibited a severe reduction of endothelial blood vessels in the injected region which 
would be in line with the upregulation of TNFSF15 in human cells and the impaired blood 
vessel function in mice (Guerra, 2010; own unpublished data). 
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HSD10 loss-of-function might activate the extrinsic apoptosis pathway as indicated by 
the upregulation of three pro-apoptotic genes associated with the extrinsic pathway, 
CD40, TNFRSF9 and TNFSF15. Therefore, the mitochondrial disintegration observed upon 
HSD10 loss-of-function (fig. 14, 15, 16 and 17) would be a secondary effect. The loss of 
an essential non-dehydrogenase function of HSD10 can induce apoptosis which is not 
necessarily initiated but followed by mitochondrial disintegration. One possible 
explanation could be that the loss of the small amount of HSD10 which has been shown 
to be localised in the cytosol triggers the initiation of the extrinsic apoptotic pathway (see 
5.3.). 
Nevertheless, the regulation of apoptotic genes upon HSD10 loss-of-function should be 
interpreted with caution because this regulation of gene expression was a result of a 
transient transfection evaluated after 48 h post transfection. Hence, it is not surprising 
that there was a mixture of pro- and anti-apoptotic genes within the regulated genes 
because the cells might try and compensate the apoptotic signals at first. This transient 
effect does probably not fully reflect the situation in patients. Also in patient fibroblasts a 
mixture of pro- and anti-apoptotic genes was regulated compared to control cells. This 
was to be expected because these cells are viable and not undergoing apoptosis in 
culture. Also, these results are based solely on transcriptional analysis of genes that are 
regulated upon HSD10 knock-down. Transcriptional regulation is by far not the only and 
not the main regulatory level of apoptosis. The strongest and the most immediate 
regulation occurs on protein level. For example, caspases are present in inactive pro-
forms and are activated by proteolytic cleavage, as well as posttranslational modifications 
such as phosphorylation which regulate protein activity. Another level of regulation is the 
subcellular re-distribution of proteins like BAX and cytochrome c that leak from 
mitochondria and then set off apoptosis in the cytosol. 
Therefore, the induction of extrinsic apoptosis upon HSD10 loss-of-function should also 
be confirmed on protein level. Antibody-protein-arrays which simultaneously detect the 
relative level of several (active) apoptosis related proteins in cell lysates are 
commercially available. Alternatively active cleaved caspase-8 and caspase-9 can be 
detected specifically on a Western Blot. Activation of these two caspases distinguishes 
clearly between intrinsic and extrinsic apoptosis pathways.  
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5.2.2.  HSD10 function under cellular stress  
Reduction, loss or mutation of HSD10 in Xenopus, mouse and humans had adverse 
effects on mitochondrial integrity and led to enhanced apoptotic cell death and reduced 
viability (Rauschenberger et al, 2010). Consistently, a protective effect in mitochondria at 
times of increased oxidative stress has been implied for overexpressed HSD10 in the 
setting of acute brain damage (Yan et al, 2000a) and in a mouse model of Parkinson’s 
(Tieu et al, 2004). One dehydrogenase-independent function of HSD10 may be to protect 
mitochondria at times of increased metabolic stress. The described induction of apoptosis 
upon overexpression of mutated HSD10 (mutation R130C and D86G; fig. 19) could be 
due to a disturbance of this protective function. 
This interpretation is compatible with the observation that infections or other stress 
situations in patients with HSD10 deficiency may trigger clinical deterioration. In 
response to metabolic stress, HSD10 protein translocates from the mitochondrial matrix 
to the inner mitochondrial membrane (fig. 13) and this might be important for 
maintaining mitochondrial integrity as this is an essential site for assembly of the 
mitochondrial membrane permeability transition pore (Tieu et al, 2004). It appears 
plausible that interaction of HSD10 with a soluble protein in the mitochondrial matrix or 
with an integral protein of the mitochondrial membrane could mediate its protective 
effect and that this interaction is disturbed by altered HSD10 protein structure due to 
specific mutations. One such protein could be CypD (cyclophilin D; Ren, 2008), which is 
localised in the mitochondrial matrix and is recruited to the inner membrane under 
oxidative stress in order to form the MPTP (mitochondrial permeability transition pore; 
Connern & Halestrap, 1994). Binding of HSD10 and CypD in the mitochondrial matrix 
might block its participation in pore formation and thus, HSD10 might have a protective, 
anti-apoptotic dehydrogenase-independent function in the mitochondrial matrix (Yan & 
Stern, 2005). This function might be disturbed upon mutation of HSD10. The functional 
interaction of HSD10 and CypD remains to be confirmed. An additional candidate for an 
interaction with HSD10 at the mitochondrial membrane that might mediate the protective 
function of HSD10 is ATP synthase (fig. 27, table 6 and 7). This interaction has been 
found in an IMAC approach for wildtype HSD10 but not for the mutated proteins.  
 
Several potential interaction partners of HSD10 inside mitochondria were identified by 
the purification of HSD10 together with bound proteins on an IMAC column. The 
comparison of the proteins eluted together with HSD10 wildtype or the mutations and a 
control protein on a silver stained gel revealed binding partners of HSD10 that show 
differences in their ability to bind to wildtype or mutated HSD10. The finding that 
mutated HSD10 protein cannot interact with certain proteins in the mitochondrial matrix 
or at the mitochondrial membrane could explain why mutant HSD10 cannot execute the 
protective function in mitochondria. In this experimental approach three proteins were of 
particular interest because they are localised in mitochondria and they play a role in 
energy metabolism and stress response: ATP synthase subunits, ribosomal proteins and 
IbpA (table 7).  
IbpA plays a role in the cellular heat shock response (Matuszewska et al, 2008; Thomas 
& Baneyx, 1998), and might interact with HSD10 under stress conditions in the 
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mitochondrial matrix. Once HSD10 is re-distributed upon oxidative stress, the wildtype 
but not the mutated protein might bind to ATP synthase at the mitochondrial membrane. 
It is interesting to note that ATP synthase also co-purified in an approach to partially 
purify RNaseP (Holzmann et al, 2008). This could be due to a physical interaction of 
HSD10 and ATP synthase subunits. Binding of HSD10 to integral proteins of the 
mitochondrial membrane like ATP synthase might protect them from oxidative stress or 
could stimulate ATP production that helps the cell to cope with increased stress. In order 
to investigate if those proteins functionally interact in the human cellular stress response, 
the physical interaction of these proteins has to be confirmed in in vitro assays like Co-IP 
or GST pull-down. 
In our IMAC approach to identify novel interaction partners of HSD10 none of the 
previously reported binding proteins in mitochondria like CypD, estrogen receptor α and 
MRPP1 and MRPP3 emerged. Therefore, an additional technique like SPINE (Strep-protein 
interaction experiment; Herzberg et al, 2007) or combination of techniques like the 
“partial purification overlap proteome” employed to purify RNaseP (Holzmann et al, 2008) 
could help to verify the interaction of these candidate proteins with HSD10 or identify 
additional binding partners of HSD10. 
 
Since patients with the R130C mutation show a severe clinical phenotype which develops 
after times of increased metabolic stress, it was expected that cells with this mutation 
are more sensitive to stress than control cells or cells with the Q165H mutation. When 
patient fibroblasts were assayed for general cell viability under stress, no stress 
conditions tested in this study caused fibroblasts with the R130C mutation to be more 
sensitive than the Q165H cells (fig. 23 und 24) 
It is possible that fibroblasts are not the most appropriate cell type to investigate the 
effect of stress on cell viability. Cells that depend on a higher energy metabolism like 
heart or muscle cells are probably more susceptive to increased stress and could display 
differences for the two mutations upon stress that fibroblasts do not. Also, cell viability 
might not be the only possible readout for these stress experiments. The cellular stress 
response might be very different in mutated cells without displaying a reduced viability. 
 
Rotenone treatment causes enhanced transcription in cell culture (Greene et al, 2010; 
MacKenzie et al, 2008; Ishikawa et al, 2009). Accordingly, control cells apparently 
reacted to oxidative stress by an activation of mitochondrial transcription and a 
subsequent accumulation of unprocessed transcripts (fig. 31). Since HSD10 has been 
found to play a role in the 5’ processing of mitochondrial tRNAs (Holzmann et al, 2008) 
these transcripts were used as a readout for mitochondrial transcription upon oxidative 
stress. 
When patient fibroblasts carrying different mutations in the HSD17B10 gene were 
assayed for tRNA precursor accumulation they displayed different behaviour upon 
oxidative stress than control cells. Control fibroblasts responded to oxidative stress by an 
increase in the amount of immature mitochondrial tRNA precursors (fig. 31A). Mutated 
fibroblasts were not able to respond in the same way but the R130C mutation rather 
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displayed a decrease in tRNA precursors (fig. 31B). Fibroblasts with the Q165H mutation 
appeared to behave more like wildtype cells than like the R130C mutation (fig. 31C).  
Therefore, fibroblasts with the R130C and Q165H mutation seem to be unable or less 
able, respectively, to stimulate tRNA transcription upon oxidative stress.  
Activation of transcription appears to be a protective reaction of mitochondria 
compensating cellular stress. HSD10 expression has been shown to be upregulated in 
stress situations like hypoxia-ischemia, nutritional stress and the presence of amyloid 
plaques (Yan et al, 2000a; Yan et al, 2000b; Yan & Stern, 2005). Similarly, oxidative 
stress induced by rotenone could stimulate HSD10 transcription, since it has been shown 
to have a protective effect in mitochondria at times of increased oxidative stress. Binding 
of HSD10 to (potential) binding partners in mitochondria that play a role in cellular stress 
response (like ATP synthase, IbpA, Rsp5p and Cmk1p) might be important for this 
protective effect of HSD10 in mitochondria. Mutation of HSD10 could abolish the binding 
to its usual interaction partners and thereby its protective function. This could cause 
general mitochondrial damage including disruption of mitochondrial structure (fig. 14). 
Consequentially, impaired mitochondria of fibroblasts with the R130C and Q165H 
mutation are unable to stimulate mitochondrial transcription in the same way as control 
cells. 
 
5.2.3.  Function of HSD10 as a component of human mitochondrial RNaseP  
HSD10 is a component of the human mitochondrial RNaseP complex and functions in the 
5’ processing of mitochondrial tRNAs (Holzmann et al, 2008). Consequentially, a knock-
down of HSD10 causes the accumulation of immature mitochondrial tRNA precursors. 
The previously published accumulation (Holzmann et al, 2008) did only occur for one of 
two tested siRNAs for HSD10 and was only shown for two tRNA precursors, which were 
very different in their level of accumulation. Also the level of total tRNA was not 
considered.  
Therefore, this effect was confirmed in this study with two siRNAs targeting HSD10 and 
for several tRNA precursors. All tested tRNA precursors accumulated upon HSD10 knock-
down but with different kinetics (fig. 28). The previously published accumulation occurred 
nine days after HSD10 knock-down and ranged from a 5- to 65-fold increase. In contrast, 
the siRNAs used here gave rise to an accumulation of immature tRNA precursors after 
three or four/five days and ranged from a 7- to 91-fold increase. The total amount of 
tRNAs was also altered upon HSD10 knock-down but in a smaller range than tRNA 
precursors, indicated by the ratio of total tRNA to tRNA precursor below 1. 
On a translational level, the reduced amount of mitochondrially encoded complex IV 
subunit COXI indicates an inhibition of mitochondrial translation caused by impaired 
mtRNaseP function (fig. 32). This indicates that the processing of mitochondrial 
transcripts is impaired upon HSD10 knock-down which, in turn, impairs mitochondrial 
translation.  
Interestingly, the nuclear encoded subunit COXIV was significantly stronger reduced 
upon HSD10 knock-down than the mitochondrially encoded subunit COXI. Just like 
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COXIV, one component of RNaseP, MRPP1, has been shown to be reduced upon HSD10 
knock-down. Both reductions of nuclear encoded protein complex subunits could be 
explained by the instability of proteins that are not integrated into a protein complex. 
Although it is possible that COXIV may need mitochondrially encoded proteins such as 
COXI in order to be stable, a secondary effect caused by primary reduction of COXI upon 
HSD10 knock-down is not very likely since the nuclear encoded subunit is reduced in a 
much higher degree than the mitochondrially encoded subunit. In contrast, it is not 
surprising that MRPP1 could be unstable if HSD10 is not present, causing deficient 
assembly of the RNaseP complex. 
An alternative explanation for the concurrent reduction of nuclear encoded COXIV and 
MRPP1 upon HSD10 knock-down could be an effect of HSD10 on general nuclear 
transcription. In fact there is preliminary evidence that a link between HSD10 and the 
transcriptional machinery may exist. Two proteins, UXT and PCBP1 that were found to 
interact with HSD10 in a yeast-2-hybrid analysis, are known regulators of transcription 
(see 5.3.). Provided that there is a cytosolic fraction of HSD10, this interaction could 
influence nuclear gene expression (see 5.3.).  
To address this question, the level of MRPP1 and COXIV mRNA upon HSD10 knock-down 
should be determined. A concurrent reduction of MRPP1 and COXIV mRNA together with 
HSD10 would suggest an effect of HSD10 on the transcriptional level. Also, protein and 
transcript levels for proteins that do not bind to HSD10 should be determined to exclude 
protein subunit instability as a cause for reduced protein amounts.  
 
The function of HSD10 in mitochondrial tRNA processing could be the underlying reason 
for the clinical phenotype in HSD10 deficiency patients. Mutations in mitochondrial tRNAs 
cause disturbances of mitochondrial translation that elicit many different clinical 
syndromes including MERRF (myoclonic epilepsy and ragged red muscle fibres; Finnila et 
al, 2001), mitochondrial myopathy (Swalwell et al, 2006), CPEO (chronic progressive 
external ophtalmoplegia; Spagnolo et al, 2001), progressive respiratory failure (Bruno et 
al, 2003), MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like 
episodes; Tzen et al, 2003) and ADPD (Alzheimer’s and Parkinson’s disease; Wallace et 
al, 1992). Like HSD10 deficiency some of these mitochondriopathies feature a 
progressive neurodegenerative clinical phenotype. MELAS patients exhibit blood vessel 
abnormalities such as dysfunction of endothelium-dependent vasodilation (Koga et al, 
2006) which could be similar to the effect of a HSD10 knock-out observed in conditional 
Tie2 knock-out mice and Xenopus embryos (Guerra, 2010; Rauschenberger, 2007).  
Mutation of one of the components of RNaseP also disrupts mitochondrial translation but 
this seems not to be the underlying reason for the clinical phenotype in HSD10 deficiency 
patients since all three mutations found in patients had considerable residual mtRNaseP 
activity in a rescue experiment. All mutations alike were able to rescue the accumulation 
of immature precursors in the knock-down situation (fig. 29). The mutations were not as 
active in their RNaseP activity as the wildtype protein, but no dominant-negative effect 
on (mt)RNaseP activity was observed. Reduced (mt)RNaseP activity of the HSD10 
mutations could result from impaired interaction of mutated HSD10 with the other two 
components of RNaseP. 
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The interpretation of this finding is somehow difficult because co-transfection of siRNA 
and DNA that can be targeted by the siRNA does probably not result in an effective 
knock-down of endogenous wildtype HSD10 combined with full expression of transfected 
HSD10. Rather it will cause mixed translation of endogenous wildtype HSD10 and 
transfected wildtype/mutated HSD10. Still, there was an effect with the mutated and the 
wildtype protein compared to the knock-down situation and the wildtype and the mutated 
proteins displayed some differences in their ability to rescue, so there had to be at least 
some expression from the transfected plasmids. 
 
In order to eliminate the difficulties of this kind of co-transfection, mitochondrial tRNA 
levels were determined in patient fibroblasts directly but tRNA precursors were not found 
to be accumulated as expected (fig. 30). In contrast, the total amount of mitochondrial 
tRNA as well as the level of precursors was strongly decreased in mutant cells. This effect 
was stronger in fibroblasts with the R130C mutation than in cells carrying the Q165H 
mutation. 
On a translational level, there was also no evidence for an inhibition of mitochondrial 
translation, since the amount of mitochondrially encoded complex IV subunit COXI was 
not reduced. Interestingly, the nuclear encoded subunit COXIV was strongly reduced 
comparable to the HSD10 knock-down situation. Thus, mitochondrial transcript 
processing and translation is not affected in patient fibroblasts like it is upon HSD10 
knock-down. 
The reduction of all tRNA forms might be the long-term response to the mutations and 
the permanently impaired (mt)RNaseP activity in patients (fig. 30) in contrast to the 
transient effects upon siRNA mediated knock-down of HSD10 shown before (fig. 28). 
Permanent impairment of RNaseP activity might cause the cells to reduce overall 
transcription since the polycistronic transcripts cannot be processed. Also, the likewise 
reduction of mitochondrial total tRNA and nuclear encoded COXIV protein levels could 
indicate an effect of HSD10 on mitochondrial and nuclear transcription which can be 
measured e.g. by the new nanostring technique or by microarrays (see 5.3.). The 
degradation of protein subunits that are not incorporated into their respective complexes 
appears unlikely to play a role in this situation since COXI was not reduced in patient 
fibroblasts. Holzmann et al, 2008, introduced an elaborate assay to measure (mt)RNaseP 
activity in vitro. The analysis of (mt)RNaseP activity of purified mutant HSD10 proteins 
would help a great deal to characterise these mutations, their impact on cellular functions 
and the contribution of possibly impaired (mt)RNaseP activity to the clinical phenotype of 
HSD10 deficiency patients.  
 
The induction of apoptosis upon HSD10 loss-of-function has been shown previously not 
to be dependent on the enzymatic dehydrogenase function of HSD10 (Rauschenberger et 
al, 2010). In this study it has also been shown to be independent of the function of 
HSD10 as a component of the (mt)RNaseP complex. Rho0 cells lack mitochondrial DNA 
and thus do not depend on mitochondrial transcript processing and translation. These 
cells induced apoptosis upon HSD10 loss-of-function just as well as wildtype cells (fig. 33 
and 34). 
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This suggests that apoptosis upon HSD10 loss-of-function is triggered by a function of 
HSD10 that is independent of its function in mitochondria and that an as yet unknown 
function of HSD10 that is independent of its dehydrogenase and tRNA 5’ processing 
function is required for cellular integrity and viability.  
 
5.3. Dehydrogenase- and RNaseP-independent function of HSD10 outside of 
mitochondria? 
As elaborated above, the function of HSD10, that is essential for cell viability and 
mitochondrial integrity, is independent of its dehydrogenase and RNaseP activity. 
Although the greater part of HSD10 is detectable in mitochondria, a small part seems to 
be distributed in the cytosol. Immunostaining and an overexpression experiment 
indicated that about 5 % of HSD10 appears to be localised in the cytosol (fig 10). Also, 
when cells initiate apoptosis and mitochondria start to permeabilise HSD10 could leak 
into the cytosol. 
Several potential interaction partners of HSD10 and with that several potential functions 
in the cytosol have been proposed previously (fig. 25, table 5 and 7).  
In an attempt to identify novel interaction partners of HSD10 a search in yeast was 
performed (table 4). Physical interaction between homologous proteins in yeast could 
point towards binding partners in humans. The yeast protein with the highest level of 
homology to HSD10 (up to 35 %) was FOX2 (multifunctional enzyme of the peroxisomal 
fatty acid β-oxidation pathway). This protein has 3-hydroxyacyl-CoA dehydrogenase 
activity but is not localised in mitochondria suggesting that HSD10 could also have a 
function outside of mitochondria. Also, none of the binding partners of FOX2 are 
mitochondrial proteins. Two interesting potential binding partners are Rsp5p and Cmk1p. 
Both proteins play a role in cellular stress response and might interact with HSD10 under 
stress conditions. Rsp5p is an E3 ubiquitin ligase involved in many different cellular 
events including transcription initiation and both, stress resistance upon heat shock (like 
IbpA, another potential binding partner of HSD10) and adaptation to a change of 
nutrients (Cardona et al, 2009). Cmk1p is a calmodulin-dependent protein kinase 
implicated in signal transduction in stress tolerance (Sakaguchi et al, 2010). Both yeast 
proteins have homologous proteins in humans: NEDD4L (neural precursor cell expressed, 
developmentally down-regulated 4-like; NP_001138439.1) and CAMK1D (calcium/ 
calmodulin-dependent protein kinase ID; NP_705718.1). In order to investigate if those 
proteins functionally interact in human cellular stress response, first of all this potential 
interaction has to be confirmed in in vitro assays like Co-IP or GST pull-down. 
 
Two potential interaction partners were identified in a yeast-2-hybrid system with HSD10 
as bait: PCBP1 and UXT. Again, both proteins interacting with HSD10 are not localised in 
mitochondria. Nevertheless, the interaction found in the yeast-2-hybrid system might 
play a role in vivo although the proteins are normally separated by compartments, but 
there also is the possibility of a HSD10 function outside of mitochondria. 
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The interaction of HSD10 with UXT (ubiquitously expressed transcript) seems possible 
since both proteins play a role in apoptosis and have been shown to act synergistically on 
the induction of apoptosis. When mutated HSD10 instead of wildtype HSD10 was used in 
a yeast-2-hybrid as bait the interaction of UXT and HSD10 appeared to be weaker for the 
two mutations associated with a severe clinical disease, although colonies in the yeast-2-
hybrid system can in fact not be analysed quantitatively. The currently available data on 
the function of UXT in cell survival or cell death are contradictory (McGilvray et al, 2007; 
Moss et al, 2007; Zhao et al, 2005; Sun et al, 2007). 
UXT is located predominantly in the nucleus and functions in androgen receptor-
dependent transcription as a cofactor that binds to the androgen receptor (Markus et al, 
2002). It has an inhibitory effect on a subset of AR-dependent genes (Taneja et al, 2004) 
including regulators of DNA damage checkpoint and cell cycle progression (Nwachukwu et 
al, 2009). Additionally a role for UXT in the cytoplasm has been proposed. UXT is located 
in centrosomes and associated with γ-tubulin (Zhao et al, 2005) and also a component of 
a multidomain organizer associated with mitochondria. This organizer integrates 
mitochondria and the microtubular cytoskeleton with chromosome remodelling, 
transcription and cytokinesis (Moss et al, 2007; Liu et al, 2002). 
UXT also seems to be regulated in tumour tissue but again overexpression as well as 
decreased expression of UXT is found in tumours (Schroer et al, 1999; Zhao et al, 2005; 
Taneja et al, 2004). 
Some publications postulate an inhibitory function of increasing amounts of UXT on cell 
proliferation and/or survival (McGilvray et al, 2007; Moss et al, 2007) others report an 
increase in apoptosis upon UXT knock-down (Zhao et al, 2005; Sun et al, 2007). UXT 
specifically interacts with NFκB in the nucleus and activates the expression of NFκB 
dependent genes (Sun et al, 2007). The knock-down of UXT inhibits NFκB dependent 
gene expression, which sensitizes cells to apoptosis by tumour necrosis factor α (Sun et 
al, 2007). 
Similarly, all apoptotic genes that were upregulated upon HSD10 loss-of-function, CD40, 
TNFRSF9 and TNFSF15, are pro-apoptotic members of the TNF superfamily, which is 
usually associated with the extrinsic pathway. If HSD10 functions together with UXT in 
the activation of gene expression by NFκB, the loss of this essential non-dehydrogenase 
function of HSD10 could induce apoptosis via the extrinsic pathway associated with TNF 
family members. As mentioned above, the involvement of TNFs and NFκB in HSD10 
function or the loss-of-function phenotype is very interesting. For example, TNFSF15, 
which is upregulated upon HSD10 loss-of-function, and UXT, which is a potential 
interaction partner of HSD10, both can activate NFκB signalling (Wen et al, 2003; Sun et 
al, 2007). NFκB signalling can regulate pro- and anti-apoptotic genes and can switch 
between both upon certain regulatory signals. NFκB also plays a role in the resistance of 
tumours against chemotherapeutic drugs and ionising radiation (Wang et al, 1996). In 
this connection it is interesting to note that HSD10 upregulation in tumour tissue has 
been found to be protective against chemotherapy and is thus correlated with poor 
response to chemotherapy (Salas et al, 2009). 
Nevertheless, a functional interaction of UXT and HSD10 in the cytosol, which prevents 
the induction of apoptosis by UXT in the nucleus, was not detected in the Xenopus 
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system (fig. 25). Instead, UXT and HSD10 had an additive effect on the induction of 
apoptosis but the mechanism remains to be investigated. The most straight forward 
approach to clarify if those two proteins interact does not involve functional studies 
because little is known about the function of both proteins. In order to elucidate the 
participation of HSD10 in UXT/ NFκB signalling, first of all the physical interaction 
between UXT and HSD10 should be confirmed in in vitro assays like Co-IP, GST pull-
down or FRET (fluorescence resonance energy transfer). Secondly, the regulation of NFκB 
dependent gene expression upon HSD10 loss- or gain-of-function could be assayed e.g. 
by qRT-PCR.  
Another potential interaction partner of HSD10 in the cytosol is PCBP1. PCBP1 (PolyC 
binding protein 1), like UXT, could be a link between HSD10 and transcriptional 
regulation. It binds to mRNAs that contain a DICE (differentiation control element) in the 
cytoplasm and thereby represses their translation, e.g. the endogenous L1 cell adhesion 
molecule mRNA. Upon phosphorylation it releases the mRNAs for translation and 
migrates to the nucleus where it is a transcription factor for several target genes like 
eIF4E (eukaryotic translation initiation factor 4E; Lynch et al, 2005) and GDF15 (growth 
differentiation factor 15; Huo et al, 2009). In vitro assays like Co-IP might confirm 
physical interaction of PCBP1 and HSD10 wildtype and especially the mutations. If PCBP1 
and HSD10 interact functionally in vivo a HSD10 gain-of-function should bind PCBP1 and 
inhibit its repressive effect on target mRNAs. So, the detection of proteins whose 
translation is normally repressed by PCBP1 should be determined on a Western Blot after 
HSD10 knock-down. In turn, the knock-down of HSD10 might release PCBP1 which 
further represses the translation of target genes. Similarly an effect of HSD10 loss- or 
gain-of-function would be detectable on target gene transcription. 
 
The potential binding of HSD10 to UXT and PCBP1 in the cytoplasm, might mediate an 
effect of HSD10 on transcription. A convenient experiment to analyse hundreds of 
transcripts in one sample is a microarray gene expression analysis or the nanostring 
technique. This new technique allows direct multiplexed measurement of gene expression 
with a high sensitivity (< 1 copy per cell). Thus, the effect of HSD10 loss-of-function on 
gene expression could be measured in patient fibroblasts and after efficient knock-down 
of HSD10 in cell culture. It would also be interesting to assay the effect of HSD10 knock-
down on mitochondrial transcription. There are commercially available gene expression 
assays that are especially designed to quantify mitochondrial transcription.  
 
If there actually is cytosolic HSD10, the suggested interaction with UXT and even PCBP1 
might be an important function in vivo. Also this function of HSD10 in the cytosol could 
mediate extrinsically induced apoptosis. Therefore, it has to be confirmed if HSD10 really 
is restricted to mitochondria under normal conditions and if it leaks into the cytosol upon 
mitochondrial permeabilisation during apoptosis and then assumes a cytosolic function. 
Very potent evidence that HSD10 has a function in the cytosol would be a rescue 
experiment with HSD10 depleted of its mitochondrial localisation signal. If this cytosolic 
form of HSD10 is able to rescue the apoptotic phenotype observed upon HSD10 knock-
down it would very strongly suggest a function of HSD10 outside of mitochondria. But to 
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be able to investigate this, the mitochondrial import sequence of HSD10 has to be 
identified. Eleven N-terminal amino acids that form a positively charged amphiphilic α 
helix have been proposed to be sufficient but not required for mitochondrial import (He et 
al, 2001). HSD10 might have one or more additional mitochondrial localisation signals, 
although an internal or C-terminal targeting signal was not found in the protein 
sequence. Preliminary own data suggest that the N-terminal sequence is not only 
sufficient but also required to direct HSD10 to mitochondria. 
 
Taken together, several experiments show that the induction of apoptosis after HSD10 
loss-of-function is not (exclusively) dependent on mitochondrial transcription and 
translation including RNaseP activity. An as yet unknown function of HSD10 that is 
independent of its dehydrogenase and tRNA 5’ processing function appears to be required 
for cellular integrity and viability.  
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6 MATERIALS 
6.1. Chemicals 
All chemicals, if not stated otherwise, were obtained from J.T.Baker, Merck, Carl Roth 
GmbH, and Sigma-Aldrich. 
ABsolute™ qPCR SYBR Green ROX Mix  Thermo Scientific 
Acetone  Merck 
Acrylamide (30 %)  Carl Roth GmbH 
Ammonium persulfate  Grüssing 
Amphotericin  Sigma Aldrich 
Ampicillin  biomol 
Antibody diluent with background reducing  DAKO 
Bacto tryptone  Carl Roth GmbH 
Bacto yeast extract  Carl Roth GmbH 
Boric acid  Merck 
Bromophenol Blue  Serva 
Calciumnitrat-Tetrahydrat (Ca(NO3)x4H2O)  Merck 
Calciumchlorid-Dihydrat (CaCl2x2H2O)  Merck 
Chloroform  Zentrallager INF 
4',6-diamidino-2-phenylindole (DAPI)  Roth 
Dimethylsulfoxid (DMSO)  Acros Organics 
Dithiothreitol (DTT)  Invitrogen 
dNTP-mix, 2 and 10 mM  Fermentas 
Dodecylsulfat (SDS)  Serva 
Dulbecco’s modified Eagle’s medium   
(DMEM, ready mix) 
 GibcoBRL 
Ethanol absolut (EtOH)  Sigma Aldrich 
Ethidium bromide  Merck 
Ethylendiamintetraacetat (EDTA)  Merck 
Ethylenglycol-bis[β-aminoethyl ether]-  
N, N, N’ N’-Tetraacetat (EGTA) 
 Sigma Aldrich 
Fluorescence mounting media  DAKO 
Formaldehyde (37 %)  Merck 
Formamide  J.T. Baker 
Gelatine from cold water fish skin  Sigma 
GeneRuler 1 kb and 100 bp DNA Ladder  Fermentas 
Glutaraldehyde  Serva 
Glycerol  GibcoBRL 
Glycine  Sigma Aldrich 
2-[4-(2-hydroxyethyl)-1-piperazinyl]-
ethansulfonic acid (HEPES) 
 biomol 
Hoechst nuclear stain  Immunochemistry Technologies  
Hyamine  Merck 
Hydrochloric acid (HCl)  Merck 
Hydrogen peroxid (33 %) (H2O2)  Merck 
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IPTG  Fermentas 
Imidazole  Sigma 
Isopropanol  Zentrallager INF 
L-cysteine  biomol 
LE Agarose  Biozym 
Lead citrate  Serva Electrophoresis 
Lipofectamine2000  Invitrogen 
Magnesium sulfate  Merck 
Magnesium sulphate heptahydrate   
(MgSO4x7H2O) 
 Merck 
Malate  Sigma Aldrich 
Methanol absolut (MeOH)  J.T. Baker and Zentrallager INF 
Mitotracker Green FM  Invitrogen 
MOPS 
(3-(N-Morpholino)propane sulfonic acid) 
 Biomol 
Mowiol  Calbiochem 
Ni-NTA Agarose  GE Healthcare 
NP40  Calbiochem 
Opti-MEM® I medium  Invitrogen 
Osmium tetroxide  Serva Electrophoresis 
PageRuler Prestained Protein Ladder  Fermentas 
Paraformaldehyde (PFA)  Merck 
PBS for cell culture  PAA Laboratories 
Penicillin  PAA Laboratories 
Phenol-chloroform-isoamylalcohol  Fluka 
Polyoxyethylensorbitanmonolaurat  
(Tween-20) 
 Carl Roth GmbH 
Ponceau S concentrate  Sigma Aldrich 
Potassium chloride (KCl)  AppliChem 
Potassium dihydrogen phosphate (KH2PO4)  Gerbu 
1-C14 pyruvate  GE Healthcare 
Pyruvate  Sigma Aldrich 
RNAse-free water  Ambion 
Sheep serum  Sigma 
Skimmed milk powder  Saliter 
SOC medium  Invitrogen 
Sodium acetate (NaAc)  Merck 
Sodium citrate  AppliChem 
Sodium chloride (NaCl)  Sigma Aldrich 
Sodium hydrogen carbonate (NaHCO3)  Merck 
Sodium hydrogen phosphate dihydrate 
(Na2HPO4x2H2O) 
 J.T. Baker 
Sodium hydroxide (NaOH)  Merck 
Sodium-ortho-vanadate  Sigma Aldrich 
Streptomycin (Strep)  PAA Laboratories GmbH 
Streptomycin sulfate  Merck 
Sucrose  Merck 
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N, N, N’ N’-Tetramethylethylenediamine 
(TEMED) 
 biomol 
Tris-(Hydroxymethyl)-aminomethane (Tris)  Carl Roth GmbH 
Triton X-100  Serva 
TRIZOL reagent  Invitrogen 
Trypan blue  Invitrogen 
UltimaGold  PerkinElmer 
Uranyl acetate  Serva Electrophoresis 
Urea (CH4N2O)  Invitrogen 
Uridine  Merck 
 
6.2. Buffers, solutions and cell culture media   
antigen retrieval buffer 1 mM EDTA, 0.05 % Tween-20 in PBS, 
pH 8.0 
bacteria lysis buffer for IMAC 8 M CH4N2O, 50 mM Tris-HCl pH 8.0, 
1 mM DTT in PBS 
bleaching solution 1 % H2O2, 5 % formamide, 0.5 x SSC 
cell culture lysis buffer 1 % Triton X-100, 2 % NP40, 0.1 mM 
sodium-ortho-vanadate, 0.05 mg 
aprotinin, 25 µM APMSF, 3 U 
benzonase, 1 x complete protease 
inhibitor 
cell culture medium (HEK293 and HeLa) DMEM ready mix, 1 % Pen/Strep 
cell culture medium (fibroblasts) DMEM ready mix, 1 % Pen/Strep, 1 % 
Amphotericin B 
cystein solution 2 % L-cystein, pH 8.0 
DNA loading buffer (6 x) 40 % glycerol, 0.25 % Bromphenol Blue 
embryo lysis buffer 10 mM Tris-HCl pH 7.5, 100 mM NaCl, 
2 mM EDTA, 1 mM EGTA, 0.5 % NP40, 
10 % glycerol, protease inhibitors 
homogenisation buffer (pyruvate turnover) 250 mM sucrose, 50 mM KCl, 5 mM 
MgCl2, 20 mM Tris-HCl, pH 7.4 
IMAC binding buffer 500 mM NaCl, 5 % glycerol, 50 mM 
HEPES pH 7.5, 50 mM imidazole  
IMAC elution buffer 500 mM NaCl, 5 % glycerol, 50 mM 
HEPES pH 7.5, 250 mM imidazole 
LB medium 1 % (w/v) Bactotrypton, 1 % (w/v) 
NaCl, 0.5 % (w/v) yeast extract 
LB-Amp 50 µg/ml ampicillin in LB 
LB-Amp plate 1.5 % agar in LB-Amp 
MBSH buffer 88 mM NaCl, 1 mM KCl, 2.4 mM 
NaHCO3, 0.82 mM MgSO4, 0.33 mM 
Na(NO)3, 0.41 mM CaCl2, 10 mM HEPES 
pH 7.4, 10 µg/ml streptomycin-sulfate, 
10 µg/ml penicillin 
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Modified Eagle’s medium (MEM) (10 x) 1 M MOPS, 20 mM EGTA, 10 mM 
MgSO4, pH 7.4 
MEMFA 0.1 M MOPS pH 7.4, 2 mM EGTA, 1 mM 
MgSO4, 3.7 % formaldehyde 
milk buffer 5 % powdered milk, 0.1 % Tween-20 in 
PBS 
mitochondria isolation buffer 0.25 M sucrose, 5 mM Tris-HCl, pH 7.4, 
1 mM EDTA, 1 x complete protease 
inhibitor 
Mowiol 20 mg Mowiol, 80 ml PBS, 50 ml 
glycerol 
PBS (10 x) 1.37 M NaCl, 27 mM KCl, 20 mM 
KH2PO4, 100 mM Na2HPO4, pH 7.4 
PBS-T 1 x PBS, 0.1 % (v/v) Tween-20 
pH 9 buffer 100 mM Tris pH 9.5, 100 mM NaCl, 
50 mM MgCl2 
SDS-PAGE running buffer 24.8 mM Tris, 192 mM glycine, 0.1 % 
SDS 
SDS-PAGE sample buffer (3 x) 150 mM Tris-HCl pH 6.8, 6 % SDS 
(w/v), 0.3 % Bromphenol Blue 
(w/v), 30 % glycerol (v/v), 300 mM 
DTT 
standard saline citrate (20 x SSC) 3 M NaCl, 0.3 M sodium citrate, pH 7.0 
TBE (10 x) 890 mM Tris-borate, 0.2 mM EDTA, 
pH 8.0 
TE buffer 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
Tris/NaCl 100 mM Tris-HCl pH 7.4, 100 mM NaCl 
trypan blue stain 0.4 % trypan blue in PBS 
Western Blot transfer buffer (10 x) 24.8 mM Tris, 192 mM glycine, 20 % 
methanol 
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6.3. Equipment 
ABI 7500 Fast Real-Time PCR cycler  Applied Biosystems 
Blotting chambers  Bio-rad 
CC-12 digital camera  Olympus 
Cellstar Tissue culture dishes, 6 and 24 
well and 10 cm 
 Greiner Bio-one 
Cell culture flasks, 75 cm² and 25 cm²  Greiner bio-one 
Cold plate  Julabo 
Cronex 5 film  Agfa 
Cryostat CM 30505  Leica 
Dounce homogeniser  Wheaton USA 
Dumont Nr. 5, forceps  NeoLab 
EasyCast electrophoresis system  Owl Scientific 
Eclipse 90i upright automated 
microscope 
 Nikon  
 
electron microscope Philips CM10  Philips 
Epi Chemi II Darkroom gel 
documentation system 
 UVP Laboratory Product 
Eppi-pestle, stainless steel, for 1.5 ml 
reaction vessels 
 Schuett biotec 
Folded Filters  Schleicher & Schuell 
Glass vials 2.0 and 4.0 ml  neoLab 
hemocytometer  Biochrom 
IM300 Microinjector  Narishige 
JC-5 centrifuge  Beckman Coulter 
KL 1500 electronic cold light source  Zeiss 
Micromanipulator  Micro Instruments 
NanoDrop ND-1000 Spectrophotometer  Thermo Scientific 
NC2010 Gel cassettes 1.0 mm  Invitrogen 
Novex xCell SureLock Mini-cell system  Invitrogen 
Optimax Typ TR x-ray film processor 
Protec 
 Medizintrechnik 
 
PCR Plate cover foil Star Seal  Star Lab 
PCR strips  Sarstedt 
PD-5 Puller for producing microneedles  Narishige 
Peltier Thermocycler PTC-200  MJ Research 
Petri dishes  Greiner bio-one 
pH-Meter Delta 320  Mettler 
Pipettes  Gilson 
Pipette tips  Sarstedt and Greiner bio-one 
Power Pac 300   BioRad 
PROTRAN Nitrocellulose Transfer 
Membrane 
 Whatman 
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Reaction tubes 0.5, 1.0 and 2.0 ml  Sarstedt 
Reaction tubes 15 and 50 ml  Greiner bio-one 
scintillation counter  Beckman Coulter 
scintillation vial  Perkin Elmer  
Sonicator  HeatSystems Ultrasonics 
Sorvall RC 5B refrigerated superspeed 
centrifuge 
 Du Pont Instruments 
spinning disc confocal ERS-FRET on 
Nikon TE2000 inverted microscope 
 Perkin Elmer  
 
Stemi SV6  Zeiss 
Stripette  Costar 
Superfrost Plus  Thermo Scientific 
SZX12 stereo microscope  Olympus 
tabletop centrifuge 5415D  Eppendorf 
Thermo Fast 96-well PCR Plates  Applied Biosystems 
Thermocycler TGradient  Biometra 
Whatman 3MM paper  Sartorius 
 
6.4. Kits 
JETquick Plasmid Miniprep Spin Kit  Genomed 
JETstar Plasmid Purification Midi Kit  Genomed 
Lumi-LightPLUS Western Blotting 
Substrat 
 Roche 
Qiagen Plasmid Midi Kit  Qiagen 
SilverQuestTM Silver Staining Kit  Invitrogen 
MasterPureTM Complete DNA and RNA 
Purification Kit 
 Epicentre Biotechnologie 
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6.5. Enzymes, proteins and markers 
All enzymes were obtained from Fermentas, Roche, and New England Biolabs if not 
stated otherwise. 
AG beads (magnetic)  ademtech 
4-Amidinophenylmethanesulfonyl fluoride 
hydrochloride (APMSF)  
 AppliChem 
anti-cleaved caspase-3 (polyclonal rabbit)  Cell Signaling Technology 
anti-digoxygenin antibody coupled to 
alkaline phosphatase (sheep) 
 Roche 
anti-Grp75 antibody  Stressgen Bioreagents 
anti-HSD10 antibody (mouse monoclonal)  Abcam 
anti-myc antibody 9E10 (mouse)  Merck 
anti-porin antibody (polyclonal rabbit)  Abcam 
aprotinin  Sigma Aldrich 
benzonase  Merck 
BM Purple AP Substrat  Roche 
DNAse I  Fermentas 
GeneRuler kb DNA ladder Plus  Fermentas 
goat anti-mouse Alexa 488  Molecular probes 
goat anti-rabbit Alexa 594  Molecular probes 
goat anti-mouse antibody coupled to 
alkaline phosphatase (GAM-AP) 
 dianova 
goat anti-mouse antibody coupled to 
peroxidase (GAM-PO) 
 dianova 
goat anti-mouse antibody coupled to 
horseradish peroxidase (GAM-HRP) 
 Biorad 
human chorionic gonadotropin  Sigma 
Maxima Reverse Transcriptase  Fermentas 
mouse IgG antibody  dianova 
normal goat serum  Dako 
PageRuler Prestained protein ladder  Fermentas 
Poly-L-Lysine  Sigma 
protease inhibitor complete Mini (10 x)  Roche 
RevertAidH-Minus M-MuLV Reverse 
Transcriptase 
 Fermentas 
 
RiboLock RNAse inhibitor  Fermentas 
RNaseOUT RNase inhibitor  Invitrogen 
Terminal deoxynucleotidyl transferase 
(5 U/µl) 
 Fermentas 
Trypsin   PAA Laboratories 
TurboDNase  Ambion 
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6.6. Oligonucleotides 
The following Morpholino antisense oligonucleotides were purchased from Gene 
Tools LLC. 
 
Morpholino 
 
sequence 5’ → 3’ 
MoCo cctcttacctcagttacaatttata 
MoHSD10ATG ccttcaggttcctcacatgcgccat 
Table 8 Morpholino antisense oligonucleotides used for HSD10 knock-down in 
Xenopus embryos. 
 
The following siRNAs were obtained from Qiagen.  
 
siRNA 
 
Target sequence 5’ → 3’ 
ctr siRNA --- 
siRNA3 aagacttccagcgagttcttg 
siRNA5 cagcgagttcttgatgtgaat 
Table 9 siRNA oligonucleotides used for HSD10 knock-down in human cells. 
 
The following oligonucleotides were ordered from Operon, Metabion, Sigma-Aldrich and 
Realtimeprimers.com. 
 
primer organism 
forward primer 
sequence 5’ → 3’ 
reverse primer 
sequence 5’ → 3’ 
apoptosis 
primer 
library 
human  
 
CHOP Xenopus aaagtgtcccatttgttagctgaaa cctggtctgctccacttcctt 
GAPDH human ccatgttcgtcatgggtgt ccaggggtgctaagcagtt 
HSD10 human gtatccgggtgatgaccatt tggccaagaagttgcaca 
ODC Xenopus gtcaatgatggagtgtatggatc tccattccgctctcctgagcac 
oligo-dT    
random 
d(N)6 
  
 
TOMM20 human gcttctgactaagctcccaaca gttgacatttgtttctcattccac 
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tRNA for 
amino acid 
primer used for 
specific reverse 
transcription 
primer sequence 5’ → 3’ product size 
tRNAs encoded on the H-strand 
TF x MT-TF-R1 ggtgatgtgagcccgtctaa  
  MT-TF-F tgtagcttacctcctcaaagca 57 
  HSP1-F ccaaagacaccccccaca 80 
TV x MT-TV-R caagttaagttgaaatctcctaagtg  
  MT-TV-F2 agaggagacaagtcgtaacatgg 113 
  MT-TV-F1 gcttaacacaaagcacccaac 50 
TL x MT-TL-R aagaggaattgaacctctgactg  
  MT-TL-F2 tatacccacacccacccaag 98 
  MT-TL-F1 cccggtaatcgcataaaact 53 
TI x MT-TI-R agggggtttaagctcctatt  
  MT-TI-F2 ttcctaccactcaccctagca 141 
  MT-TI-F1 aaatatgtctgataaaagagttactttg 59 
TM x MT-TM-R cgggaagggtataaccaaca  
  TM-F aaggtcagctaaataagctatcg 60 
  TQ-F agaatcgaacccatccctga 125 
TW x MT-TW-R tgcaacttactgagggctttg  
  TW-F gaaatttaggttaaatacagaccaaga 53 
  ND2-F ccacgctactcctacctatctcc 99 
tRNA for 
amino acid 
primer used for 
specific reverse 
transcription 
primer sequence 5’ → 3’ product size 
tRNAs encoded on the L-strand 
TQ x MT-TQ-F agaatcgaacccatccctga  
  TQ-R aggatggggtgtgataggtg 60 
  TM-R cgggaagggtataaccaaca 125 
TC x MT-TC-int-F ccccggcaggtttgaag  
  TC-R agctccgaggtgattttcat 63 
  15-R aatagtcaacggtcggcgaac 163 
TP x MT-TP-F agaaaaagtctttaactccacca  
  TP-R agaatcttagctttgggtgct 46 
  TyrPro11-R tggtacccaaatctgcttcc 95 
Table 10 Primer oligonucleotides used for amplification of different mRNA and tRNA 
transcripts. 
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6.7. Plasmids  
 
clone 
 
 
source 
Fadd J.W.G. Janssen 
pcDNA4/HisMaxB_hUXT J. Zschocke (Susanne Theiß) 
pCS2+_myc/xHSD10 xHSD10 was amplified from pCS2+/xHSD10 
and ligated into an empty pCS2+_myc 
pET15b/hHSD10 J. Zschocke (Beate Grziwa) 
p11_His/ R130C J. Zschocke (Astrid Nümann) 
p11_His/ D86G J. Zschocke (Astrid Nümann) 
p11_His/ Q165H J. Zschocke (Astrid Nümann) 
pT-Rex-DEST30/hHSD10 J. Zschocke (Katja Schöler) 
pT-Rex-DEST30/R130C J. Zschocke (Katja Schöler) 
pT-Rex-DEST30/D86G J. Zschocke (Katja Schöler) 
pT-Rex-DEST30/Q165H J. Zschocke (Katja Schöler) 
Table 11 Plasmids used for expression in Xenopus embryos, human cells or bacteria. 
 
6.8. Bacteria 
E.coli BL21(DE3) Rosetta  
E.coli XL1 chemocompetent  
 
6.9. Cell lines 
 
cell line 
 
 
source 
BTK-143 Hans Mayr, Kinderspital Salzburg 
fibroblasts N18 (control) Jürgen Okun, Kinderklinik Heidelberg 
fibroblasts N32 (control) Jürgen Okun, Kinderklinik Heidelberg 
fibroblasts NHDF (control) Jürgen Okun, Kinderklinik Heidelberg 
fibroblasts R130C Jürgen Okun, Kinderklinik Heidelberg 
fibroblasts D86G Jürgen Okun, Kinderklinik Heidelberg 
fibroblasts Q165H Jürgen Okun, Kinderklinik Heidelberg 
HeLa Kyoto Heiko Runz, Humangenetik Heidelberg 
HEK293 LGC Promochem 
Table 12 List of cell lines used in this study. 
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6.10. Animals 
Xenopus laevis used for experiments in embryos were obtained from Xenopus Express. 
Material from mice was kindly prepared by Afsaneh Majdazari (Max Planck Institute for 
Brain Research, Frankfurt) or B. Arnold (Molecular Immunology, DKFZ). All experiments 
with model organisms were performed in agreement with the applying Protection of 
Animals Act. 
 
6.11. Software  
AnalySIS  Soft Imaging System GmbH 
Adobe PhotoshopTM 7.0 and  
Adobe Photoshop CS 
  
Adobe 
endnote  endnote 
LabWorks analysis software  UVP laboratory prodcut 
Microsoft Office  Microsoft 
NIS-Elements 2.30 Nikon   Nikon 
PhotoStudio 5  ArcSoft 
SAS 9.1  SAS Institute 
 
6.12. Online databases 
National Center for Biotechnology 
Information 
  
www.ncbi.nlm.nih.gov/ 
primer design  http://biotools.umassmed.edu 
/bioapps/primer3_www.cgi 
proteomics tools  www.expasy.org/tools 
tRNA database  http://mamit-trna.u-
strasbg.fr/Sequences.asp 
Xenopus Web Resource  www.xenbase.org 
Saccharomyces Genome database  http://www.yeastgenome.org 
Human gene compendium  http://www.genecards.org 
apoptosis database  http://deathbase.org/index.php 
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7 METHODS 
7.1. Embryological methods 
7.1.1. Embryo culture and microinjection 
In vitro fertilisation and manipulation of embryos was performed as previously described 
(Rauschenberger, 2007). In brief, eggs were obtained from female Xenopus laevis 
injected with 500 U human chorionic gonadotropin, and were fertilised in vitro. Embryos 
were dejellied using 2 % L-cysteine (pH 7.8-8.0), cultured in 0.1 x MBSH and 
microinjected in 1 x MBSH. For microinjections antisense Morpholino oligonucleotides or 
DNA plasmids diluted in an injection volume of 5 nl were injected into 2- or 4-cell stage 
embryos. The dorsal blastomeres of 4-cell embryos were identified according to Klein 
(Klein, 1987). Animal caps were dissected at stage 8 or 9 and cultured in 0.5 x MBSH 
until they reached the desired stage. Embryo stages were determined according to 
Nieuwkoop and Faber (Nieuwkoop & Faber, 1967).  
 
7.1.2. TUNEL assay (Terminale deoxynucleotidyl transferase-mediated dUTP 
digoxygenin nick end labelling) 
The TUNEL assay specifically stains apoptotic cells. An enzyme called TdT (terminal 
deoxynucleotidyl transferase) adds labelled dNTPs coupled to a DIG-dUTP (digoxygenin) 
to the single strand DNA breaks that happen during apoptosis. This DIG label is then 
detected by an anti-DIG antibody (Hensey & Gautier, 1997). 
Embryos that reached the desired stage according to Nieuwkoop and Faber were fixed in 
MEMFA for 2 h at RT, washed twice with methanol for 30 min and stored in methanol at  
-20 °C. The following TUNEL assay protocol takes 4 days: 
- 2 x PBS-T for 15 min at RT 
- 2 x PBS for 15 min at RT 
- 1 x TdT-buffer for 30 min at RT  
- 1 x TdT-Puffer containing 0,5 µM digoxygenin-dUTP and 150 U/ml TdT o/n at RT  
 
- 2 x PBS-T containing 1 mM EDTA for 1 h at 65 °C  
- 4 x PBS for 1 h at RT  
- Blocking: PBS-T with 20 % goat serum for 1 h at RT 
- Blocking solution containing anti-DIG antibody coupled to alkaline phosphatase 
1 : 10,000 o/n at 4 °C 
 
- 6 x PBS for 1 h at RT 
- PBS o/n at RT 
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- pH 9 buffer for 30 min at RT 
- pH 9 buffer / BM Purple 1 : 1 until the staining is visible (usually 3-4 h) 
- Stop: 2 x PBS for 5 min at RT 
- Postfixation: 3.7 % formaldehyd in PBS o/n at 4 °C (no agitation) 
- 2 x PBS for 5 min at RT 
Subsequently, Xenopus laevis embryos that were stained with the TUNEL assay were 
bleached for a better visualisation of apoptotic spots. Bleaching solution was applied and 
the embryos were incubated for several hours on a light source at 4 °C until the 
pigmentation of the embryos was gone. The embryos were washed once with methanol 
and stored in methanol at -20 °C. 
 
7.1.3. Tissue preparation from mice 
Animals were killed and immediately dissected to collect brains or ganglia. Tissues were 
fixed in 4 % formaldehyde and 1 % glutaraldehyde in PBS. Fixed brains were cut in 
Vibratome sections (50 µm) and the appropriate regions of the brain (locus coeruleus) 
were identified by pigmentation and dissected from these Vibratome sections prior to 
electron microscopy. 
Fixed ganglia were embedded for cryosectioning (15 µm). For that reason ganglia were 
washed in PBS, incubated in Tris/NaCl for 1 h and rinsed again in PBS. Ganglia were then 
embedded in 15 % cold water fish gelatine and 15 % sucrose o/n followed by 25 % cold 
water fish gelatine and 15 % sucrose o/n. Specimens were frozen in 15 % cold water fish 
gelatine at -80 °C. 15 µm sections were cut in a Cryostat CM 30505 at -19 °C, collected 
on Superfrost Plus precoated glass slides and dried at 37 °C o/n. The dried cryosections 
were fixed with acetone and mounted in Mowiol. 
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7.2. Molecular biology 
7.2.1. Isolation of DNA (midiprep)  
Transformation of competent bacteria was achieved by mixing 100 ng of purified plasmid 
DNA with 50 µl chemocompetent cells and incubating them on ice for 20 min. Bacteria 
were heat shocked for 30 s at 42 °C and then put on ice for 1 min. After the addition of 
1 ml LB or 250 µl SOC medium bacteria were incubated for 1 h shaking at 37 °C and 
then 20-150 µl were plated on LB plates containing antibiotics and cultured o/n at 37 °C. 
One of the resulting colonies was picked and cultured in 50 ml LB-medium containing 
antibiotics o/n shaking at 37 °C. Plasmid DNA was isolated from bacteria with the 
appropriate kit (see 6.4.) according to the manufacturer’s instructions. 
 
7.2.2. Isolation of RNA 
Total RNA from approximately 15 Xenopus animal caps was isolated using 1 ml TRIZOL 
reagent. The tissue was homogenised with an Eppi-pestle and incubated at RT for 
10 min. Subsequently, 200 µl of chloroform were added and samples were mixed 
thoroughly by vortexing. Centrifugation for 15 min at 13,000 rpm at 4 °C separates the 
upper aqueous phase which was transferred to a new tube and RNA was precipitated by 
the addition of 250 µl isopropanol and 250 µl 0.8 M sodium citrate/1.2 M NaCl and 
incubation at RT for 10-30 min. Subsequently, RNA was pelleted by centrifugation for 
15 min at 13,000 rpm at 4 °C and the pellet was washed twice with 75 % ethanol and 
resuspended in an appropriate volume of nuclease-free water.  
Isolation of total RNA from cells was achieved with the appropriate kit (see 6.4.) 
according to the manufacturer’s instructions. 
To avoid possible genomic DNA contaminations a DNAse I digest was performed within 
the scope of the RNA isolation procedure. 1 µg of total RNA was incubated with 1 µl 
DNAse I or TurboDNase and incubated for up to 1 h at 37 °C. DNAse was inactivated by 
the precipitation of proteins during the RNA isolation procedure. 
 
7.2.3. Phenol-chloroform purification of nucleic acids 
Purification of nucleic acids from lipids and proteins was performed by phenol-chloroform 
extraction. The aqueous solution of nucleic acids was mixed with the same volume of 
phenol-chloroform-isoamylalcohol and centrifuged for 15 min at 13,000 rpm at RT. The 
upper phase containing the nucleic acids was transferred to a new tube, mixed with the 
same volume of chloroform and centrifuged again for 15 min. The upper phase was 
transferred to a new tube and the nucleic acid was precipitated with ethanol or 
isopropanol. 
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7.2.4. Precipitation of nucleic acids 
Alcohol precipitation of nucleic acids was performed to purify RNA or DNA. To precipitate 
nucleic acids from aqueous solutions 1/10 volume 3 M sodium acetate (pH 5.2) and 
2.5 volume 100 % ethanol or 1 volume isopropanol were added, and the mixture was 
incubated on ice for 15 min or o/n at -20 °C and centrifuged at 13,000 rpm. The nucleic 
acid pellet was washed once with 75 % ethanol and resuspended in a suitable volume of 
water or TE buffer. 
 
7.2.5. Concentration and quality of nucleic acids 
The concentration and quality of nucleic acid solutions were measured photometrically 
using a NanoDrop ND-1000. 
Quality of total RNA was additionally assessed by gel electrophoresis. RNA samples were 
mixed with 6 x loading buffer and loaded onto 1 % agarose gels in 1 x TBE-buffer 
containing 5 µg/ml ethidium bromide. RNA fragments were then electrophoretically 
separated in 1 x TBE buffer at 100-135 V for 30-60 min. To visualise the separated 
nucleic acids, the agarose gel was illuminated by UV light and imaged on a gel 
documentation system. 
 
7.2.6. cDNA synthesis (reverse transcription) 
To detect the relative expression level of a target gene RT-PCR (reverse transcription 
Polymerase Chain Reaction) followed by qPCR (quantitative Polymerase Chain Reaction) 
was used. 
Total RNA was reverse transcribed by RevertAidH-Minus-MuLV-RT or Maxima Reverse 
Transcriptase using random hexamer or oligo-dT primers or specific primers listed in 
table 10. Maxima Reverse Transcriptase and specific primers were used for RT-PCR of 
tRNA genes, since this enzyme can tolerate higher temperatures than RevertAidH-Minus-
MuLV-RT and this and the binding of specific primers helps to dissolve the secondary 
structure of tRNA genes that otherwise disturbs reverse transcription. RT-PCR of mRNA 
transcripts was performed according to the following protocol: 
- heat 1 µg RNA and 250 ng d(N)6 in a volume of 11 µl to 70 °C for 10 min 
- cool down to 4 °C 
- add 4 µl 5 x M-MuLV RT buffer, 1 µl 10 mM dNTP, 0.5 µl RNase inhibitors and 
2.5 µl water  
- incubate at 25 °C for 5 min 
- cool down to 4 °C 
- add 1 µl RevertAidH-Minus-MuLV-RT to a final volume of 20 µl 
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- use PCR program: 
25 °C 10 min 
42 °C 2h 
70 °C 10 min 
  4 °C ∞ 
For further use the reaction was filled to a total volume of 100 µl with nuclease-free 
water. 
 
cDNA synthesis for tRNA genes was performed according to the following protocol: 
- heat 1 ng - 5 µg RNA, 10 mM dNTP and 100 µM primer in a volume of 7 µl to 
70 °C for 3 min 
- cool down to 4 °C for oligo-dT and d(N)6 and keep on 55 °C for specific primers 
- add 2 µl 5 x first strand buffer, 0.5 µl RNaseOUT RNase inhibitor and 0.5 µl 
Maxima Reverse Transcriptase to a final volume of 10 µl 
- use PCR program for  
 
oligo-dT primers 
 
 
d(N)6 primers 
 
specific primers 
50 °C 30 min 25 °C 10 min 55 °C   5 min 
55 °C 10 min 50 °C 30 min 50 °C 30 min 
60 °C 10 min 55 °C 10 min 55 °C 10 min 
65 °C 10 min 60 °C 10 min 60 °C 10 min 
85 °C   5 min 65 °C 10 min 65 °C 10 min 
 85 °C   5 min 85 °C   5 min 
Table 13 PCR programs for cDNA synthesis using different primers. 
For further use the reaction was filled to a total volume of 20 µl with nuclease-free water. 
 
7.2.7. Quantitative PCR 
To quantify gene expression qPCR (quantitative realtime PCR) was performed on an 
ABI 7500 Fast Real-Time PCR cycler. The qPCR reaction was set up in the following 20 µl 
or 10 µl PCR reaction and the following PCR programs were used. 
qPCR for mRNA transcripts 
 
 
qPCR for tRNA transcripts 
2 µl cDNA 0,6 µl 
10 µl ABsolute™ qPCR SYBR Green 
ROX Mix 
5 µl 
0.4 µl (10 µM each) Primer 4 µl (0.2 µM each) 
7.6 µl H2O 1 µl 
20 µl total 10 µl 
Table 14 qPCR reaction for the quantification of mRNA or tRNA transcripts. 
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qPCR for mRNA transcripts 
 
 
qPCR for tRNA transcripts 
 
temperature 
 
 
time 
 
cycle 
 
temperature 
 
time 
 
cycle 
25 °C 15 min   1 x 25 °C 20 min   1 x 
95 °C 15 min   1 x 95 °C   1 min   1 x 
95 °C 15    s 40 x 96 °C   2 s 40 x 
60 °C   1 min  63 °C 40 s 40 x 
Dissociation 
stage 
  72 °C 30 s 40 x 
   25 °C 10 s   1 x 
   Dissociation 
stage 
  
Table 15 PCR program used for the quantitative amplification of mRNA or tRNA 
transcripts. 
 
CT values measured in the qPCR were normalised against housekeeping genes like 
GAPDH in human and ODC in Xenopus samples and relative expression levels were 
calculated using a standard curve or the ddCT method. 
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7.3. Proteinbiochemistry 
7.3.1. SDS-PAGE  
Discontinuous SDS-PAGE (polyacrylamid-gel electrophoresis) was performed according to 
Laemmli, 1970. Protein extracts boiled with 1 x SDS sample buffer and stained protein 
molecular weight standards were separated at constant voltage of 100-200 V in a 12-
15 % separating gel topped with 6 % stacking gel. A 12 % separating gel topped with 
6 % stacking gel was prepared as follows for a standard size SDS gel; amounts used for 
large size gels were adapted according to the size of the gels: 
 
 
10 ml separating gel 3 ml stacking gel 
H2O [ml] 4.18 1.69 
1 M Tris pH 8.8 [ml] 1.67 --- 
0.5 M Tris pH 6.8 [µl] --- 760 
30 % acrylamide  4 ml 500 µl 
20 % SDS [µl] 50 15 
10 % APS [µl] 100 30 
TEMED [µl] 4 3 
Table 16 Separating and stacking gel for discontinuous SDS-PAGE. 
 
7.3.2. Silver staining 
Proteins separated in a large size SDS-PAGE were silver stained using the SilverQuestTM 
Silver Staining Kit by Invitrogen according to the manufacturer’s instructions. This 
technique specifically detects proteins in the polyacrylamide gel with a very high 
sensitivity. The SilverQuestTM Silver Staining Kit from Invitrogen is compatible with 
subsequent mass spectrometry. 
 
7.3.3. Western Blot 
Proteins that were separated in SDS-PAGE were transferred electrophoretically to a 
nitrocellulose membrane by wet transfer at constant amperage (400 mA, 80 min) in 
Western blot transfer buffer. A correct transfer as well as protein amounts in each sample 
were checked by Ponceau S staining and the membrane was blocked in 5 % milkpowder 
in PBS-T for 1 h at RT. Antibody incubation times were o/n at 4 °C for primary, and 1 h 
at RT for secondary antibodies with six washing steps in PBS-T at RT before and after 
each incubation step. 
Specific protein bands were visualised by chemoluminescence using the Lumi-LightPLUS 
Western Blotting substrate (Roche). The luminescence was detected on X-ray film, which 
was developed using an X-ray film processor (Protec Medizintechnik). 
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7.3.4. Co-immuno precipitation of protein complexes  
This pull-down method was used to isolate HSD10 together with potential binding 
partners from injected Xenopus embryos overexpressing xHSD10_myc or endogenous 
HSD10 from mitochondrial lysate from untreated HEK cells. 
For the preparation of embryo extract injected embryos were washed once with lysis 
buffer and then lysed in lysis buffer containing proteinase inhibitors by pipetting up and 
down. The lysate was incubated on a head-over-head rotator at 4 °C for 5-10 min and 
then centrifuged for 5 min at 10,000 rpm at 4 °C. After separating the proteins from the 
pigment pellet and the overlaying yolk they were centrifuged again for 5 min at 
10,000 rpm at 4 °C.  
For the preparation of mitochondrial proteins see 7.4.3. 
An aliquot “input” was removed from both, embryo extract and mitochondrial proteins, 
and prepared for SDS-PAGE. The remaining input was divided in two parts and mixed 
with 2 µg IgG and anti-myc or anti-HSD10 antibody, respectively. Proteins and antibodies 
were incubated on a head-over-head rotator for 1 h at 4 °C. Subsequently, the mixture 
was centrifuged for 15 min at 10,000 rpm at 4 °C and the supernatant was processed by 
the addition of 30 µl magnetic AG beads. The protein/antibody-complexes were incubated 
for 2-3 h or o/n on a head-over-head rotator at 4 °C with the magnetic AG beads. 
Afterwards the beads were washed 4-5 times with lysis buffer and finally resuspended in 
1 x SDS-PAGE sample buffer, incubated at 95° C for 5 min and the supernatant was used 
for SDS-PAGE. 
 
7.3.5. IMAC (immobilised metal ion affinity chromatography) 
Protein purification of HSD10 wildtype and mutations was achieved by the expression of 
the proteins in E.coli BL21(DE3) Rosetta. For that reason 50 µl competent bacteria were 
transformed with 100 ng prokaryotic expression plasmids (pET15b_His/hHSD10 and 
p11_His for the mutations) by incubating cells and DNA on ice for 10 min, heat shocking 
at 42 °C for 90 s and cultivating shaking in 1 ml LB at 37 °C for 1 h before plating them 
on LB/Amp plates and cultivation at 37 °C o/n. 
For protein expression an o/n pre-culture of 2-3 ml was inoculated with a single colony. 
This small o/n pre-culture was then used to start a 250 ml culture that was incubated 
shaking until OD600 ≥ 0.5. Then protein expression was induced by the addition of 
0.4 mM IPTG and again incubated shaking at 37 °C for 3 h. Subsequently, cells were 
centrifuged for 15 min at 6,000 rpm and the pellet stored at -80 °C. 
For cell lysis the pellet was resuspended and incubated shaking for 30 min at 4 °C in 
bacteria lysis buffer. Centrifugation at 12,000 rpm and 4 °C for 15 min yielded the 
protein containing supernatant. This supernatant was charged on a column filled with 
1 ml Ni-NTA agarose and then washed with 10-20 ml IMAC binding buffer and 20-30 ml 
PBS. Mitochondrial lysate (see 7.4.3.) was subjected to the column and subsequently 
washed again with 10 ml PBS. Elution was achieved by adding 3 ml IMAC elution buffer 
to the column. 
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7.3.6. Pyruvate turnover 
Xenopus animal caps were homogenised in 500 µl homogenisation buffer using a Potter-
Elvehejm-system and 7 downstrokes. The suspension was incubated with 50 µl 10 mM 
malate and 50 µl 1-C14 pyruvate (5 µCi/ml) for 1 h at 37 °C in a scintillation vial that 
contains a tube with 200 µl hyamine. This tube was transferred in a new scintillation vial 
containing 7 ml UltimaGold and measured in a scintillation counter. 
 
7.3.7. Protein extract from cell culture cells 
Adherent cells were washed with PBS and then incubated pivoting on ice for 15 min in 
cell lysis buffer. The cells were scraped from the culture dish, transferred to tubes and 
cell debris was pelleted by centrifugation for 20 min at 4 °C at 13,200 rpm. The 
supernatant was mixed with SDS-PAGE sample buffer and boiled for 5 min at 95 °C. 
 
7.3.8. Acetone precipitation 
Acetone precipitation of proteins was performed to concentrate proteins in aqueous 
solutions. Four volumes cold acetone were added, vortexed vigorously and incubated for 
60 min at -20 °C. Centrifugation at 13,000 x g for 10 min pellets the proteins and the 
pellet was washed once with acetone. The remaining acetone was allowed to evaporate 
and the protein pellet was resuspended in an appropriate volume of buffer.  
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7.4. Cell culture methods 
 
7.4.1. Cultivation of cell lines 
All adherent cell lines used in this study were grown in DMEM Ready Mix supplemented 
with 100 µg/ml penicillin and streptomycin at 37 °C in a humidified 5 % CO2 incubator. 
These cell lines are HEK293, HeLa Kyoto, BTK-143 osteogenic sarcoma cells and 
fibroblasts. Patient and control fibroblasts are additionally protected from fungal growth 
by 100 µg/ml amphotericin B. 
BTK-143 osteogenic sarcoma cells were used as wildtype or rho0 cells. Rho0 cells are 
depleted of their mitochondrial DNA and hence do not assemble a functional respiratory 
chain in mitochondria. These cells were supplemented with 2.5 mM pyruvate and 
100 µg/ml uridine.  
At 80-90 % confluence cells were subcultured using trypsin and a split ratio of 1 : 20 for 
HEK293 cells and trypsin/EDTA for all other cell lines and a split ratio of 1 : 10 for HeLa 
and BTK-143 cells and 1 : 3 for fibroblasts. 
For microscopic analyses cells were seeded onto coverslips coated with poly-L-lysine. 
 
7.4.2. Transfection of cultured cells 
HeLa and BTK-143 cells were transfected using Lipofectamine2000 and Opti-MEM 
according to the manufacturer’s instructions. For efficient HSD10 knock-down 60 pmol 
siRNA (3 µl 20 µM siRNA) were used with 2 µl Lipofectamine to yield a final concentration 
of 30 nM in 2 ml culture medium. For rescue experiments 60 pmol siRNA were 
transfected together with 1 µg DNA using 2 µl Lipofectamine.   
 
7.4.3. Isolation and fractionation of mitochondria from HEK293 cells  
For the preparation of mitochondrial proteins HEK293 cells were harvested and the cell 
pellet was resuspended in 5 volumes of mitochondria isolation buffer. Cells lysis was 
achieved by 10 downstrokes and cellular debris was removed by centrifugation at 750 x g 
for 10 min. Mitochondria were pelleted by centrifugation at 16,400 x g for 10 min. The 
resulting supernatant represents the cytosol fraction and the resuspended pellet the 
isolated mitochondria. After washing the mitochondrial pellet once, an aliquot 
“mitochondria” was removed and prepared for SDS-PAGE or the mitochondrial proteins 
were subjected to pull-down or IMAC experiments. Alternatively, isolated mitochondria 
were sonicated for 20 s and the matrix and membrane fraction were separated by 
centrifugation at 44,000 x g for 1 h.  
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7.4.4. Trypan blue staining  
Trypan blue is a negatively charged chromophore that only enters cells when the 
membrane is damaged. Therefore, all cells that exclude the dye are viable (Freshney, 
1987 ). 0.1 ml of 0.4 % trypan blue stain was added to 0.5 ml cell suspension and mixed 
thoroughly. After 5 min incubation at RT the cells were counted in a hemocytometer. 
 
7.4.5. Immunofluorescent staining of cultured cells  
Adherent cells were washed twice with PBS and then fixed for 20 min at RT in 4 % 
formaldehyde in methanol. After washing the cells 3 x for 3 min with PBS, they were 
incubated for 20 min in antigen retrieval buffer at 95 °C followed by another 3 x for 
3 min in PBS. The cells were permeabilised for 15 min with 0.1 % Triton X-100 in PBS, 
washed 3 x for 3 min with PBS and once 3 min with PBS-T (0.5 % Tween-20). Unspecific 
antibody binding sites were blocked with 10 % normal goat serum in PBS-T for 30 min 
and the first antibody was incubated for 1 h at RT in “antibody diluent with background 
reducing”. After 3 x 3 min washing with PBS-T the cells were incubated for 1 h at RT with 
the second antibody diluted in PBS-T. The cells were washed again 3 x with PBS-T, 
stained with 20 µg/ml DAPI in PBS-T for 10 min, washed again 2 x for 3 min with water 
and mounted on slides with “fluorescence mounting media”.  
 
7.4.6. Nuclear staining of cultured cells 
Cultured fibroblasts were washed with PBS and then fixed for 20 min at RT in 4 % 
formaldehyde in methanol or 3.7 % formaldehyde in PBS. After washing the cells 3 x for 
3 min with PBS, they were permeabilised for 15 min with 0.1 % Triton X-100 in PBS, 
washed again 3 x for 3 min with PBS and once 3 min with PBS-T. The cells were stained 
with 20 µg/ml DAPI or Hoechst in PBS-T for 10 min, washed again 2 x for 3 min with 
water and mounted on slides with “fluorescence mounting media” or Mowiol.  
 
7.4.7. Mitochondrial staining of cultured cells 
Fibroblasts were fixed for 15 min at 37 °C in 3.7 % formaldehyde in culture medium. 
Cells were rinsed with PBS and incubated for 15 min with 300 nM Mitotracker Green FM 
in PBS. The cells were rinsed again with PBS followed by mounting in Mowiol. 
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7.5. Microscopy 
Fluorescent images were obtained on an Eclipse 90i upright microscope or a spinning disc 
confocal ERS-FRET on Nikon TE2000 inverted microscope at the Nikon Imaging Centre at 
the University of Heidelberg. 
 
7.5.1. Electron microscopy 
Primary fixation was done with 2.5 % glutaraldehyde in PBS. For easier handling tissue 
culture cells were scraped off and embedded in 2 % agarose. All samples were postfixed 
with 1 % osmium tetroxide in 100 mM phosphate buffer pH 7.2 for 1 h on ice, washed 
extensively with water, block-stained with 1 % aqueous uranyl acetate for 1 h at 4 °C, 
dehydrated in a graded series of ethanol at RT, infiltrated with mixtures of ethanol/Epon 
and finally embedded in Epon. Ultrathin sections were stained with uranyl acetate and 
lead citrate (Venable & Coggeshall, 1965) and viewed in a Philips CM10 electron 
microscope at 60 kV using a 30 µm objective aperture. Mitochondria were quantitatively 
classified into groups according to their morphology by examiner who was blinded to the 
nature (wt/mutant/knock-out) of the samples. Group 1 is distinguished by a regular 
arrangement and shape of the cristea stacks. Group 3 characteristics are a reduced 
cristae compartment resulting in less electron dense material in the mitochondria and an 
irregular arrangement and shape of the cristae stacks. Group 2 is represented by an 
intermediate morphological phenotype (fig. 14, 15, 16 and 17). 
All samples were sectioned at random angles resulting in cross and longitudinal sections 
of mitochondria. For the morphological analyses the plain of sections was not relevant. 
 
7.6. Statistics 
For the statistical evaluation of mitochondrial morphology the density of each 
mitochondrium was used as an ordinal variable (dense, medium or depleted). The 
variable was evaluated as a categorical variable within a logistic model framework. The 
hypothesis of equal density distribution rates for different treatments was tested 
controlling for a suitable covariante (animal cap, brain sections or patient) in the 
respective experiment. All analyses have been performed with SAS 9.1 on PC (SAS 
Institute, Inc, cary, NC). Differences were counted as significant if the p-values were 
lower than 5 % adjusted for multiple testing within one experiment.  
Significance in all other experiments was calculated by the student t-test. Differences 
were counted as significant if the p-values were ≤ 0.01. 
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9 APPENDIX 
9.1. Abbreviations 
17βHSD10 17β-hydroxysteroid dehydrogenase type 10 
ABAD amyloid β-binding alcohol dehydrogenase 
ADPD Alzheimer's disease and Parkinson's disease 
AIF apoptosis inducing factor 
ANT adenine nucleotide transporter 
AP  alakaline phosphatase 
BioGRID Biological General Repository for Interaction Datasets 
cDNA  copy DNA 
CHOP C/EBP homologous protein 
CNS central nervous system 
COX cytochrome c oxidase 
CPEO chronic progressive external ophtalmoplegia 
CPM counts per minute 
ctr control 
CypD cyclophilin D 
DBH  dopamine β-hydroxylase 
DICE differentiation control element 
DISC death-inducing signalling complex 
dNTP  2’-desoxy-nucleoside-5’-triphosphate 
DSF differential scanning fluorimetry 
E.coli  Escherichia coli 
eIF4E eukaryotic translation initiation factor 4E 
EMS ethyl methanesulphonate 
ER endoplasmic reticulum 
ERAB endoplasmic reticulum-associated amyloid b-peptide 
binding protein 
FADD Fas associated death domain protein 
FOX2  Multifunctional enzyme of the peroxisomal fatty acid β-
oxidation pathway 
Grp75 75 kDa glucose regulated protein 
GST glutathione S-transferase 
h  hour(s) 
HADH2 L-3-hydroxyacyl-CoA dehydrogenase type II 
HRP  horse radish peroxidase 
IAPs  inhibitors of apoptosis proteins 
IMAC immobilised metal ion affinity chromatography 
kb kilo bases 
kD kilo Dalton 
LB medium Luria Bertani medium 
LC locus coeruleus 
LOF loss-of-function 
MELAS mitochondrial encephalomyopathy, lactis acidose, stroke-
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like episodes 
MHBD 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase 
min  minute(s) 
MMP mitochondrial membrane permeabilization 
Mo Morpholino antisense oligonucleotides 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin 
MPTP mitochondrial permeability transition pore 
mRNA messenger RNA 
MRPP1 Mitochondrial Ribonuclease P Protein 1 
MS mass spectrometry 
mt  mitochondrial 
n number 
NF  Xenopus stages according to Nieuwkoop and Faber 
NFκB  nuclear factor κ-light-chain-enhancer of activated B cells 
o/n  overnight 
OAR1  Mitochondrial 3-oxoacyl-[acyl-carrier-protein] reductase 
OD  optic density 
ODC Ornithine decarboxylase 
p.f. post fertilisation 
PCBP1  PolyC binding protein 1 
pH pondus hydrogenii 
PNS peripheral nervous system 
ROS reactive oxygen species 
RNaseP  ribonuclease P 
rpm  rounds per minute 
RT  room temperature 
SCG  superior cervical ganglia 
SCHAD short chain 3-hydroxyacyl-CoA dehydrogenase 
SCHMAD short chain L-3-Hydroxy-2-Methylacyl-CoA Dehydrogenase 
SDR short chain dehydrogenases/reductases 
Smac second mitochondria-derived activator of caspase 
SPINE Strep-protein interaction experiment 
TM  tunicamycin 
TNFR tumour necrosis factor receptor 
TOMM20  translocase of outer mitochondrial membrane 20 
TF, TL, TI and so on tRNA coding different amino acids  
tRNA transfer RNA 
TUNEL Terminale deoxynucleotidyl transferase-mediated dUTP 
digoxygenin nick end labelling 
U Unit 
UPR unfolded protein response 
UXT ubiquitously expressed transcript 
VDAC voltage dependent anion channel 
(v/v)  volume-volume ratio 
WT wildtype 
(w/v)  weight-volume ratio 
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